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ABSTRACT

ABSTRACT
Cancer is one of the major public health problems all over the world. Over the past
several decades, enormous efforts have been made to combat cancer. One of particular
interest is the use of nanoparticles (NPs) in cancer treatment. Nanomaterials are making great
significant contributions to a new strategy for developing anticancer agents due to their
distinct and versatile physicochemical properties, endowed by their size, shape, crystal
structure, surface properties, and elemental composition. Among these materials, inorganic
metal oxide or so-called “ceramic” NPs are of particular interest because, through a variety of
engineering designs, multifunctional nano-ceramic systems, also known as nano-ceramic
theranostic systems, can be constructed. Such ceramic nano-systems normally combine
multiple functionalities in one single platform, for instance: the functions of targeting,
diagnosis, therapy, radiation dose enhancement, and radiation protection. In addition, the
most common strategy for using ceramic NPs as anticancer agents is to generate reactive
oxygen species (ROS) to destroy cancer cells.
Indium-based NPs are easily engineered and synthesized. They are intrinsically
fluorescent and have a high atomic number, which could be used for applications for
diagnosis, and have never been explored as a theranostic agent for cancer treatment.
Therefore, the aim of this project is to synthesize and characterize the indium-based NPs
from the aspect of their physicochemical properties and to explore their cytotoxic effects,
selectivity, and biomedical potentials in malignant and non-malignant cells.
Part of this doctoral work has been to synthesize and characterize air-calcined tin
doped indium oxide (ITO) NPs and to investigate the selective cytotoxicity of these NPs
towards gliosarcoma 9L, human breast cancer MCF-7 cells, and non- malignant Madin- Darby
canine kidney (MDCK) cells. The synthesized ITO NPs exhibit extreme killing ability
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towards both gliosarcoma 9L and human breast cancer MCF-7 cells. Results from clonogenic
assays demonstrate a surviving fraction of less than 1% in 9L cells, and around 30% in MCF7 cells at a concentration of 50 µg/mL after incubation for 24 hours with the as-prepared ITO
NPs. In contrast, at the same concentration, the ITO NPs did not harm to the MDCK cells
with a surviving fraction more than 90%.
After revealing the high selectivity of air-calcined ITO NPs between malignant and
non- malignant cells, another type of ITO NPs was fabricated through a specific engineeringdesign to explore their biomedical potentials and their possibility of selective killing or
protection in human breast cancer MDA-MB-231, MCF-7, and human breast non-malignant
MCF-10A cell lines through controlled prevention and generation of oxidative stress.
Experimental results demonstrated that the specifically nano-engineered ITO material can
selectively increase the generation of ROS in both breast tumor cell lines, resulting in
activation of apoptosis, and can also greatly suppress the cellular proliferation in both types
of tumor cells. In contrast, the ITO NPs exhibited ROS scavenging- like behavior and
significantly decreased the ROS levels in MCF-10A cells exposed to additional ROS in the
form of hydrogen peroxide (H2 O 2 ), so that they provided protection against the proliferation
of non- malignant MCF-10A cells from ROS damage. Regarding the biomedical potentials of
ITO NPs, fluorescent microscope images demonstrated that ITO NPs can emit strong
fluorescence, which could be used to reveal their location. Moreover, imaging performed by
computed tomography (CT) also demonstrated that ITO NPs exhibit a comparable capability
for anatomical contrast enhancement to the commercial contrast agent, iobitridol. The results
suggest that these designed ITO NPs can be a novel theranostic agent for cancer treatment.
Finally, another type of indium-based nanoparticles, zinc doped indium oxide (IZO)
NPs, have been fabricated and investigated for their physicochemical properties and their
selectivity in a variety of human malignant and non-malignant cells. Human breast malignant
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MDA-MB-231, and MCF-7 cells, human pancreatic malignant PANC-1 and MIA PaCa-2
cells, human breast non- malignant MCF-10A cells, and human prostate non-malignant
RWPE-1 cells were used to investigate the selectivity of the synthesized IZO NPs using the
tetrazolium dye MTT cell viability assay. The clonogenic assay was also used to probe the
long-term cytotoxicity of the IZO NPs for the aforementioned breast tumor and normal breast
cells. MTT assays revealed significant decreases in cell viability in all tested human
malignant cells in a dose dependent manner at concentrations ranging from 0 µg/mL to 200
µg/mL of IZO NPs for 24 hours exposure, while a high cell viability of more than 80%
remained in all tested human non- malignant cells under the same treatment conditions.
Regarding the long-term toxicity of IZO NPs, the clonogenic assays presented high
mortalities in both types of human breast tumor cells – MDA-MB-231 and MCF-7 cells, with
surviving fractions of 15% and 30%, respectively. In contrast, IZO NPs did not produce
noticeable cytotoxicity towards human breast non- malignant MCF-10A cells, with a
surviving fraction around 80%. These results demonstrate the high tumor-killing ability and
high selectivity of IZO NPs, showing the therapeutic capacity of this nanomaterial.
Interestingly, the cytotoxic results on MCF-10A cells from the clonogenic assay are
consistent with those from the MTT assay, confirming that IZO NPs are highly biocompatible
with breast normal cells. On the basis of these results, IZO NPs can be postulated to be highly
biocompatible with other human non-malignant cells that have not been tested through
clonogenic assay in this study.
The research work presented in this doctoral thesis underlines the importance of the
physicochemical and biological features of these two different types of indium-based
nanoparticles. Both of them present high toxicity in tumor cells, while IZO NPs produce no
noticeable cytotoxicity to normal cells, and the engineered-ITO NPs even offer significant
protection from ROS in normal cells. Engineered ITO NPs are of particular interest, as they
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are capable of remarkably increasing the ROS level in cancer cells but significantly reducing
it in normal cells, which can reduce systematic toxicity and can be possibly used for
treatment of other ROS related diseases. Moreover, ITO NPs can be used as a multimodal
imaging tool for fluorescent and CT imaging due to their innate fluorescence and high atomic
weight. Future work focusing on exploring the complete mechanism of the cytotoxicity with
reference to the physicochemical properties of both ITO and IZO nanomaterials on the
molecular level and in in vivo cytotoxic studies, will be critical in achieving the best
therapeutic capability for both nano-ceramic materials in cancer treatment.
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1.1 Background and Motivation
Cancer is one of the major public health problems worldwide and the second leading
cause of human mortality in the United States, with an estimated 1,762,450 new cancer cases
and over 600,000 annual deaths that are projected to occur in 2019 [1]. Figure 1.1 presents
the number of estimated new cancer cases and deaths for some of the most common cancer
types in the United States in 2019 [2].

Figure 1.1. The number of estimated new cancer cases and deaths for some of the most
common cancer types in the United States in 2019. The data were obtained from the
American Cancer Society [2], and have been revised and presented. Note that the breast
cancer data include both female and male.
To combat cancer, the use of chemotherapeutic drugs is the gold standard strategy as
they are toxic compounds and can inhibit the fast proliferation of the cancer cells [3]. One of
the most important mechanisms of chemotherapeutic drugs is generation of reactive oxygen
species (ROS), which then exceed the level of ROS that can trigger cellular apoptosis,
consequently resulting in cell death. Nevertheless, the current use of chemotherapeutic agents
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in cancer treatment has been hindered by low aqueous solubility, short biological half- life,
lack of cancer cell targeting, dose- limiting cellular toxicity, and the development of patient
multidrug tolerance [3]. Moreover, the currently used chemotherapeutic drugs often lack the
selectivity to differentiate between cancerous and normal cells, which leads to a variety of
side effects and eventually results in systematic toxicity [4]. These highlight the importance
of developing an alternative anticancer strategy, and a theranostic system that combines
diagnostic and therapeutic features seems to be a reasonable approach for developing a new
therapeutic strategy for cancer treatment.
Nanomaterials (1-100 nm) are making great and highly significant contributions to the
new strategy for developing anticancer drugs due to their distinct and versatile
physicochemical properties, endowed by their size, shape, crystal structure, surface properties,
and elemental composition. Many studies have reported that specifically engineered
nanoparticles (NPs) demonstrate higher therapeutic efficiency than those generally used
chemotherapeutic drugs alone, through providing enhanced drug protection, controlled drug
release, extended circulation, and improved targeting to diseased tissues [5-7]. Inorganic NPs
are of particular interest because, aside from the aforementioned advantages of NPs, they can
additionally provide

stimulus‐ responsive

functions originating

from their

unique

physicochemical properties, such as functions of thermal heating, magnetic resonance
imaging (MRI), and magnetic targeting, which individual drugs or other non-colloidal
molecules do not offer [5]. Additionally, many inorganic NPs can be designed and
formulated with incorporation of ligands or polymers to form multifunctional NP systems in
order to further enhance their biological functionalities [8]. Moreover, it is well known that
NPs can easily enter the tumor interstitial space and preferentially accumulate in solid tumor
tissue by the enhanced permeability and retention (EPR) effect [9]. Among a variety of
inorganic NPs, metal oxide NPs have attracted much attention. Metal oxide NPs, also known

3

CHAPTER 1 – Introduction
as ceramic NPs, show useful chemical, physical and bio-chemical properties that are
instrinsically combined, which make them ideal candidates for the design of perfect
multifunctional system or so-called theranostic systems, where one material possess all the
required imaging, therapeutic, and selective properties rather than using a complex assembly
of composite theranostic particles containing four different components such as a drug carrier,
a drug agent, an imaging agent, and a target vector [10-12]. Although nano-theranostic
systems have a variety of advantages, they are often complex and require complicated
processes for synthesis [13-15]. Therefore, a novel nano-theranostic system with low overall
complexity, chemical instability, and fabrication costs is highly desirable. Indium-based NPs
are easily engineered and synthesized and have been extensively applied in a variety of fields,
such as light-emitting diodes, displays, functional glasses, and solar cells [16-20]. They are
innately fluorescent and have a high atomic number, which could be used for the diagnostic
applications, and have never been well-explored as a theranostic agent for cancer treatment.
This research on indium-based NPs has provided comprehensive insights for some of the
work in this doctoral thesis and also triggered a strong motivation to engage in this work.
Therefore, the aim of this work is to engineer and synthesize indium-based
theranostic NPs and to study the different indium-based ceramic NPs with a focus on the
characterization of their physicochemical properties and on exploration of their cytotoxic
effects, selectivity, and biomedical potentials in the field of cancer therapy.

1.2 Thesis Structure
For the purpose of developing and studying different indium-based NPs, detailed
structural characterizations and physiochemical measurements were carefully performed.
Moreover, the biological interactions between indium-based NPs and a number of malignant
and non- malignant cells have been characterized and investigated in this work in order to
further their application in cancer therapy. The scope of this thesis work is briefly outlined as
4
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follows:
Chapter 1introduces the research background and motivation for this doctoral thesis,
and outlines its structure in detail.
Chapter 2 provides a comprehensive review on the fundamentals of cancer, and an indepth look at the key idea for a variety of theranostic systems is also described. A literature
review on different nanomaterials for the development of various theranostic systems and
their functions of diagnostics, therapeutics, and targeting for cancer treatment is presented. A
brief introduction to some indium-based NPs is also included.
Chapter 3 presents the detailed preparation methods for the different indium-based
nanomaterials studied in this thesis work, as well as the various structural, physiochemical,
morphological, and biological in vitro characterization techniques that have been used in this
work.
Chapter 4 investigates air-calcined tin doped indium (ITO) NPs regarding their
physicochemical properties, cytotoxicity, and selectivity towards human breast cancer MCF7 cells, gliosarcoma 9L cells, and normal Madin-Darby canine kidney (MDCK) cells in vitro.
Chapter 5 focuses on the development of a ceramic nano-theranostic system based on
an ITO nanomaterial, which demonstrates the controlled generation and prevention of ROS
that can differentiate between malignant breast MDA-MB-231 and MCF-7, and nonmalignant breast MCF-10A cells, showing its selective killing ability towards tumor cells and
its capablity of protecting normal cells. The biological activity, and the fluorescent and
contrast-enhancing properties of the system are all studied in vitro.
Chapter 6 investigates zinc doped indium oxide (IZO) NPs regarding their
physicochemical properties, cytotoxicity, and selectivity towards human malignant breast
MDA-MB-231 and MCF-7 cells, human malignant pancreatic PANC-1 and MIA-PACA-2
cells, human non- malignant breast MCF-10A cells, and human non- malignant prostate
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RWEP cells in vitro.
Chapter 7 contains the general conclusions summarized from the work in this doctoral
thesis and provides future prospects for further research on the indium-based NPs.
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2.1 General Cancer Characteristics
2.1.1 The Difference between Normal and Cancer Cells
Cancer, or malignant tumor, is a group of genetic diseases defined by the
uncontrollable, rapid proliferation, and immortal reproduction of abnormal cells that are
capable of invading surrounding healthy tissues and can metastasize to remote sites in the
body [1-3]. In contrast to normal cells, cancer cells may have gene or chromosome mutations
that provide the cancer with the ability to control of its own growth signals and to ignore the
anti-growth signals from the surrounding normal cells to undergo programmed cell death or
apoptosis, which eventually results in uncontrollable reproduction and division of the cancer
cells [4]. Furthermore, cancer cells are unspecialized and can continuously activate
angiogenesis even when growth is not necessary. They also lack the adhesion molecules that
cause stickiness, which provides them with the ability to travel via the bloodstream and
lymphatic system to any part of the body [5]. Moreover, unlike normal cells, cancer cells are
able to invade nearby tissues and are capable of evading the immune system long enough, by
either escaping detection or by secreting chemicals that inhibit immune cells, to grow into a
tumor [5]. Table 2.1 presents some of the key differences between normal and cancer cells.
Table 2.1. Key differences between normal and cancer cells, adapted from [4].
Normal Cell

Cancer Cell

Uniform

Irregular

Spheroid shape, single nucleus

Irregular shape, multi-nucleation is common

Chromatin

Fine, evenly distributed

Coarse, aggregated

Nucleolus

Single, inconspicuous nucleolus

Multiple, enlarged nucleoli

Cytoplasm

Large cytoplasmic volume

Small cytoplasmic volume

Controlled

Uncontrolled

Mature into specialized cells

Remain immature and undifferentiated

Normal angiogenesis
(occurs during development/ healing)

Normal angiogenesis
(occurs during development/ healing)

Cell shape
Nucleus

Growth
Maturation
Blood supply
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Oxygen

Favoured (for aerobic respiration), but
will undergo anaerobic respiration if
required

Not required
(thrive in hypoxic conditions),
favour anaerobic respiration

Location

Remain in their intended location

Can spread to different locations in the body
(metastasis)

2.1.1.1 Development of a Cancer
Cancer is a group of diseases caused by genetic mutations. As mutations accumulate
in a given cell, there are changes leading to progressive loss of regulation of the cell cycle,
differentiation, and cellular biological interactions. These changes are accompanied by
progressive abnormalities in the morphology of the cells [6]. Hyperplasia, the first
progression of evolution of a cancer, is characterized by an increase in the number of mutated
cells that are likely to divide faster than normal cells, but the morphology of the cells and
their relationship to one another remains normal [6]. Dysplasia, is defined as the growth of
cells with abnormal proliferation that present a distinctly abnormal and variable appearance.
Without treatment, the abnormal cells will keep developing into a cancerous s tructure,
although they are still confined to the epithelial layer from which they arose, so that they are
thus called a cancer in situ. The in situ cancer may acquire further mutations, gain the ability
to invade neighboring tissues, and be able to transmit cells into the blood or lymph. Such a
tumor is therefore defined as an invasive (malignant) cancer [6]. Different progressive stages
in cancer development from normal cells to invasive cancer cells are illustrated in Figure 2.1
[6].
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Figure 2.1. The evolution of cancer, adapted from [6]. Normal cells go through different
progressive stages (hyperplasia and dysplasia) to form cancer cells, and eventually become
invasive cancer cells.
2.1.1.2 Cancer Metastasis
Metastasis is defined as the phenomenon in which cancer cells spread from their
primary location (where the cancer began) to another region of the body. Cancers can
metastasize to nearly any part of the body, but some of the more common sites are the bones,
lungs, liver, and brain [7]. Cancer cells can spread because they lack some adhesion
chemicals that keep different cells together in their proper region, and they usually travel
through the bloodstream, the lymphatic vessels, the airway (lung cancer), or locally [7].
Metastasis is a critical characteristic used to differentiate malignant (cancerous) tumors from
benign (non-cancerous) tumors [7]. Some benign tumors can grow to be quite large and cause
significant problems, even though these tumors do not spread to other regions of the body [7].
Figure 2.2 shows how the cancer spreads throughout the body [8].
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Figure 2.2. Schematic diagram illustrating how cancer cells spread throughout the body.
Adapted from [8].

2.1.2 Risk Factors for Cancer
Cancer is a genetic disease caused by inherited gene mutations or by many of other
external factors that alters the genes, which is schematically displayed in Figure 2.3 [9].
Generally, there are 3 categories of main external factors that activate genetic mutations,
which include [9]:


Physical carcinogens: ultraviolet (UV) and ionizing radiation.



Che mical carcinogens: components of tobacco smoke, aflatoxin (a food
contaminant), some heavy metals such as arsenic (a drinking water contaminant),
heterocyclic amines (HCAs), and polycyclic aromatic hydrocarbons (PAHs).



Biological carcinogens: infections by certain viruses or other microorganisms.

There are some other factors that can also cause cancer, including obesity, alcohol
consumption, angiogenesis and dietary inhibitors of angiogenesis, and AIDS-related cancers
(an indirect cause of cancer) [6].
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Figure 2.3. Cancer is caused by certain changes or mutations to genes, the basic physical
units of inheritance, which are arranged by pairing of nucleotide bases to form long strands of
tightly packed DNA, and are found in nucleus. Adapted from [10].
The genetic changes that drive the development of cancer generally affect three main
types of genes: proto-oncogenes, tumor suppressor genes, and DNA repair genes [10]. Protooncogenes are involved in the reproduction and replication of normal cells, but may become
cancer-causing genes (or oncogenes) once mutations are acquired, resulting in uncontrolled
cells growth and survival [10]. Tumor suppressor genes are also involved in the controlled
reproduction and replication of cells. Alterations in tumor suppressor genes may lead to
uncontrolled cell division [10]. DNA repair genes are responsible for fixing damaged DNA,
and mutations in these genes generally lead to the development of additional mutations in
other genes [10]. Figure 2.4 illustrates how carcinogens induce a transformation from normal
cells into malignant cells, a process that is called carcinogenesis [10].
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Figure 2.4. Schematic diagram illustrating how the carcinogens and inherited gene mutations
induce a transformation from normal cells into malignant cells. Adapted from [6].

2.1.3 Types of Cancer
There are more than 100 different types of cancer, and cancer types are typically
named for the organ, tissue, or cells where they arise [11]. A list of cancer types categorized
by where they originate and develop is described as follows [10, 11]:


Carcinoma: cancer arises in epithelial tissue, which covers the outside of the
body, such as the skin, and lines organs, vessels, and cavities.



Sarcoma: cancer develops in muscle, bone, and soft connective tissues, including
adipose tissue, blood and lymph vessels, tendons, and ligaments.



Leukemia: cancer originates in bone marrow cells forming white blood cells.



Lymphoma: cancer develops in white blood cells called lymphocytes, and
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typically affects B cells and T cells.


Melanoma: cancer arises in melanocytes and is typically formed on pigmented
tissues, such as the skin and the eye.



Myeloma: cancer originates from plasma cells in bone marrow and forms tumors
in bones.



Germ cell tumors: Cancer originates from germ cells.

2.1.4 Current Anticancer Treatment and Cancer Prevention
There are many types of cancer treatment. Depending on the location, distribution,
size, complexity, and cell type of the tumor, different types of cancer treatments are carefully
selected for implementation on patients. The typical main types of current cancer treatment
include:


Cancer surgery (Surgical treatment)



Radiotherapy



Chemotherapy

Surgery is the main option in the treatment of many cancerous tumors, particularly for
a tumor that is in early stage and is easy to reach [12]. The goal of surgery to treat cancer is to
remove the cancerous tumor and the healthy tissue surrounding it to prevent the further
spread of the local tumor [12]. Common risks associated with cancer surgery are pain,
bleeding, and infection [10].
Radiotherapy uses high energy, ionizing radiation to destroy cancer cells and to
reduce tumor by damaging the structure of dividing cells [12]. Cancer cells typically replicate
faster than in normal tissue, and thus, they are particularly vulnerable to radiotherapy [12].
The importance of radiotherapy in cancer treatment is increased, because by combination
with other cancer treatments, a synergistic effect can be realized and improved treatment
outcomes can be achieved [12].
15

CHAPTER 2 – Literature Review
Chemotherapy is the use of highly-effective cytotoxic drugs to destroy tumors,
improve the outcomes of surgery or radiotherapy, and reduce metastases [12]. The cytotoxic
chemotherapeutic drugs are transported in the bloodstream to various parts of body, and can
inhibit cell division to cause cancer cells to die [12]. Chemotherapeutic drugs affect all
dividing cells, however, including those of healthy tissue, so they are usually associated with
many side effects, such as nausea, diarrhea, and fatigue [12]. Several types of cytotoxic drugs
are used together in cancer therapy that have different kinds of effects, and the effectiveness
of chemotherapy depends on the type of tumor, tumor composition, rate of growth, and
proportion of cells in the metastatic stage [12].
Aside from those typical therapies, a number of new applied treatments are
undergoing

vigorous

development,

such

as

hormone

therapy,

targeted

therapy,

immunotherapy, antibody therapy, and interferon therapy [12].
Cancer prevention relates to a number of actions taken to control the risks of cancer,
and there are many ways to prevent cancer, including [10]:
•

Evasion of the known factors that cause cancer;

•

Changes in diet and lifestyle;

•

Early detection of precancerous condition;

•

Chemoprevention (treatment of a precancerous condition or medicine used to keep
cancer from starting);

•

Risk-reducing surgery.

2.2 Nanomaterials for Cancer Treatment
2.2.1 Definition of Nanotechnology and Nanomaterials
Nanotechnology is the creation and utilization of materials, devices, and systems
through the control of matter on the scale of 10-9 meter, which involves a combination of
many fields, such as biotechnology, materials science, computer science, medicine, pharmacy,
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and engineering [13, 14]. Nanotechnology makes it possible to create novel materials for
biomedical applications with a particular emphasis in therapy and diagnostics, and such
materials are commonly known as nanomaterials [15]. Nanomaterials are generally
characterized as materials fabricated with nanoscale dimensions between 1 and 100 nm
(Figure 2.5 [16]), and they have unique and versatile physicochemical properties that are
attributable to their size, shape, surface characteristics, mechanics, elemental composition,
and crystal structure [17-19]. Due to the unique physical and chemical properties of
nanomaterials, a new emerging field of research aimed at the development of biomedical
applications based on nanomaterials has recently become prominent.

Figure 2.5. Comparison of nanosized materials (yellow region) with other everyday objects
and organisms. Adapted from [16].
Nanomaterials are widely applied in a number of fields, such as the solar energy,
catalysis, display, and cosmetics industries [20-27]. Furthermore, nanomaterials are versatile
agents with a number of biomedical applications, including their uses in biosensors [28, 29],
labelling and imaging [30-32], targeting [33-35], and drug and gene delivery [36-39]. In
addition, there is an increased trend of releasing nanomaterials into the ecosystem owing to
the fast growing industrial applications of engineered nanomaterials, and therefore,
nanomaterials are thoroughly evaluated for their potentials of eco-, geno-, and cytotoxicity
[40-42].
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Engineered nanoparticles (NPs) are usually designed to deliver and enhance the drug
concentration inside the cancer cells through both active and passive targeting [43]. More
significantly, due to the rapid growth of numerous tumor tissues, tumors commonly present
with defective vasculature and poor lymphatic drainage, resulting in an enhanced
permeability and retention (EPR) effect, which allows the NPs to accumulate preferentially at
the tumor site, making NPs excellent tumor-targeting vehicles [43].

2.2.2 Definition of a (Multifunctional) Theranostic System
The term “theranostics” is defined as a field of medicine relating to proposed single
nanosized platforms that combine therapeutic and diagnostic modalities [44], although,
besides these two fundamental characteristics, a theranostic system can integrate even more
functionalities, such as drug carrying and targeting to become a multifunctional theranostic
system, as illustrated in Figure 2.6 [45].
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Figure 2.6. The various functional components of a theranostic system. Adapted from [45].
The aim of a multifunctional theranostic system is to perform multimodal synergistic
therapy, which is defined as cooperation among various different treatments that are
integrated into a single nanoplatform, which produces much stronger therapeutic effects than
the mere combination of the corresponding individual treatments [46].
Theranostic systems offer several remarkable advantages over small individual
molecular probes in biomedical applications; firstly, through a simple surface modification by
proteins, peptides, and other biomolecules, a threanostic system could be rendered the ability
to reduce nonspecific uptake from the reticuloendothelial system (RES) and to further
specifically bind to overexpressed tumor cell receptors fo r enhanced accumulation [46-49].
Secondly, theranostic systems are excellent carriers due to their the unique surface features,
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which enable them to efficiently entrap high payloads of drugs, genes, and other therapeutic
compounds and can protect them from enzymatic degradation in the complex physiological
microenvironment [46, 50]. Furthermore, specially designed theranostic systems are able to
control the release of the loaded therapeutic compounds though a variety of internal and
external stimuli (e.g., pH, Glutathione, light, etc.) [51, 52], which avoid premature drug
release in healthy tissues and reduce the potential side effects [46]. Moreover, the sizes of
theranostic systems can be precisely tailored, and their tissue accumulation can therefore be
carefully controlled [53].

2.2.3 Nanomaterials Used for Building Theranostic Systems
Generally, theranostic systems can be fabricated using two basic types of
nanomaterials – organic and inorganic nanomaterials as displayed in Figure. 2.7 [54, 55]. By
using the distinctive architectures and the innate functionalities of these nanomaterials, a
variety of theranostic systems can be built to achieve multimodal synergistic effects in cancer
treatment [55].

Figure 2.7. Examples of different types of nanoparticles made from organic and inorganic
materials. Adapted from [54].
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To be noted, although carbon-related compounds suppose to be categorize into
orgainc materials, in this chapter, only the pure polymer-based nanomaterials were classified
as organic materials, and the carbon-based nanomaterials were categorized into inorgainc
materials based on their functionality.
2.2.3.1 Organic Nanoparticles
Organic or polymeric nanomaterials provide a variety of advantages, such as their
versatile surface and core chemistry, high degree of biodegradability, effective endocytosis
by the target cell and high payload loading efficiency, making them attractive building blocks
for the design of theranostic NPs [55, 56]. Significantly, polymeric nanomaterials can be
designed to react in response to a number of stimuli, such as temperature, pH value, light, and
applied electrical or magnetic field [57]. Their stimulus-responsive features make such
polymeric nanomaterials superior candidates for the construction of promising theranostic
systems.
Organic NPs can roughly be divided into several types, which include polymeric NPs,
polymeric micelles, liposomes, and dendrimers [53].
Polymeric NPs can be further characterized as either nanospheres or nanocapsules
[54]. The nanospheres consist of a solid polymer matrix that enables them to encapsulate
hydrophobic drugs. In contrast, nanocapsules are more suitable for loading with hydrophilic
compounds such as DNA/RNA due to the properties of their aqueous hydrophilic core [58].
The payload flexibility increases the versatility of polymeric NPs, and the polymeric NP-improved
payload stability provides a constant drug release rate, making these nanomaterials attractive
candidates as nanocarriers [54, 59].
Polymeric micelles (PMs) are spherical, nano-sized colloidal particles with a core of
aggregated hydrophobic polymers linked with hydrophilic polymeric chains that form a shell
[53, 54, 60, 61]. Their hydrophobic core enables them to safely entrap hydrophobic drugs,
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enhancing safety when they are transported throughout the body. Their small size and
hydrophilic feature allow them to avoid rapid renal excretion, significantly increasing their
circulation time [53, 54].
Liposomes consist of natural lipids with hydrophilic and hydrophobic components which
self-assemble into colloidal particles. Generally, they have an aqueous core that enables them to
effectively encapsulate water-soluble drugs and various small bioactive molecules, such as
enzymes and nucleic acids [62, 63]. Their hydrophobic lipid bilayer also allows the
entrapment of small lipophilic bioactive compounds [64, 65].
Dendrimers are characterized by highly branched three-dimensional polymer
complexes [66-68]. They could load drugs, gene, and other small bioactive molecules through
electrostatic interactions, encapsulation, and covalent conjugations, which are attributed to
their high density of the surface functional groups that exist in their natural internal cavities.
This functionality makes them attractive carriers for cancer therapeutics.
2.2.3.2 Inorganic Nanoparticles
Inorganic NPs exhibit versatile unique properties, such as photochemical,
photothermal and magnetic properties that make them attractive for theranostic applications.
Furthermore, their rigid outer surface and durable core are useful for making various vectors
for a number of drugs or active agents [55]. Due to these excellent properties, a number of
inorganic-based nanomaterials have been extensively explored in the field of cancer therapy,
including silica-based NPs, carbon-based nanomaterials, quantum dots, metal NPs, magnetic
NPs, metal oxide based NPs, and lanthanide-doped NPs.
Silica-based NPs are a kind of ceramic nanomaterials and have been extensively
developed and studied. Silica-based NPs can generally be categorized into two types, one is
solid silica NPs (SiNPs), and the other is mesoporous silica NPs (MSNs) [53]. SiNPs are
biocompatible and photophysically stable, with favorable colloidal properties, which make
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them excellent optical imaging contrast agents for biomaging applications [55]. In addition,
the particle surface of SiNPs can be modified with a series of functional groups such as
aptamers and antibodies, making them attractive drug delivery carriers [69, 70]. MSNs are
applied as excellent drug delivery vehicles due to their unique properties, such as their stable
and rigid frameworks, high surface area to volume ratio with abundant pore volumes, and
controllable pore sizes. [55, 70-73].
Carbon-based nanomaterials, including carbon nanotubes (CNTs), fullerenes and
graphene, can be designed as nanocarriers for drug delivery and as contrast probes for
biomedical imaging due to their unique electronic properties, high biocompatibility, high
surface area to volume ratio, good thermal conductivity and rigid structural properties for
post-chemical modification [53, 74, 75]. In addition, due to their unique thermal conductivity
and optical properties, they can also be used for the development of the nanothermal cancer
therapy, killing cancer cells through local hyperthermia [76].
Quantum dots (QDs) are mostly semiconductor nanocrystals with a tunable particle
size ranging from 2-100 nm, which enables their fluorescent emission to be tuned to any
wavelength between blue and infrared depending on their size dependent optical properties [77].
QDs are much brighter than organic dyes and they are exceptionally photochemically stable,
which make them excellent long-term imaging agents [77, 78]. QDs could act as either photosensitizers or as an activator for another photo-sensitizer as an energy supplier in
photodynamic therapy (PDT) [53, 79].
Gold nanoparticles (AuNPs) can be fabricated in a variety of shapes, such as
nanospheres, nanorods, nanoshells, and nanocages. Due to their unique size dependent
physicochemical and optical properties, they are widely applied in labeling, computed
tomography (CT) imaging, photothermal therapy, radiotherapy, biosensing, drug delivery,
and combined imaging and therapy in cancer treatment [80-85].
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Various types of magnetic nanomaterials such as metal NPs (Fe, Ni, Co), metal alloy
NPs (FePd, FePt), and metal oxide NPs, have been widely evaluated for their magnetic
properties [86]. Among them, iron oxides are of particular interest due to their great potential
in the fields of magnetic separation and biomedical applications [86]. Magnetic nanoparticles
are promising in many biomedical applications, which include cell labeling [87], targeted
drug delivery [88-90], magnetic resonance imaging [91, 92], and cancer magneto-thermal
therapy [93-96]. The versatile functionalities of magnetic NPs make them excellent building
blocks for the construction of theranostic systems.
Lanthanide-doped NPs are a class of fluorescent NPs, which enable low energy light
such as near infra-red (NIR) to be converted to and emit high energy visible or ultraviolet
(UV) light [55]. This upconversion effect originating from the intrinsic properties of
lanthanides yields long-lasting luminescence, making them an excellent candidate for
photodynamic therapy in cancer treatment [97-99].
2.2.3.3 Hybrid Nanoparticles
Hybrid NPs that are composed of both organic and inorganic components can be
fabricated to form a variety of core-shell structures [100]. Typically, the inorganic core of
hybrid NPs can provide imaging and/or therapeutic modalities, while the organic shell
enables further functionalization with bioactive compounds, including antibodies, therapeutic
drugs, and other polymers. [101, 102]. A schematic diagram of a typical hybrid nanoparticle
is presented in Figure. 2.8 [102].
Organic and inorganic combined hybrid nanoparticles are able to fulfill a variety of
different theranostic purposes, including the controlled release of multiple therapeutic drugs,
as well as targeting and imaging capabilities [100]. Moreover, through the beneficial features
of the integrated polymer component, hybrid NPs show improved dispersion stability and
biocompatibility [103, 104]. In addition, like the polymeric nanomaterials discussed in
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section 2.2.3.1, the hybrid NPs can be designed to keep the stimulus-responsive features
originating from their polymer component. These attractive characteristics make hybrid NPs
a promising nanomaterial for building multifunctional theranostic systems.

Figure 2.8. Schematic diagram of a hybrid nanoparticle. Hybrid nanoparticles can be
fabricated to form core shell structures. The shell-surface of nanoparticles can be engineered
with a variety of antibodies and polymers to achieve targeting capability and improved
biocompatibility. The interior core of nanoparticles can be encapsulated or integrated with
various bioactive compounds to realize different theranostic purposes [102]. Scale of the
molecules is not shown. Adapted from [102].
Generally, to form organic and inorganic combined hybrid nanoparticles, two
methods are used to apply surface coatings of polymers onto the inorganic core [105]. One
method is physical surface coating, where the functional polymers are bonded onto the
inorganic core through physical adsorption, and can further react to form a complete shell
[106]. The major drawback of this technique is that such adsorbed polymer layers are
vulnerable to removal [105]. Another approach is chemical surface coating, where the
inorganic core provides reactive sites to covalently bond to the polymers, and to further form
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a homogeneous shell [107]. This method generally offers enhanced adhesion between the
inorganic core and polymer shell [105].

2.2.4 Therapeutic Effect and Mechanism of Nanoparticles
A variety of anticancer drugs have shown therapeutic effects, making them excellent
building blocks for theranostic systems, although the effectiveness of currently used
chemotherapeutic drugs has suffered from a range of confounding factors, including systemic
toxicity due to a lack of specificity, rapid drug metabolism, and both intrinsic and acquired
drug resistance [108, 109]. These highlight the importance of developing an alternative
anticancer strategy.
Conventional chemotherapy typically uses anticancer drugs to affect the cell cycle or
to induce apoptosis in cancer cells. It is well known that drug- induced reactive oxygen
species (ROS) generation can activate apoptosis in cancer cells, and therefore, ROS-induced
activation of cancerous apoptosis has been developed as a novel strategy for cancer treatment
[110, 111]. Many studies have demonstrated that a variety of NPs exhibit anticancer
capability through the mechanism of apoptosis pathways triggered by NP-induced generation
of ROS [112-114].
2.2.4.1 Definition and Classification of Reactive Oxygen Species
Oxidative stress is a global damaging mechanism that exists in all biological systems,
and is caused by an imbalance between the production of ROS and a biological system‟s
ability to readily detoxify the reactive intermediates or easily repair the resulting damage.
Free radicals can be defined as species containing at least one unpaired electrons in their
outermost atomic orbital and are able to exist independently, but the odd number of electron(s)
of free radicals make them unstable, short- lived, and highly reactive [115]. ROS and relative
nitrogen species (RNS) are the terms collectively used to describe reactive oxygen and
nitrogen derived free radicals, respectively, and both can be categorized into two groups:
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radicals and non-radicals, as listed in Table 2.2 [116].
Table 2.2. Examples of different types of reactive oxygen species and reactive nitrogen
species, adapted from [116].
Free oxygen radicals

Symbol

Non-radical reactive oxygen species

Symbol

Superoxide

O2 •-

Hydrogen peroxide

H2 O2

Hydro xy l

OH•

Singlet oxyge n

1O
2

Alkox yl radical

RO•

Ozone

O3

Peroxyl Radical

ROO•

Organic peroxide

ROOH

Hypochlorous acid

HOCl

Hypobromous acid

HOBr

Free nitrogen radicals

Symbol

Non-radical reactive nitrogen species

Symbol

Nitric oxide

NO•

Perox yn itrite

ONO O -

Nitrogen dioxide

NO2 •

Nitrous acid

HNO2

Peroxynitrous acid

ONOOH

Nitro syl cation

NO

Nitro xy l anion

NO -

Dinitrogen trioxide

N2 O3

Dinitrogen tetraoxide

N2 O4

Nitryl chloride

NO2 Cl

+

Note: R represents an abbreviation for an R group, which is a group that contains carbon and hydrogen atoms
attached to the rest of the molecule.

2.2.4.2 Biological Significance of Reactive Oxygen Species
ROS are significant biological molecules; cellular production of ROS plays a very
significant positive role in physiological responses in a number of cases, such as oxygen
sensing, angiogenesis, control of vascular tone, and regulation of cell growth, differentiation,
migration, and programmed cell death or so called apoptosis [117, 118]. ROS also plays very
important role in cell signaling processes (known as redox signaling), and a basal ROS level
is essential for cell homeostasis [119, 120], Moreover, ROS generated by the human body
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can be one of the major defense mechanism against disease [119, 121].
Excessive ROS that cannot be eliminated by the biological antioxidant system will
lead to oxidative stress damages to all cell components, such as protein oxidation, lipids
peroxidation, and deoxyribonucleic acid (DNA) damage [117, 122, 123]. It has been revealed
that oxidative stress is involved in many human diseases, including Alzheimer‟s disease,
Parkinson‟s disease, diabetes, inflammation disorders, cancer, and so on [118, 124-126].
Typically, in comparison with their normal counterparts, cancer cells have incre ased levels of
endogenous ROS, which may support tumor growth and progression. In addition, such
increased levels of ROS in cancer cells are assoc iated with their capabilities towards drugs
resistance [127].
Although imbalanced ROS could lead dysfunction o f normal cells and cause cancer,
novel cancer therapeutic strategies also use ROS as a weapon to destroy cancer cells through
the activated mitochondrial apoptosis pathway [128]. Such strategies aim to apply ROSgeneration agents and antioxidants to increase ROS production and to inhibit elimination of
ROS in cancer cells, which will promote ROS accumulation in such cells, reduce the drug
resistance, and enhance cancer-cell cytotoxicity. [127].
Although some ROS-generation agents show promising therapeutic effects both in
vitro and in vivo, challenges still remain in understanding the underlying mechanism of ROS
production, and future research towards understanding this mechanism and the toxicity of
these agents is essential [127].
2.2.4.3 Nanoparticles Functioning as Reactive Oxygen Species Generators
Due to their unique and versatile physicochemical properties, various nanoparticles
can be engineered or designed to function as selective ROS-generation agents in cancer cells,
where the production of ROS can be directly induced by the NP itself or indirectly by
external stimulation agents applied on the NPs, which will then promote ROS generation.
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ZnO NPs have been demonstrated to have selective cytotoxicity towards breast cancer
MCF-7, prostate cancer PC-3, and glioma cells (LN18 and LN229) through apoptosis
activated by ROS generation induced by ZnO NPs, while they exhibit only slight harm to the
normal counterpart MCF-10A, RWPE-1, and astrocyte cells [113]. It has been shown that
ZnO NPs are able to selectively induce ROS generation in human liver cancer HepG2 and
human lung adenocarcinoma A549 cells, which activates apoptosis and kills those cells,
while no cytotoxic effects on primary rat hepatocytes and astrocytes cells was observed [114].
Studies, both in vitro and in vivo, also show that cuprous oxide NPs could selectively
activate the apoptosis of melanoma tumor cells through ROS generation [111, 112].
It has been reported that iron oxide nanoparticles (NPs) can transform near- infrared
radiation (NIR) or an oscillating magnetic field (MF) into toxic stimuli to promote ROS
generation, and to further induce apoptosis of MCF-7 and Caco-2 human tumor cells [110].
Silver NPs (AgNPs) have also been shown to display cytotoxicity in different cancer
cells. A recent report has shown that AgNPs could induce MDA-MB-231 cell death through
ROS generation, activation of caspase 3, and DNA fragmentation [129]. AgNPs were
observed to cause a dose-dependent reduction in the mitochondrial function of human
adenocarcinoma A549 cells, which depletes the antioxidant defense mechanism of the cells,
leading to ROS accumulation, and ultimately results in apoptotic and necrotic cell death
[130].
2.2.4.4 Nanoparticles Functioning as Reactive Oxygen Species Scavengers
As discussed in section 2.2.4.2, excessive ROS can cause cell damage, and lead to
development of a number of diseases. Therefore, NPs that possess anti-oxidative properties
and can function as ROS-scavenging agents for therapeutic purposes are highly in demand in
the advanced life sciences for the improvement of quality of life and longevity [131].
There are a variety of different NPs that possess long-lasting antioxidant properties,
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including: carbon nanomaterials such as fullerenes and their derivatives [132-134], non-toxic
metal NPs such as gold, platinum, and silver [135-137], metal oxide NPs such as cerium
oxide (ceria) [138, 139], yttrium oxide (yttria) [140], and aluminium oxide (alumina) [141],
as well as other organic-polymer nanoparticles [142-144]. Among these particular NPs,
cerium oxide NPs (CONPs) are the most typical anti-oxidative NPs and have been
extensively investigated.
CONPs have a unique feature, coexistence of both +3 and +4 oxidative states on the
surface, and are capable of carrying out redox reactions due to their sufficient surface oxygen
deficiencies which are determined by their particle size. This feature makes CONPs
advantageous compared to other NPs [131]. The potential for the redox reactions where the
Ce3+ and Ce4+ ions can be autoregenerated is strongly dependent on the size of the nanoceria.
For instance, when the size of the CONPs is decreased, the ratio of Ce3+ will increase, which
enhances their reducing potential [131, 145]. It is well known that CONPs are capable of
mimicking both superoxide dismutase (SOD) and catalase activities to scavenge superoxide
free radicals and to break H2 O2 into molecular oxygen and water, hence protecting cells from
oxidative damage [122, 146-149]. Such antioxidant and catalytic properties are believed to be
mediated by surface area and by oxygen vacancies on ceria nanostructures with different
Ce3+/Ce4+ ratios [150-153].
Figure 2.9 [154] displays the postulated model for the SOD- like mechanism that is
used by CONPs to dismutate superoxide. As illustrated in Figure 2.9, where (4) is the original
state, superoxide can bind to the oxygen vacancy sites with two Ce3+ on the surface of
CONPs (5). Next, a Ce3+ is oxidized to Ce4+, transporting an electron to an oxygen atom, and
two protons from the environment bind to the two electronegative oxygen atoms to form
one molecule of H2 O2 , which is released (6). A second superoxide molecule can bind to
the remaining oxygen vacancy (7), repeating the reaction once again. After completing the
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second round of reaction, a second H2 O2 is released, and the 2Ce3+ will be oxidized to
2Ce4+ (1). An oxygen vacancy site with a 2Ce4+ binding ligand on the surface of a CONP
allows the binding of one molecule of H2 O2 (2). Here, the H2 O2 plays the role of a
reducing agent. After releasing protons, the 2Ce4+ will be reduced back to 2Ce3+ (3) by
receiving electrons. Finally, an oxygen is released and the fully reduced oxygen vacancy
site returns to its initial state (4) [154, 155].

Figure 2.9 A model of the SOD-like mechanism that is performed by cerium oxide
nanoparticles (CONPs) to dismutate superoxide. Adapted from [154].
Figure 2.10 [154] demonstrates a possible model of the catalase- like mechanism for
the complete dismutation of hydrogen peroxide that is performed by CONPs. The overall
reaction mechanism can be split into two half-reactions, namely the oxidative half reaction
and the reductive half reaction. Figure 2.10 (1 – 4) shows the oxidative half reaction. One
molecule of H2 O2 binds to the surface oxygen vacancy site and reacts with Ce 4+, reducing it
to Ce3+ and releasing protons and O 2 . Figure 2.10 (4 – 6 – 1) displays the reductive half
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reaction, where a second H2 O2 molecule could bind to the oxygen vacancy site (5), oxidizing
the Ce3+ back to the initial Ce4+ state and releasing H2 O [154, 155].

Figure 2.10. A model of the reaction mechanism that is carried out by cerium oxide
nanoparticles (CONPs) to completely dismutate hydrogen peroxide. Adapted from [154].
In addition, CONPs can act as a radioprotectant due to the ir free-radical scavenging
properties, which originate from shifting oxidation states from Ce3+ to Ce4+ [131]. An in vivo
study has reported that CONP acts as a radioprotectant to prevent radiation- induced
dermatitis, and to decrease xerostomia in athymic nude mice after head and neck radiation
[156]. It has also been reported that CONPs treated with normal human breast cell lines and
human breast tumor cells (MCF-7) exhibit very high protection of normal cells from
radiation- induced cell death, while no protection of tumor cells is observed [139]. Overall,
the unique anti-oxidative and radio-protective properties make CONPs one of the most
attractive subjects in life science.
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2.2.5 Chemotherapeutic Drugs
Many chemotherapeutic drugs have been developed and currently available, such as
daunorubicin, doxorubicin,

leucovorin,

vincristine,

irinotecan, 5- fluorouracil, etc.

Nevertheless, individual use of the single anticancer drug often results in poor therapeutic
efficacy, and thus, many approaches that combine the use of multiple anticancer drugs with
the aim of maximizing the therapeutic effects have been developed. A study of metastatic
colorectal cancer showed that a triple-drug therapy combining irinotecan with fluorouracil
and leucovorin benefited patients with higher rates of tumor reduction and longer
progression-free survival [157].
The currently used chemotherapeutic drugs still have various side effects due to
difficulties in differentiating between cancerous and normal cells, which eventually result in
systematic toxicity [108]. Cardiotoxicity is being reported as a consequence of cancer
therapies [158, 159]. Moreover, hepatotoxicity has also been reported as a side effect for
some chemotherapeutic drugs [160]. These all highlight the importance of developing for an
alternative anticancer strategy, and the development of theranostic systems with
combinations of different therapies could be a novel approach.

2.2.6 Modalities of Diagnostics and Imaging for Bio-applications
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Figure 2.11. Overview of typical molecular imaging modalities and representative
instruments for biomedical applications. Adapted from [161, 162].
2.2.6.1 Optical Imaging
The principle of optical imaging is the detection of photons emitted from
bioluminescent or fluorescent probes, and it is one of the more common modalities used in
research [161]. One of the advantages of optical imaging over other imaging modalities that it
is a relatively inexpensive way to detect low energy photons. Furthermore, even without
exposure to ionizing radiation, the broad optical spectrum from visible to near- infrared (NIR)
light provides good spatial resolution for imaging [161]. Optical imaging, however, suffers
from tissue autofluorescence and light absorption from the environment [163], tissue
scattering of photons in the visible light range (395 – 600 nm), and poor tissue penetration (0
- 2 cm) [164]. Despite these challenges, the NIR window (700 - 900 nm) used for optical
imaging provides an opportunity to reduce autofluorescence, reduce tissue scattering, and
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enhance tissue penetration, which makes it most suitable for in-vivo imaging [161].
2.2.6.2 Computed Tomography
X-ray computed tomography (CT) is one of the most e xtensively used imaging
modalities in diagnostic medicine due to its many advantages, including cost-effectiveness,
deep tissue penetration, and high resolution [165-167].
The basic principles of spiral CT scanning are illustrated in Figure 2.12 [168]. In brief,
a motorized table moves the patient through the CT imaging system, and simultaneously, a
source of X-rays rotates in synchrony, with multiple rows of X-ray detectors positioned
directly opposite the radiation source. The X-ray source produces a narrow, fan-shaped beam,
and the table moves continuously as the X-ray source and detectors rotate, producing scanned
data in the form of spiral path relative to patient. All the data are processed by computer to
produce a series of tomographic image slices which can be stacked together to generate a
three-dimensional view of the scanned organ or body region [168].
The use of CT scanning to provide the images that can distinguish different body
tissues, is based on the fact that the different tissues provide different absorptions of the
incoming X-rays which have energies ranging from 80 to150 kVp, where differences in
absorption between bone, fat, air, and water produce high contrast images of anatomical
structures [169, 170].
CT imaging, however, suffers from relatively poor soft-tissue contrast, and it can be
very challenging to sufficiently differentiate between tumors and surrounding tissue. In this
regard, contrast-enhancing agents, are commonly required to increase the visibility of organs
and tumors [169]. Contrast between different tissues is based on different degrees of X-ray
attenuation, which can be defined from Lambert-Beer‟s law, and is shown in Equation (2.1)
[171]:
(2.1)
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where I is the transmitted X-ray intensity, I0 is the incident X-ray intensity, x is the thickness
of the X-ray absorber, and μ is the mass attenuation coefficient. The mass attenuation
coefficient is a characteristic of an individual material and strongly depends on both the
electron density (bulk density) ρ, the atomic number , and the X-ray energy , as shown in
Equation (2.2) [171]:
⁄
where

(2.2)

represents the nearly energy- independent Klein-Nishina coefficient and

is a

constant.

Figure 2.12. The basics of spiral computed tomography scanning. Adapted from [168].
2.2.6.3 Typical X-ray Contrast Agents and Their Potential Replacements.
Typical X-ray contrast enhancement agents for clinical use are either a barium sulfate
based solution or iodine-based compounds [170]. Figure 2.13 displays the whole-body CT
images taken from a MatBIII breast tumor bearing rat (A) without treatment with a contrast
agent, and (B) 5 min after treatment with a liposomal contrast agent (2 g of iodine per kg).
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The results clearly demonstrated that the visibility of the tumor vasculature is significantly
enhanced by the administration of the contrast agent [172].
Some drawbacks, however, still remain. The currently used contrast agents are
typically small hydrophilic molecules with low molecular weight, which exhibit rapid
extravasation and clearance [170]. In addition, some conventional ionic contrast media are
hyperosmolar and will greatly increase toxicity and side effects [170]. To overcome the
drawbacks of traditional contrast agents, recent research has demonstrated that iodine-based
liposomal contrast agents exhibit prolonged blood circulation times, which may make them
suitable agents for vascular CT [173]. Moreover, inorganic NP-based contrast agents such as
Au-, Bi-, and Ta-based NPs have been reported as promising contrast enhancement agents
that possess less toxicity [174-176].

Figure 2.13. Whole-body CT images of a rat with a MatBIII breast tumor (arrow) (A)
without treatment and (B) 5 min after treatment of liposomal contrast agent (2 g of iodine per
kg), demonstrating its ability to visualize tumor vasculature. Adapted from [172].

2.2.7 Nanoparticles for Radiation Therapy
Radiation therapy is one of the major therapeutic methods for cancer treatment.
Radiation therapy is not a selective antitumor treatment, so the main challenge of this
anticancer therapy is to increase its therapeutic efficacy without increasing damages to the
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surrounding healthy tissues. Therefore, the purpose of using NPs in radiation therapy is to
increase the differential effect between healthy and tumor tissues [177]. Depending on the
physiochemical properties of different NPs, mechanisms of interaction between X-rays and
NPs can be generally characterized by four types. The first type of mechanism is to use NPs
containing atoms with a high atomic number Z, which can enhance the photoelectric and
Compton effects to increase the efficacy of conventional radiation therapy [177]. The second
one is to use drug-releasing NPs triggered by X-rays. When NPs are under X-ray irradiation,
they will release the loaded drugs in the targeted tumor site to increase the overall therapeutic
efficacy [178]. The third type of mechanism is to use photodynamic NPs, which typically
contain a lanthanide-doped high-Z core to achieve dual functionalities for anticancer
treatment. Once irradiated by X-rays or light, the core will emit visible or UV light to activate
a photosensitizer in the outer shell, which can generate ROS and further damage cancer cells,
performing photodynamic therapy. In addition, the high-Z core of these NPs can also enhance
the efficacy of conventional radiation therapy [179]. The last one is to use radioprotective
NPs, such as cerium oxide NPs, to protect the normal surrounding tissues while performing
radiotherapy [139].
Although these are typical mechanisms, novel theranostic systems based on NPs
including more therapeutic features may present more possible mechanisms in advanced
radiation therapy in the near future.

2.2.8 Examples of Typical NP-Based Theranostic Systems
NP-based theranostic systems hold great promise in nanomedicine and biomedical
applications due to their unique physiochemical properties. NPs can be designed to possess
several unique features including targeting, imaging, and therapeutic functionality within a
single nanosized platform. In contrast to small molecules, theranostic NPs can be tailored
with various features, such as optical, electrical, magnetic and biological properties and can
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carry large payloads along with contrast agents [180]. A theranostic system generally has an
active therapeutic ingredient with at least one imaging modality, but advanced theranostic
systems aim to combine these with more supportive or therapeutic features, such as sensing,
targeting,

radiation protection,

photodynamic therapy,

photothermal therapy,

and

enhancement of radiation therapy. The designed strategy is to use both organic and inorganic
nanomaterials as backbones to form a variety of theranostic systems. Some pre-clinical
theranostic NPs are presented in Table 2.3.
Table 2.3. Pre-clinically available theranostic NPs for biomedical applications.
Class of

Therapeutic

Additional

agent

components

Imaging agent
backbone

Further features

References

Chemotherapeutic
Photothermal
Inorganic NPs

Gold

drugs

--

[181]
therapy

(DOX, PTX)
Inorganic/organ

Targeting delivery;
Chemotherapeutic

PEG;

drug (DOX);

Liposome;

ic hybrid NPs

Gene therapy;
Iron oxide

[182-184]
Hyperthermia

siRNA;

Peptides
therapy
Sensing;

Chemotherapeutic
Quantum dot

Phospholipid

Targeting;

s; Aptamer

Photodynamic

drug (DOX);

[185-188]

(QD)
siRNA

therapy
Chemotherapeutic
Mesoporous
drug (DOX);

[189, 190]

silica

PEG

Targeting

siRNA
Photothermal
Graphene oxide/

Folic acid;

therapy;

PEG;

Photodynamic

Phospholipid

therapy;

Chemotherapeutic
Carbon naotube

[191-194]

drug (PTX)
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Drug delivery
Chemotherapeutic
Dendrimers-

Targeting;

Organic NPs

drugs

[195, 196]

FITC conjugates

Folic acid

Drug delivery

(MTX, 2-ME)
Abbreviations: doxorubicin (DOX), paclitaxel (PTX), interfering ribonucleic acid (siRNA), polyethylene glycol
(PEG), (3-aminopropyl) triethoxysilane (APTES), fluorescein isothiocyanate (FITC), Methotrexate (MTX), 2 methoxyestradiol (2-ME)

2.3 Indium-Based Nanomaterials
Indium-based nanomaterials are widely used for various applications in many
different fields. Nanomaterials such as InP and InAs are semiconductor nanocrystals, known
as quantum dots (QD), which can be used in the area of biomedicine [197]. Tin doped indium
oxide (ITO), zinc doped Indium oxide (IZO), indium fluoride (InF), and indium gallium
oxide (IGO) NPs are ceramic oxide NPs and commonly known as transparent conductive
oxide (TCO) nanomaterials [198], which have two very important features, good electrical
conductivity and low absorbability of light, so that they can be used in a variety of
applications, including biosensors, flat-panel displays, polymer-based electronics, and thin
film photovoltaics [199].
In this thesis work, ITO and IZO NPs have been mainly chosen and investigated for
their biomedical potentials and their selective cytotoxicity towards a variety of non-malignant
and tumor cells.

2.3.1.1 Tin Doped Indium Oxide (ITO) and Zinc Doped Indium Oxide
(IZO) Nanoparticles
ITO NPs represent a heavily doped n-type degenerate semiconductor with a
large bandgap, where electrons are the major charge carriers [200]. Typically, ITO NPs have
a bixbyite crystal structure [201], where some of the In atoms are randomly substituted by the
Sn atoms, and this difference of valence between In3+ and Sn4+ results in the donation of a
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free electron to the lattice [200]. The body-centered lattice is similar to that of fluorite, but
only three- fourths of the anions found in fluorite are present. As shown in Figure 2.14, each
cation (In3+ and Sn4+) resides at the center of a distorted cube with six corners that are
occupied by oxygen anions, and the remaining two corners are empty and play an important
role in the defect chemistry of ITO, as they are the location of oxygen interstitial anions,
which are commonly known as oxygen deficiency sites [202]. The defect structures of ITO
nanomaterials contribute in part to their superior optical and electrical properties, which are
exploited in various transparent electrode applications [202], and may be used for the
development of a possible theranostic system, which will be discussed in Chapter 5.

Figure 2.14. The oxygen defect site found in the ITO crystal structure.
IZO NPs are one of the TCOs, and are one of the alternative materials for ITO. For
the purpose of saving indium usage, decreasing processing difficulty, and improving
electrical homogeneity, IZO NPs have been developed [203]. In addition, IZO
nanostructures with high-quality single-crystallinity have shown the potentiality for many
applications, such as luminescence and optoelectronic devices, transparent conductors, field
emitters, and gas sensors [204, 205]. In addition, IZO NPs may exhibit cytotoxicity towards
cancer cells and show selectivity in cancer treatment as discussed in Chapter 6.
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3.1 Synthesis of Nanomaterials
3.1.1 Materials
Indium metal (> 99.8%), Zinc metal (> 99.9%), anhydrous Tin tetrachloride (>
99.9%), ammonium hydroxide (28–30%), denatured ethanol, and reagent-grade ethanol were
all purchased from Sigma-Aldrich. Hydrochloric acid (36%) was purchased from UNIVAR.
All commercial materials were used without further purification.

3.1.2 Synthesis of Tin Doped Indium Oxide (ITO) and Zinc Doped Indium
Oxide (IZO) Nanoparticles
ITO and IZO NPs were synthesized through a classical co-precipitation method [1, 2].
Typically, this method contains several steps as: firstly, the precursors of the active
components, such as metal indium and tin salt, or metal indium and zinc metal, are dissolved
in a suitable acidic medium, respectively, to form a homogeneous solution. Secondly, a
precipitation step is carried out when the homogeneous salt-containing solution is subjected
to pH adjustment by adding an alkaline solution to force the indium and tin or indium and
zinc salts to co-precipitate. During this precipitation, the salts may be hydrolyzed into
hydroxide forms or oxides. Thirdly, the solid mass is then collected, filtrated and gradually
dried at about the boiling point of the medium for several hours. Finally, by heating at a
suitable temperature, a calcination (annealing) step is carried out to convert the hydroxide
form of the active components into oxides, and the atmosphere for sample calcination can be
selected based on the experimental design (e.g. air / H2 -Ar / N 2 , etc.). The experimental setup
for synthesis of ITO/IZO NPs is schematically shown in Figure 3.1.
3.1.2.1 Synthesis of Air-calcined Tin Doped Indium Oxide Nanoparticles
The ITO precursor were first synthesized through a classical coprecipitation method,
as described in Section 3.1.2. Briefly, 5 g of indium metal (0.044 mmol) was dissolved in 20
mL of 36% HCl with 0.514 mL (0.0045 mmol) of anhydrous tin tetrachloride. Then, 30%
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ammonium hydroxide was added to the flask until a white precipitate precursor was obtained.
The precipitate precursor of ITO was then aged for 24 hours, filtered, and washed with
deionized water. The washed precursor, the so-called indium tin hydroxide (ITOH), was
dried for 12 hours at 353 K and was calcined in a horizontal LABEC tube furnace at 673 K
for 1.5 hours in air, yielding the air-calcined ITO NPs.
3.1.2.2 Synthesis of 5% Hydrogen-Argon-calcined Tin Doped Indium Oxide
Nanoparticles
5% hydrogen-argon-calcined ITO NPs were synthesized as follows: First, in a threeneck flask, 5 g of metal Indium (0.044 mmol) was dissolved in 20 mL of 36% hydrochloric
acid with magnetic stirring at 70℃. When fully dissolved, 0.514 mL (0.0045 mmol) of
anhydrous Tin tetrachloride was added, and the solutions were allowed to mix by a controlled
magnetic stirring and cool to room temperature. Once room temperature was reached, 30%
ammonium hydroxide was added to the flask, and testing the pH value until it reached around
8, and a white precipitate precursor was obtained. The precipitate precursor of ITO was then
aged for 24 hours, collected by filtration, and then washed with deionized water. After
washing, the precursor of ITO or so-called indium tin hydroxide (ITOH) was dried for 12
hours at 353 K. The dried sample was annealed in a horizontal LABEC tube furnace at 673 K
for 1.5 hours under 5% hydrogen-argon mixed gas.
3.1.2.3 Synthesis of Zinc Doped Indium Oxide Nanoparticles
IZO NPs were synthesized as follows: First, 4 g of indium metal (0.035 mmol) and
0.204 g of zinc metal (0.003 mmol) were dissolved in 40 mL of 36% HCl. Then, 30%
NH4 OH was added dropwise until a white precipitate was formed. The precipitate was
filtered via centrifugation (Eppendorf), and washed seven times with deionized (DI) water.
After washing, the precursor of IZO or so-called indium zinc hydroxide (IZOH) was dried for
12 hours at 353 K. The dried sample was annealed in a horizontal LABEC tube furnace at
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673 K for 1.5 hours under argon atmosphere.

Figure 3.1. Schematic illustration of the experimental setup for synthesis of ITO/IZO NPs

3.2 Physical and Chemical Characterizations of Nanoparticles
3.2.1 Materials
Phosphate-buffered saline (PBS) was purchase from Life Technologies, and
denaturated ethanol, sodium acetate (≥ 99.0%), sodium carbonate decahydrate (≥ 99.99%),
acetic acid (≥ 99.7%), and sodium bicarbonate (≥ 99.7%) were purchased from SigmaAldrich.

3.2.2 Measurement of Specific Surface Area (Brunauer-Emmett-Teller)
The Brunauer- Emmett- Teller (BET) method is extensively used for measuring the
specific surface area and the pore size distribution of nanopowders, based on the adsorption
of gas molecules onto the surface of a material. The theory of this method assumes that a
weakly bonded monolayer will be formed after the tested material has adsorbed gas, and the
adsorbed volume of gas is correlated with the surface area of the tested material [3]. The
monolayer density is also correlated with porosity of the tested material [4]. The method is
conducted by using an inert gas, typically nitrogen, at a constant temperature with various
64

CHAPTER 3 – Materials and Methodology
relative pressures, and the adsorbed and desorbed volumes of nitrogen can be determined,
which can subsequently be used to calculate the specific surface area [3] and the pore size
distribution [4].
In this thesis work, the BET surface area of the synthesized nanomaterials was
measured using a Nova 1000 high speed gas adsorption analyser from Quantachrome. The
adsorption of N 2 at the temperature of liquid nitrogen was determined, and the samples were
degassed at 60°C for 15 h in vacuum prior to measuring.

3.2.3 Thermogravimetric Analysis (TGA)
TGA is a useful analytic technique to investigate the weight changes of a material
during a heating process, providing information about the composition, stability, and
degradation of a material. The sample is typically placed in an inert or high- temperatureresistant crucible, which is then placed in a temperature controlled furnace equipped with a
highly sensitive weight balance that can precisely measure the weight changes, as shown in
Figure 3.2. In addition, various atmospheres such as oxygen, nitrogen, argon, and air can be
chosen, and the highest temperature that can be applied is up to 1200 ℃ within a heating
program. Generally, during the heating procedure, certain processes, including evaporation,
sublimation, or the generation of volatiles, will result in a decrease in the weight, while an
increase in the weight can be attributed to oxidation of a sample [5].

Figure 3.2. Schematic illustration of a thermogravimetric analyser.
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The stability of the ITO NPs was investigated using a Metter Toledo TGA/DSC 1
STARe system. Each sample was placed in an aluminum oxide crucible and heated from 10 1080℃ at a heating rate of 5℃/min in air atmosphere.

3.2.4 X-ray Diffraction (XRD)
XRD is widely used to identify the phases and crystal structures of materials. A
crystalline sample provides a diffraction grating for X-ray wavelengths, with identified
spacing distances of the planes in a crystal lattice, as illustrated in Figure 3.3 [6].

Figure 3.3. Schematic diagram showing the principle of X-ray diffraction. An irradiated
crystalline sample with angle θ of the incoming and diffracted beam on lattice planes with
spacing d. Adapted from [6].
X-ray photons that reach to the atoms in the crystalline structure, are scattered through
the electron shell of the irradiated atom. The resulting constructive scattered radiation
(constructive interference) is recorded by a detector with a reflective angle of 2θ, showing the
visible characteristic reflections in the XRD pattern, which can be used to investigate the
crystal structure [6]. The conditions for presenting the XRD constructive interference are
determined by the Bragg‟s law, as shown in Equation (3.1) [7].
(3.1)
where

is the spacing between diffraction planes,

is the angle of incidence with the lattice

plane,

is the diffraction order, any integer, and

is the X-ray wavelength of the incident

beam. Typically, Cu Kα radiation is used with a wavelength of 0.1542 nm.
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In addition, by applying the Miller indices hkl to the particular diffraction angles, the
lattice plane difference can also be calculated based on Equation (3.2) [8].

( )

( )

()

(3.2)

Where a, b, and c are the lattice parameters of a unit cell.
When the size of the crystal is very small, the diffracted beam is broadened, which
can be described by the Scherrer equation [9], as shown in Equation (3.3). By applying the
Scherrer equation, the mean crystallite size can be calculated.
(3.3)

where d represents the average crystallite size, k is the shape factor, which is
equal to 0.89 (assuming that the shape of the crystallite is spherical), and λ is the
wavelength of the X-rays, 1.54056 Å . β is the full width at half maximum of the
particular diffraction peak, and θ is the Bragg diffraction angle.
In this doctoral work, the crystal structures of all produced and as-received NPs
were characterized using an Enhanced Mini- Materials Analyzer X-Ray Diffractometer
(GBC Scientific) and a Mac Science M03XHF22 diffractometer with Cu Kα radiation at
40 kV and 25 mA in the range of 20° to 65° at a scanning rate of 2° min-1 in UOW.

3.2.5 X-Ray Photoelectron Spectroscopy (XPS)
XPS is a surface-sensitive quantitative spectroscopic technique that gives information
about the elemental composition, quantity, chemical state, binding energies and densities of
the electronic states of a material [10].
XPS spectra are recorded by irradiating a sample with X-rays while simultaneously
measuring the kinetic energy and the emitted electrons with an escape depth of less than
10 nm that are ejected from analyzed sample, as illustrated in Figure 3.4 [11]. When
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operating the XPS, an ultra-high vacuum (< 10-9 mbar) is required to minimize the loss of
emitted photoelectrons caused by inelastic collisions or recombination. The energies and
intensities of the photoelectron peaks are characteristic of each element and can be
individually identified, except for hydrogen [10].

Figure 3.4. Working principle of X-ray photoelectron spectroscopy. Adapted from [11].
In this thesis work, surface features, including the chemical composition and surface
defects of the synthesized nanopowders, were evaluated using X-ray photoelectron
spectroscopy (XPS), which was conducted using a SPECS PHOIBOS 100 Analyzer installed
in a high- vacuum chamber with the base pressure below 10 -8 mbar. The X-ray excitation
source was provided by Al Kα radiation with a photon energy of 1486.6 eV at the high
voltage of 12 kV and power of 120 W. The binding ene rgy scale of all measurements was
calibrated using the C 1s peak at 284.8 eV. All XPS data was analysed using CasaXPS 2.3.15
software.
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3.2.6 Ultraviolet-Visible (UV-Vis) Spectroscopy
UV-vis spectroscopy is used to determine the UV-vis absorption properties of
samples, and it can also be used to evaluate the band gap of semiconductor materials [12].
A UV-vis spectrometer typically contains several important components, including
the UV-vis source, wavelength selectors (filters or monochromators), beam splitters, sample
containers (cuvettes), detectors, and readout devices. Generally, a UV-vis source generates a
light beam that passes through a beam splitter, separating it into two equal intensity beams.
One beam passes through a cuvette containing the sample in a solvent/dispersant, while the
other beam passes through another cuvette containing only the solvent/dispersant, which
serves as the reference. Detectors measure the intensity of both light beams, where the
intensity of the sample beam is defined as

and the intensity of the reference is defined as

[13], and a readout device outputs the absorption spectrum, as illustrated in Figure 3.5.

Figure 3.5. Working principle of an ultraviolet- visible spectrometer.
If the concentration of a sample is unknown, it can be calculated and obtained by
applying the Beer-Lambert law as shown in Equation (3.4) [14].
( )

(3.4)
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where A is the absorbance or, as formerly called, the optical density, ɛ is the extinction
coefficient, c is the concentration of a sample, l is the length of the beam in the absorbing
medium, and α is the absorption coefficient.
The use of UV-vis spectroscopy to evaluate the band gap of materials is based on
their properties relating to electronic transitions. When irradiated with UV- vis light, if the
energy is high enough, the electronic configuration of the irradiated molecules will be
changed from the ground state to an excited state, emitting photons; or electron will move
from the valence band to the conduction band. Such phenomena can be studied to investigate
the band gap of materials. The relationship between the optical absorption behaviour and
band gap of materials is described and shown in Figure (3.5) [12].
(3.5)
where α is the absorption coefficient of a sample material, h is the Planck constant
,

is the light frequency, B is a constant, and

is the band gap of the sample

material. The value of m depends on the type of optical transition, and generally, m = 2 for a
direct transition and m = 0.5 for an indirect transition [12].
In this doctoral thesis, all tested nanomaterials were first suspended in ethanol, a nd
sonicated for 2 hours in a sonication bath (Branson 3800, Ultrasonics Corp). A designed
absorbance close to 1.0 was carefully produced by dilutions prepared in the concentration
range from 25 – 50 µg/mL. A UV-3600 spectrophotometer (Shimadzu Corp) was used to
record the absorbance throughout the range of 800 – 200 nm by using 1.4 mL quartz cuvettes
with a path length of 1 cm.

3.2.7 Computed Tomography
An overview of computed tomography (CT), including its working principle and the
use of CT contrast enhancing agents, has been presented in section 2.2.6.2.
In this thesis work, the capability for anatomical contrast enhancement of the ITO
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NPs alone was demonstrated using CT. Suspensions of ITO NPs with a range of
concentrations from 0 to 20 mg/mL were placed in 1.5 mL vials and imaged together using a
Toshiba Asteion (model TSX-021A) whole body X-ray CT scanner with a 200 mA tube
current, 120 kV tube voltage, 1 mm slice thickness, and 93 mm field of view diameter. The
CT images were captured using the standard patient image reconstruction algorithms
integrated with the scanner.

3.2.8 Dynamic Light Scattering (DLS)
Dynamic light scattering (DLS) is a useful technique for studying the diffusion
behaviour of small molecules and for determination of the geometric size distr ibution profile
of nanosized particles in liquid suspensions or emulsions [15, 16].
DLS is based on the Brownian motion of particles dispersed in a liquid. The principle
of Brownian motion is that particles are constantly colliding with solvent molecules, leading
to constant transfer of energy which induces random particle movement. As a consequence,
small particles are moving faster than large particles. It is worth noting that the particle size
measured by DLS refers to the hydrodynamic diameter of partic les, which includes a
hydration layer that is formed around the particles or molecules when they are dispersed in an
aqueous solution. The relationship between the speed of the particles and the particle size is
described by the Stokes-Einstein equation, as shown in Equation (3.6) [15, 16].

Where

is the diffusion coefficient that represents the speed of the particles,
is the hydrodynamic radius of the particles,
,

is the temperature, and

is the Boltzmann constant

is the viscosity.

During the DLS measurement, a laser beam irradiates the sample particles and the
fluctuations of scattered light are detected by a photon detector. The fluctuations are caused
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by Brownian motion and correspond to the individual particles, showing different patterns
between small and large particles (Figure 3.6), so that they can be used to calculate the
particle size and particle size distribution [15].
In this thesis work, a Malvern – Zetasizer APS2000 was used to determine the
hydrodynamic diameter of the nanomaterials suspended in PBS. The prepared NPs were
first dispersed in PBS at the concentration of 1 mg/mL and sonicated for 2 hours using a
sonication bath (Branson 3800, Ultrasonics Corp), and then a diluted final concentration of
50 µg/mL was used to perform the DSL experiments in three independent measurements
using an 830 nm laser at room temperature. The incorporated Malvern – Zetasizer 7.03
software was used to analyze and obtain the hydrodynamic diameter and size distribution
from the suspensions of the tested nanomaterials.

Figure 3.6. Schematic diagram of working principle of dynamic light scattering in two
samples: small particles on the top and larger particles on the bottom.

3.3 Morphological Characterization of Nanomaterials
Generally, electron microscopy is the one of the main methods for morphological
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characterization of nanomaterials.
Electron microscopy can be generally divided into scanning electron microscopy
(SEM) and transmission electron microscopy (TEM), as well as scanning transmission
electron microscopy (STEM), which is a mode in between TEM and SEM. The principle of
these techniques is using an electron beam to interact with the atoms of a specimen, which
generates signals that can be detected and used to obtain information about the particle size
and morphology of a specimen. The imaging methodology of SEM, TEM, and STEM is
illustrated in Figure 3.7 [17]. The elemental composition of a specimen can be investigated
by electron energy loss spectroscopy (EELS) or energy dispersive X-ray spectroscopy (EDS).

Figure 3.7. Schematic illustration of SEM, TEM, and STEM imaging methodology. (a)
Serial collection of data points in SEM. (b) Parallel image acquisition in TEM. (c) Serial
collection of transmitted electrons in STEM. Adapted from [17].
In this doctoral work, SEM, STEM, and TEM images and EDS data were captured
and acquired using a JSM7500FA cold field emission gun scanning electron microscope
(FEGSEM, JEOL), a JEOL JEM-2010 transmission electron microscope, and a JEOL JEMARM200F atomic resolution microscope.
Regarding the sample preparation for morphological characterization by electron
microscopies, the nanomaterials were first suspended in denaturated ethanol (Sigma-Aldrich)
and sonicated for 0.5 – 2 hours using a sonication bath (Branson 3800, Ultrasonics Corp). A
drop of the as-prepared suspension was then placed on a 200 mesh carbon coated copper grid,
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which was dried at room temperature, and before proceeding to imaging using the electron
microscope. Specimens for EDS bulk analysis were directly placed on carbon film and
mounted to the specimen holder.

3.3.1 Scanning Electron Microscopy
SEM uses a high-energy electron beam to scan and generate indirect images of a
sample. The electrons interact with the sample atoms, producing signals that can be detected
and presented as the surface topography and composition. The electron beam generally scans
in a raster scan pattern, and the position of the beam on the sample directly corresponds to the
detected position in the image. In SEM operation, an ultra-high vacuum (10-3 Pa) is needed in
order to minimize the recombination and collision of electrons. A schematic illustration of a
SEM is shown in Figure 3.8 [17].
In this doctoral work, SEM images were captured using a JSM7500FA cold field
emission gun scanning electron microscope with an accelerating voltage of 15 kV.

Figure 3.8. Schematic illustration of the core components of a scanning electron microscope.
Adapted from [17].
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3.3.2 Transmission Electron Microscopy (TEM) and Scanning
Transmission Electron Microscopy
TEM is the technique that is of particular use for analyzing the internal structure of a
specimen.
In the TEM mode, when an electron beam passes through a sufficiently thin specimen,
the electrons interact with atoms of the specimen, and the energy is high enough to allow the
transmission of electrons, which eventually leads to the formation of an image. A schematic
illustration of TEM is displayed in Figure 3.9 [17].

Figure 3.9. Schematic illustration of the core component of a scanning electron microscope.
Adapted from [17].
TEM can be used to observe the morphology, and the crystal and electronic structures
of a specimen. STEM is one type of TEM. Some TEM instruments are fitted with scan coils,
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which can scan a focused electron beam across the specimen in a raster pattern [17]. This
STEM mode is extremely useful for carrying out sequential chemical analysis across areas of
the specimen. High-resolution TEM (HRTEM) imaging is a crystallographic imaging method
that can be performed by the use of STEM. When specimens are ultrathin (< 100 nm), the
elastic scattering dominates the inelastic scattering. The electrons interacting with the crystal
lattice diffract and form complex interference patterns visible at magnifications of 400k or
more. Under some imaging conditions, the patterns correspond to atom positions, and they
can be used to investigate the growth planes of a crystal structure [17].
In this thesis work, the TEM images were collected using a JEOL JEM-2010
transmission electron microscope (JEOL, Japan). High-resolution TEM images were obtained
using a probe-corrected JEM-ARM200F atomic resolution microscope (equipped with a cold
field emission gun, a high resolution pole-piece, and a Centurio EDS detector) at an
accelerating voltage of 200 kV, and the converted fast Fourier transform (FFT) image was
obtained using Gatan Digital Micrograph software.

3.3.3 Energy-Dispersive X-Ray Spectroscopy
EDS units are typically supplied with SEM and TEM microscopes, and are very
useful to determine the elemental composition of a material. In addition, an EDS mapping
can help to determine the elemental distribution of the area of the specimen.
When a specimen is exposed to a high-energy electron beam, an electron in an inner
shell of an element can be excited and ejected, resulting in formation of an electron-hole pair,
as illustrated in Figure 3.10 [18]. Electrons from the outer shells with higher energy can then
fill this hole, releasing energy in the form of X-rays, which are characteristics of each
element present in the sample and can be collected by an EDS detector. As the atomic
structure of an element is unique and the energy difference between two shells is known, a
distinctive spectrum is acquired, and the elemental composition is subsequently obtained.
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Figure 3.10. Principle of energy-dispersive X-ray spectroscopy. Adapted from [18].
In this doctoral work, A JSM7500FA cold field-emission gun scanning electron
microscope equipped with an X-Flash 4010 10 mm2 , 127 eV silicon drift detector (SDD)
energy dispersive X-ray detector (Bruker, USA) was used to perform the EDS bulk analysis.
An accelerating voltage of 20 kV was used to obtain X-ray spectra of photons between 0 – 20
keV with a real time acquisition period of at least 120 s.
A JEM-ARM200F atomic resolution microscope fitted with a Centrino SDD 100 mm2
detector (JEOL, Akishima, Japan) was used to acquire high-resolution EDS mappings.

3.4 Cell Culture Methods
3.4.1 Materials
Dulbecco‟s Modified Eagle Medium (DMEM), DMEM/F-12 medium, Roswell Park
Memorial Institute (RPMI) 1640 Medium, fetal bovine serum (FBS), horse serum, insulin,
epidermal growth factor (EGF), hydrocortisone, cholera toxin, penicillin, streptomycin,
Dulbecco‟s phosphate-buffered saline (DPBS, with/without Ca2+ and Mg2+), phosphatebuffered saline (PBS), and trypsin ethylenediaminetetracacetic acid (trypsin-EDTA) were
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purchased from Life Technologies. Dimethyl sulfoxide (DMSO, ≥99.9%), Trypan blue
solution (0.4%), and denaturated ethanol were purchased from Sigma-Aldrich.
All cell culture procedures were conducted inside a Euroclone – Safemate 1.2 ABC
Class II biological safety cabinet.

3.4.2 Cell Lines
Eight different cell lines were used to study the biological activities of the synthesized
nanomaterials, including three non-malignant cell lines, and five malignant cell lines. The
cells were purchased from the European Collection of Cell Cultures (ECACC) and the
American Type Culture Collection (ATCC).
3.4.2.1 Non-malignant Madin-Darby Canine Kidney (MDCK) Cells
The MDCK cell line, derived from a kidney of an adult female cocker spaniel [19], is
one of the non- malignant cell lines tested to investigate the biocompatibility of the
synthesized NPs. General information about MDCK cells is given in Table 3.1, and the cell
morphology is illustrated in Figure 3.11.
Table 3.1. Information on Madian-Darby canine kidney cells
[19].
Species

Dog

Tissue

Kidney

Morphology

Epithelial

Culture properties

Adherent

Disease

---

Freezing medium

95% (v/v) growth medium

Figure 3.11. Microscopic image of

+ 5% (v/v) DMSO
Abbreviation: dimethyl sulfoxide (DMSO)

Madian-Darby canine kidney cells [19].

3.4.2.2 9L Rat Brain Cancer Cells
The 9L rat brain cancer cells were used to study the potential selectivity of the
synthesized NPs in comparison to the MDCK cells. 9L rat brain glioma cells were derived
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from an N-nitrosomethylurea- induced tumor and have been reported to exhibit high
resistance against both chemotherapy and radiotherapy [20, 21]. General information on 9L
cells is given in Table 3.2, and the cell morphology is illustrated in Figure 3.12.
Table 3.2. Information on 9L rat brain tumor cells [21].
Species

Rat

Tissue

Brain

Morphology

Fibroblast

Culture properties

Adherent

Disease

Glioma

Freezing medium

95% (v/v) growth medium
+ 5% (v/v) DMSO

Figure 3.12. Microscopic image
of 9L rat brain tumor cells [21].
3.4.2.3 MCF-7 Human Breast Cancer Cells
MCF-7 cells are breast adenocarcinoma cells, which were established from a 69-year
old female, and are the most studied human breast cancer cells in the world [19, 22]. General
information on MCF-7 cells is given in Table 3.3, and the cell morphology is illustrated in
Figure 3.13.
Table 3.3. Information on MCF-7 human breast tumor cells [19].
Species

Human

Tissue

Breast

Morphology

Epithelial

Culture properties

Adherent

Disease

Adenocarcinoma

Freezing medium

95% (v/v) growth medium

Figure 3.13. Microscopic

+ 5% (v/v) DMSO

image of MCF-7 human

breast tumor cells [19].
3.4.2.4 MDA-MB-231 Human Breast Cancer Cells
MDA-MB-231 cells are highly aggressive, invasive, and poorly differentiated triplenegative human breast cancer cells, which were established from a 51-year old female, and
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are widely used in medical research laboratories [21, 23]. General information on MDA-MB231 cells is given in Table 3.4, and the cell morphology is illustrated in Figure 3.14.
Table 3.4. Information on MDA-MB-231 human
breast tumor cells [21].
Species

Human

Tissue

Breast

Morphology

Epithelial

Culture properties

Adherent

Disease

Adenocarcinoma

Freezing medium

95% (v/v) growth medium

Figure 3.14. Microscopic image

+ 5% (v/v) DMSO

of MDA-MB-231 human breast
tumor cells [20].

3.4.2.5 MCF-10A Human Breast Non-malignant Cells
The MCF 10A cell line is a non-tumorigenic epithelial cell line, and is responsive to
insulin, glucocorticoids, cholera toxin, and epidermal growth factor (EGF), which can be
added as supplements in the growth medium preparation [19]. General information about
MCF-10A cells is given in Table 3.5, and the cell morphology is illustrated in Figure 3.15.
Table 3.5. Information on MCF-10A human breast nonmalignant cells [19].
Species

Human

Tissue

Breast

Morphology

Epithelial

Culture properties

Adherent

Disease

Fibrocystic disease

Freezing medium

95% (v/v) growth medium

Figure 3.15. Microscopic image
of MCF-10A human breast non-

+ 5% (v/v) DMSO

malignant cells [18].
3.4.2.6 RWPE-1 Human Prostate Non-malignant Cells
RWPE-1 cells are non- malignant cells, which were established from epithelial cells
derived from human prostate that were transfected with a single copy of the human papilloma
virus 18 (HPV-18) [19]. General information about RWPE-1 cells is given in Table 3.6, and
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the cell morphology is illustrated in Figure 3.16 [19].
Table 3.6. Information on RWPE-1 human prostate
non-malignant cells [19].
Species

Human

Tissue

Prostate

Morphology

Epithelial

Culture properties

Adherent

Disease

---

Freezing medium

95% (v/v) growth medium

Figure 3.16. Microscopic image of RWPE-1

+ 5% (v/v) DMSO

human prostate non-malignant cells [18].

3.4.2.7 PANC-1 Human Pancreatic Cancer Cells
The PANC-1 cells are tumorigenic epithelial cell cells derived from a 56-year old
male suffering from human pancreas carcinoma [19]. General information on PANC-1 cells
is given in Table 3.7, and the cell morphology is illustrated in Figure 3.17.
Table 3.7. Information on PANC-1 human pancreatic cancer
cells [19].
Species

Human

Tissue

Pancreatic

Morphology

Epithelial

Culture properties

Adherent

Disease

Epithelioid carcinoma

Freezing medium

95% (v/v) growth medium

Figure 3.17. Microscopic image of PANC-1

+ 5% (v/v) DMSO

human pancreatic cancer cells [18].
3.4.2.8 MIA PaCa-2 Human Pancreatic Cancer Cells
The MIA PaCa-2 cell line was established from tumor tissue from a pancreas obtained
from a 65-year-old male [19], and was used to investigate the cytotoxicity of the synthesized
NPs. General information about MIA PaCa-2 cells is given in Table 3.8 and the cell
morphology is illustrated in Figure 3.18.
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Table 3.8. Information on MIA PaCa-2 human pancreatic
cancer cells [19].
Species

Human

Tissue

Pancreatic

Morphology

Epithelial

Culture properties

Adherent

Disease

Epithelioid carcinoma

Freezing medium

95% (v/v) growth medium
+ 5% (v/v) DMSO

Figure 3.18. Microscopic image of MIA
PaCa-2 human pancreatic cancer cells [18].

3.4.3 Subculture of Cells
The eight different types of cells were all regularly maintained in the exponential
growth phase in T-75 cm2 cell culture flasks (Greiner Bio-one). MDCK, 9L, MCF-7, and
MDA-MB-231were cultured with DMEM culture medium. PANC-1, MIA PaCa-2, and
MCF-10A cells were cultured with DMEM/F-12 medium. RWPE-1 cells were cultured with
RPMI 1640 Medium. All media contained phenol red, L- glutamine, and glucose, and were
supplemented with FBS (10% (v/v)) and penicillin/streptomycin (1% (v/v)). In addition, the
medium for culturing MCF-10A cells was additionally supplemented with horse serum,
insulin, epidermal growth factor (EGF), hydrocortisone, and cholera toxin. All cell cultures
were maintained at 37℃ and with 5% (v/v) CO 2 in a cell culture incubator (Heracell 150i),
and were discarded after they have been cultured for 30 passages.
During a subculture, the growth medium was replaced with fresh growth medium and
the monolayer of cells was washed twice with 5 mL of pre-warmed DPBS. Afterwards, the
cells were detached using 0.05% trypsin- EDTA, and were incubated for 5 – 10 min at 37ᵒC
and 5% (v/v) CO 2 . After the cells were detached, the trypsin-EDTA was neutralized with prewarmed complete growth medium, and an aliquot of cells was taken to perform cell counting.
The concentration of cells in the suspension was calculated , and the appropriate volume of
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the desired cells was transferred into a new T-75 cm2 flask containing 20 mL of fresh growth
medium. All maintained cell cultures were tested monthly for mycoplasma contamination.

3.4.4 Cell Counting
A Neubauer haemocytometer was used to evaluate the concentration of cells in the
suspension. During the process of cell counting, Trypan blue was used, which is a bluecolored dye. It can permeate into dead cells and stain them blue, while viable cells have an
intact membrane, so they are impermeable and hence remain clear. The cell concentration
was calculated based on the counting of viable cells only. When cell counting was
performed, generally, an equal volume of cell suspension was mixed with a solution of
0.4% Trypan blue. Then, 10 µL of the mixture was injected into the counting chamber of a
haemocytometer and the amount of viable cells could be determined, as illustrated in Figure
3.19 [24].

Figure 3.19. Cell counting using a Neubauer haemocytometer. Adapted from [24].

3.4.5 Cryopreservation of Cells
To reduce the risk of microbial contamination or cross contamination with other cell
lines, and to have cells at consistent low passage, cryopreservation of cells is required. It
generally includes the freezing and thawing of cells. The details are outlined below.
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3.4.5.1 Freezing of Cells
Prior to freezing cells, the freezing medium should be prepared and stored at 2 °C to
8°C until use. The freezing medium was prepared by the addition of a cryoprotective agent,
such as 10% DMSO into the required growth medium used for culturing the specific cell
lines (See section 3.4.3). In addition, on the day of cell freezing, 4 – 6 T-75 cm2 flasks should
be ready to harvest, with their medium replaced with fresh growth medium 24 hours before
freezing.
When performing cell freezing, cells were gently detached from the tissue culture
flasks by following the procedure described for the subculture method, and the concentration
of cells was determined. Cells were resuspended in the pre-warmed growth medium required
for that cell type, and the cell suspension was placed on ice. The cells were then centrifuged
at 1200 – 1500 rpm for 5 min at 4°C to obtain a cell pellet. The supernatant was aseptically
decanted without disturbing the cell pellet, and the cell pellet was re-suspended in cold
freezing medium at the recommended viable cell density, generally 2 – 4

cells/mL. The

freezing suspension was aliquoted with frequently mixing of the cells to keep cell suspension
homogeneous, and the aliquot was then transferred into 2 mL Nalgene® cryogenic vials.
Afterwards, the cryovials were placed in a Nalgene® Mr. Frosty freezing container with 250
mL of isopropanol and were stored at –80°C overnight. On the next day, the frozen vials
were transferred to a storage vessel containing permanent gas phase liquid nitrogen.
These frozen vials are considered as the „seed stock‟. They should be protected, and
not be made available for general laboratory use. To confirm successful freezing of the cells,
a frozen vial is taken from the „seed stock‟ after 24 h storage inside the liquid nitrogen vessel
and thawed for confirmation. Once the cell viability is confirmed, the thawed cells
represented the „working stock‟ and are available for laboratory use up to 30 passages.

84

CHAPTER 3 – Materials and Methodology
3.4.5.2 Thawing of Cells
The thawing procedure is important for frozen cells, and working carefully and
quickly can ensure that a high proportion of the cells survive from the procedure.
First, the frozen cryovial containing the frozen cells is removed from the liquid
nitrogen storage and placed in a 50 mL tube containing pre-warmed 70% ethanol. Afterwards,
the tube is placed in a 37°C water bath and left until the cell suspension is thawed. The
thawed cell is then transferred into a new 50 mL tube. The desired amount of suitable prewarmed complete growth medium is transferred dropwise into the tube containing the thawed
cells. The cell suspension is gently mixed, and an aliquot is taken for cell counting, and the
cell concentration is determined. The cell suspension is then transferred into a new T-75 cm2
flask and kept in an incubator supplied with 5% (v/v) CO 2 at 37ᵒC for 24 hours. After 24
hours, the old growth medium is replaced with fresh pre-warmed growth medium when the
cells are attached to the flask in order to expel the DMSO. The cell growth is monitored until
it reaches a confluence of 80 to 90%, and the cells can then be continuously passaged for 30
times.

3.5 In Vitro Biological Characterization
3.5.1 Materials
2‟,7‟-dichlorodihydrofluorescein diacetate (H2 DCF-DA), N-acetyl- L-cysteine (NAC),
crystal violet solution (2.3% crystal violet, 0.1% ammonium oxalate, 20% ethyl alcohol),
Trypan blue solution (0.4%), 3-(4,5- dimethylthiazol-2- yl)-2,5-diphenyltetrazolium bromide
(MTT, 98%), dimethyl sulfoxide (DMSO, ≥99.9%), denatured ethanol, reagent-grade ethanol,
reagent-grade

methanol,

pharma- grade

anhydrous

4-(2-hydroxyethyl)

piperazine-1-

ethanesulfonic acid (HEPES), sodium hydroxide (NaOH, 99.99%), sodium chloride (NaCl,
99.99%), and calcium chloride dihydrate (CaCl2 ∙2H2 O, > 99.5%) were all purchased from
Sigma-Aldrich.
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Dulbecco‟s Modified Eagle Medium (DMEM), DMEM/F-12 medium, Roswell Park
Memorial Institute (RPMI) 1640 Medium, fetal bovine serum (FBS), horse serum, insulin,
epidermal growth factor (EGF), hydrocortisone, cholera toxin, penicillin, streptomycin,
Dulbecco‟s phosphate-buffered saline (DPBS, with/without Ca2+ and Mg2+), phosphatebuffered saline (PBS), and trypsin ethylenediaminetetracacetic acid (trypsin- EDTA), were
purchased from Life Technologies.
Indium tin oxide (ITO) and indium zin oxide (IZO) NPs were synthesized through a
coprecipitation method (See sections 3.1.1 to 3.1.3).
3.5.1.1 Preparation of Stock Solutions
NaCl (140 mM), CaCl2 ∙2H2 O (2.5 mM), and HEPES (10 mM) were dissolved in
Milli-Q (MQ) water, after the pH value was adjusted to 7.4; the Annexin-V binding medium
was prepared; MTT (5 mg/mL) was dissolved in PBS; H2 DCF-DA (125 µg/mL) was
dissolved in denatured ethanol. NAC (250 mM) was dissolved in PBS, and was syringe
filtered for sterilization.

3.5.2 Statistical Analysis
Data are presented as means ± standard deviation (SD). Significant differences
between the treatments and the control were evaluated using the one-way analysis of
variances (ANOVA) paired with Tukey‟s HSD post-test and the two-tailed T-test, depending
on the design of the experimental purpose. Data analysis was performed using Prism 7 for
Mac (GraphPad Software, San Diego, CA). A value of p < 0.05 was considered statistically
significant.

3.5.3 Preparation of Nanoparticle Suspensions
In this doctoral work, all NP suspensions that were used for in vitro biological
characterizations were started with autoclaving (Getinge, H5 5510 EC1) at 121°C and 15 psi,
and they were then suspended in PBS at a concentration of 1 mg/mL. The suspensions were
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sonicated for 2 hours using a sonication bath (Branson 3800, Ultrasonics Corp) and were
added to the growth medium to yield final concentrations of 50 – 200 µg/mL.

3.5.4 Live Cell Imaging and Cellular Internalization of Nanoparticles
Live cells can be imaged at high resolution using fluorescent microscopies. A
fluorescent microscopy could be used to reveal the fluorescence emitted from the observed
NPs, and that emitted light could be used to reveal the location of those NPs. Hence, the
cellular internalization of the NPs could be observed.
3.5.4.1 Fluorescence Microscopy
Fluorescence microscopy is a major tool in biological and material science, including
cell biology, molecular biology, and biotechnology, and it is widely used to investigate the
basis of cell metabolism, exchange, mutation, and toxicity by tracing the particular
fluorescent molecules in the cells. Modern fluorescence microscopy can provide threedimensional (3D) optical resolution, in which 3D resolution can be realized using a Z-stack
created by subsequently removing the contributions from out-of- focus planes. A Z-stack is a
series of images taken of a specimen at different focal planes, which could be particularly
useful for observing the cellular uptake of fluorescent molecule.
Generally, fluorescence microscopes are equipped with a high intensity light source
(typically a mercury or xenon arc lamp), to generate incident light to illuminate the sample
from above, and the objective lens is used as both the condenser of the excitation light and
the emission (fluorescent) light collector, as shown in Figure 3.20 [25]. An excitation
wavelength is chosen by placing a filter after the light source that limits light transmission to
a narrow range of wavelengths. The light then impinges on a dichroic mirror (beam splitter)
and is reflected down through the objective lens and onto the sample. Pigment molecules
within the specimen (either intrinsic or applied) absorb the light and emit the energy in a form
of fluorescent light. The objective lens collects this light emission, which then passes through
87

CHAPTER 3 – Materials and Methodology
the dichroic mirror. Any reflected excitation light is blocked by a third filter (barrier filter).
Thus, only light emitted from fluorescent molecules within the specimen are observed [26].

Figure 3.20. Basic working principle of a fluorescence microscope. Adapted from [25].
In this thesis, fluorescence microscopy was used for imaging living cells and for
observation of cellular internalization of the synthesized NPs. Briefly, cells were first seeded
on a µ-Slide 8 Well Glass Bottom (ibidi, Germany) chamber slide, and were allowed to attach
to the surface for 24 hours before the addition of ITO NPs at a concentration of 50 µg/mL.
After 24 hours of exposure to the ITO NPs, the cells were washed with PBS, and were then
proceeded to imaging. During the imaging, slides of the live cells were imaged under a 63X
oil immersion objective and the images captured using a Leica - DMi8 Fluorescent
Microscope and LAS X software (excitation at 400 nm, emissions collected at 470-550 nm).
Cells were imaged along the z-axis from top to bottom with the same intervals, creating a
number of z-sections with different strengths of fluorescence emitted from the nanoparticles,
and the locations of the nanoparticles could be navigated by analysing the z-sections of the
cell images.
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3.5.5 Flow Cytometry
Flow cytometry provides rapid analysis of biophysical and biochemical characteristics
of single cells or particles in suspension, including cell size, cytoplasmic complexity, DNA or
RNA content, latex beads, and a wide range of membrane-bound and intracellular proteins
[27]. In particular, fluorescent dyes and antibody conjugated fluorescent dyes that bind to
specific proteins on cell membranes or inside cells can be detected by using flow cytometry
[27]. With the results obtained from flow cytometry, information about cellular
internalization, intracellular ROS changes, and cellular apoptosis can be acquired.
A flow cytometer generally consists of three systems, fluidic, optical, and signal
detection and processing systems, as illustrated in Figure 3.21(A-B) [28, 29]. When the
fluidic system transports the cells from a solution, it generally creates hydrodynamic focusing,
which allows uniform illumination of a single cell while the cells are passing through the
laser beam generated by the optical system [29]. After this event, two outcomes could be
obtained: first, if the cells or particles have been stained with a fluorescent dye prior to
measurement by flow cytometry, the fluorescent emission can be detected. Second, two types
of light scattering called forward scattering (FSC) and side scattering (SSC) can be detected
after the laser beam strikes the cells [29].
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Figure 3.21(A). Schematic working principle of flow cytometry. Adapted from [28].

Figure 3.21(B). Schematic overview of a flow cytometer; the detection and processing
component is indicated. Adapted from [29].
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In this thesis work, the cellular internalization of NPs, the intracellular ROS changes,
and the cellular apoptosis were investigated using a Becton Dickinson fluorescence-activated
cell sorting (FACS) flow cytometer (BD LSR II; BD Biosciences, USA).

3.5.6 Detection of Cellular Uptake of Nanoparticles
In flow cytometry, when a cell or particle is hit by a focused laser bea m, the laser
light is scattered and can be classified into two types of light scattering, called forward
scattering (FSC) and side scattering (SSC), as shown in Figure 3.22 [29]. A number of factors
will affect total light scatter, including the membrane, nucleus, granularity of the cell, cell
shape, and surface topography [29]. FSC light is a result of diffraction detected along the
same axis as the laser beam and is proportional to the cell-surface area or size, while SSC
light is a measurement of mostly refracted and reflected light, which is detected at
approximately 90° with repect to the laser beam, and SSC light is proportional to the cell
granularity or internal complexity [29]. Theoretically, if a cell has been exposed to NPs, the
intensity of FSC light does not change, while the SSC light changes to a certain degree, and
thus, it can be concluded that the NPs have been internalized by the cell because the internal
complexity is increased by cellular uptake of NPs [30]. Therefore, by analysis of these two
types of light scattering, the cellular internalization of NPs can be examined.

Figure 3.22. FSC and SSC light scattering. FSC is proportional to size while SSC is
proportional to cell granularity or internal complexity. Adapted from [29].
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In this thesis work, a BD-LSR-II flow cytometer was used to investigate cellular
uptake of the synthesized NPs. First, the suspensions of nanoparticles were added to the
target cells, with a final concentration of 50 µg/mL. After treatment for 24 hours, the cells
were harvested using 0.05% trypsin- EDTA, and then centrifuged and washed twice with PBS.
The individual cell pellets were resuspended in 500 µL of PBS, transferred into 5 mL
polystyrene flow tubes, and transferred to a BD-LSR-II flow cytometer for the measurements.

3.5.7 Detection of Intracellular Reactive Oxygen Species (ROS)
2′,7′-dichlorodihydrofluorescein diacetate (H2 DCF-DA) is commonly employed as a
fluorescent probe and may react with several ROS, including hydrogen peroxide, hydroxyl
radicals, and peroxynitrite [31]. The H2 DCF-DA is initially non- fluorescent and is cell
permeable, so that it can passively diffuse into cells. After cleavage by intracellular esterases
through de-esterification reaction, the 2′,7′-dichlorodihydrofluorescein (DCFH2 ) is formed
[31] (Figure 3.23, red frames, top). Upon undergoing a two-electron oxidation by intracellular
ROS, the non-fluorescent DCFH2

is converted to

the highly

fluorescent 2',7'-

dichlorofluorescein (DCF) [31] (Figure 3.23, red frames, middle) . The green fluorescence
can be detected by a confocal microscope, a fluorescence microscope, or a plate reader, or by
flow cytometry, with excitation at 485 ± 10 nm and emissions at 530 ± 12.5 nm band-pass
filter [32].
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Figure 3.23. Schematic illustration of ROS detection. The production of fluorescent DCF by
intracellular ROS.
In this thesis work, cells with and without treatment by NPs were stained with
H2 DCF-DA, and the intracellular ROS levels were measured using a BD-LSR-II flow
cytometer. In brief, cells were first treated with ITO NPs at a concentration of 50 µg/mL for
24 hours. At the end of treatment, cells were harvested by following the standard procedure
described in 3.4.3 and 3.4.4. Afterwards, cells were incubated with 500 µL of 40 µM
H2 DCFDA in the dark for 30 minutes, then washed three times with PBS. Cells were then
resuspended with 500 µL of PBS and transferred into 5 mL polystyrene tubes. Data was
acquired using a LSR-II flow cytometer (excitation at 488 nm, emissions collected with a
515/20 nm band-pass filter), and the relative fluorescent intensity of dichlorofluorescein
(DCF) was determined using FlowJo software. To be noted, in some MDA-MB-231 and
MCF-7 experiments, ITO NP-induced ROS generation was examined. MDA-MB-231, and
MCF-7 cells were preincubated in the absence or presence of 0.5 mM and 5 mM of the ROS
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scavenger, NAC, respectively for 1 hour prior to ITO NPs addition. In the MCF-10A
experiments, ITO NP-mediated ROS scavenging was examined. Cells were incubated with
ITO NPs for one hour, and then incubated in the absence or presence of 0.5 mM H 2 O2 , where
H2 O 2 served as an additional source of ROS. In all experiments, cells incubated with NAC or
H2 O 2 alone served as negative or positive control samples, respectively. Cells preincubated
with NAC for 1 hour prior to addition of H2 O 2 served as a quality control sample for testing
the validation of the experiment.

3.5.8 Detection of Apoptosis
Apoptosis, well known as programmed cell death, has been demonstrated to be
involved in a number of diseases, including cancer. Apoptosis is also a carefully regulated
cellular process that is responsible for many biological processes, including tissue growth
regulation, selective cell removal, proper function of the immune system, and many others
[33]. Dysfunction of apoptosis leads to a number of diseases and health concerns. In this
regard, understanding the process of apoptosis is crucial for developing the correlated
therapies. Over the years, several standard techniques, such as elec tron microscopy, the
TUNEL assay, and flow cytometry have been discovered and developed to detect apoptosis
[33].
Flow cytometry is a common method used in apoptosis detection or verificat ion, and
it gives information on the ratio of apoptotic cells while also measuring cell viability [33].
Furthermore, this technique makes it possible to assay caspase activity, DNA cleavage,
membrane dynamics, the viability of dyes, and a number of other apoptosis parameters such
as light scattering [33].
In this doctoral work, cells with and without treatment by NPs were stained with
H2 DCF-DA, and the intracellular ROS levels were measured using a BD-LSR-II flow
cytometer. In brief, cells were first treated with ITO NPs at a concentration of 50 µg/mL for
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24 hours. At the end of treatment, cells were harvested by following the standard procedure
described in 3.4.3 and 3.4.4. Afterwards, cells were incubated with 500 µL of 40 µM
H2 DCFDA in the dark for 30 minutes, then washed three times with PBS. Cells were then
resuspended with 500 µL of PBS and transferred into 5 mL polystyrene tubes. Data was
acquired using a LSR-II flow cytometer (excitation at 488 nm, emissions collected with a
515/20 nm band-pass filter), and the relative fluorescent intensity of dichlorofluorescein
(DCF) was determined using FlowJo software. To be noted, in some MDA-MB-231 and
MCF-7 experiments, ITO NP-induced ROS generation was examined. MDA-MB-231, and
MCF-7 cells were preincubated in the absence or presence of 0.5 mM and 5 mM of the ROS
scavenger, N AC, respectively for 1 hour prior to ITO NPs addition. In the MCF-10A
experiments, ITO NP-mediated ROS scavenging was examined. Cells were incubated with
ITO NPs for one hour, and then incubated in the absence or presence of 0.5 mM H 2 O2 , where
H2 O 2 served as an additional source of ROS. In all experiments, cells incubated with NAC or
H2 O 2 alone served as negative or positive control samples, respectively. Cells preincubated
with NAC for 1 hour prior to addition of H2 O 2 served as a quality control sample for testing
the validation of the experiment.
3.5.8.1 Annexin-V and 7-aminoactinomycin-D (7-AAD) Double Staining
Apoptosis can be characterized by a variety of morphological features, including loss
of membrane asymmetry and attachment, condensation of the cytoplasm and nucleus, and
endonuclease cleavage of DNA [34]. Membrane phospholipid phosphatidylserine (PS) can be
an indicator for apoptosis. Under normal physiological conditions, PS is predominantly
located in the inner leaflet of the plasma membrane. Upon initiation of apoptosis, PS loses its
asymmetric distribution across the phospholipid bilayer and is translocated from the inner to
the outer leaflet of the plasma membrane [34].
Annexin-V is a Ca2+-dependent phospholipid binding protein with a high affinity for
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PS, which can bind to the exposed PS during apoptosis [35]. Annexin- V cannot exclude the
late apoptosis (dead cells) or necrosis, because PS translocation also occurs in such
conditions [35]. Therefore, a DNA binding protein, 7-AAD, is a viability dye that penetrates
the plasma membrane only when the membrane integrity is damaged as this occurs in late
apoptosis and necrosis, so that 7-AAD is used as an indicator of late apoptosis or necrosis
[35]. In combination, using flow cytometry, with double staining by fluorescein-conjugated
Annexin-V and 7-AAD viability dye, the early apoptotic, late apoptotic, and viable cells can
be examined, as illustrated in Figure 3.24.

Figure 3.24. Working principle of fluorescein-conjugated Annexin-V and 7-AAD double
staining for the detection of apoptosis. The data readout from flow cytometry is indicated.
In this doctoral thesis, cells with and without treatment by NPs were stained with

96

CHAPTER 3 – Materials and Methodology
Annexin-V conjugated Alexa-488 and 7-AAD, and the cell apoptosis could be examined by
analyzing the emitted fluorescence intensity from both dyes measured using a BD-LSR-II
flow cytometer. In brief, cells were treated with ITO NPs at a concentration of 50 µg/mL for
24 hours. At the end of treatment, cells were typsinized, centrifuged, and washed once with
Annexin-V binding medium (NaCl medium containing 5 mM CaCl2 ) [36]. Cells were then
incubated with Annexin-V binding medium containing Annexin- V conjugated Alexa-488 and
7-AAD at room temperature in the dark for 15 minutes. Data were then acquired using a
LSR-II flow cytometer (excitation at 488 nm, emissions collected with 515/20 nm and 695/40
nm band-pass filters for Annexin- V conjugated Alex 488 and 7-AAD, respectively). To be
note, in some MDA-MB-231 and MCF-7 experiments, cells were preincubated in the absence
or presence of 0.5 mM and 5 mM of NAC, respectively, for 1 hour prior to addition of ITO
NPs, where NAC used as a ROS scavenger to assess whether the ITO NP-induced ROS
generation was associated with activation of cellular apoptosis. In some MCF-10A
experiments, cells were first incubated with ITO NPs for one hour and then incubated in the
absence or presence of 0.5 mM H2 O2 , where H2 O2 was used as an additional ROS source to
assess whether the ITO NP-mediated ROS scavenging behaviour was associated with
reduction of cellular apoptosis.
3.5.8.2 Alternative Method for Identifying Apoptosis
Although the fluorescein-conjugated Annexin- V and 7-AAD double staining is a
common method used to detect early apoptotic, late apoptotic, and viable cells populations. In
some adherent growth cell lines, however, membrane damage during the cell- harvesting
process can cause substantial experimental bias [36]. In some cases, cells are detached
enzymatically by standard trypsizination or mechanically by scraping or wash-down with a
water jet, which will cause cell membrane damage and therefore lead to false-positive
Annexin-V binding [36]. In order to avoid such experimental bias introduced by the false-
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positive Annexin-V staining, an alternative experimental method or alternative analytic
method should be considered for identifying apoptosis.
Single staining of 7-AAD has been reported to correctly identify early and late
apoptotic/dead cell populations and that it can be used for analysis of apoptosis by flow
cytometry [37, 38]. Generally, at low concentrations (0.5 – 5 µg/mL), 7-AAD is used to
exclude the dead cells in flow cytometry. At higher concentrations (10–20 µg/mL), 7-AAD
can be used to distinguish between viable cells (7-AADnegative) and apoptotic cells (7-AADdim)
or dead cells (7-AADbright ) by its permeability through the cell membrane, so that the
fluorescence intensity is low in early apoptotic cells and high in late apoptotic and dead cells,
as illustrated in Figure 3.25 [38]. 7-AAD successfully labels cells during the early phase of
apoptosis to a degree comparable to Annexin- V, which binds to extracellular
phosphatidylserine of early apoptotic cells [38].

Figure 3.25. Data readouts and gating method for 7-AAD single stained sample cells,
adapted from [38]. Black dots represent untreated unstained control cells. Gray dots represent
cytostatic and saponine-treated stained cells (20 µg/mL, 20 min, 4 ℃). FSC-A: forward
scattering - area; 7-AAD-A: 7-AAD - area.
In this doctoral thesis, cells with and without treatment by NPs were stained with
Annexin-V conjugated Alexa-488 and 7-AAD, and the fluorescence intensity of 7-AAD was
measured using a BD-LSR-II flow cytometer. The acquired data were analyzed using the
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same gating method presented in Figure 3.25, and the total number of apoptotic cells,
including early apoptotic and late apoptotic/dead cells, was determined.

3.5.9 Cell Survival and Proliferation
Cell survival and proliferation were studied using clonogenic cell survival assay and
MTT cell viability assay. The clonogenic assay was initially used for ionizing radiation in
cancer therapy, and it is now widely used to investigate the effects of agents with potential
biomedical applications in the clinic, including chemotherapy agents such as etoposide and
cisplatin, antiangiogenic agents such as endostatin and angiostatin, and cytokines and their
receptors, either alone or in combination therapy [39]. This assay is time-consuming and has
low efficiency, however, leading researchers to investigate alternative methods with short
turn-around times but higher efficiency in terms of preclinical drug-screening for rapid drug
sensitivity testing.
Alternatively, the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide
(MTT) assay is a faster, simpler, highly sensitive, and high- throughput screening assay, and
has become the gold standard for determination of cell viability and proliferation [40]. A
study of drug-screening tests comparing clonogenic with MTT assays in five lung cancer cell
lines was reported, and the results obtained from both methods revealed good correlation
coefficients, which depend on the drugs used in treatments. The correlation coefficient
showed a high value of 0.939 for treatment by platinum analogues, while it decreased to
0.611 with treatment by anthracyclines/anthracenedione [41].
In this thesis work, MDCK, 9L, MCF-7, MDA-MB-231, and MCF-10A cells were
exposed to ITO NPs to examine the cell survival using the clonogenic cell survival assay.
RWPE-1, PANC-1, and MIA PaCa-2, MDA-MB-231, MCF-7, and MCF-10A cells were
exposed to IZO NPs to evaluate the cytotoxicity of IZO NPs using the MTT cell viability
assay.
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3.5.9.1 Clonogenic Cell Survival Assay
The in vitro clonogenic cell survival assay has been used for decades and is based on
the ability of a single cell to form a colony, which is defined as a cluster of at least 50 cells,
so that it is also known as the colony formation assay [42]. This assay is a gold standard but
not limited to radiobiology, because it basically examines every individual cell in the
population for its capability to undergo theoretically unlimited cell division [42, 43]. This
technique is commonly selected to investigate cell reproductive death after treatment with
ionizing radiation, but it is also be widely used to examine the effectiveness of other
cytotoxic compounds and other anti-cancer therapeutics on cell survival and proliferation
[43].
The clonogenic assay is performed in several steps (Figure 3.26), including seeding of
cells, exposure of cells to cytotoxic compounds (NPs), drugs or ionizing radiation, where
sample cells without any exposure serve as the control, trypsinization of all seeded cells, and
then plating of cells, and incubation of plated cells for 15 doubling times to allow the cells to
grow into colonies. The final step is to wash, fix, and stain the formed colonies, and to count
them under a microscope to determine of the surviving fraction in each sample.
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Figure 3.26. Schematic illustration of the procedure for the clonogenic cell survival assay.
The obtained number of cell colonies is used to determine the plating efficiency (PE)
for both the untreated control and the treated cells. PE is the ratio of the number of counted
colonies (

to the number of cells seeded (

), as shown in Equation (3.7)

[42]:

The PE is then used for further determination of the surviving fraction (SF in %) of
the treated cells. The relationship between PE and SF is described in Equation (3.8) [42]:
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where

is the plating efficiency of the treatment, and

is the plating efficiency of the

control.
Determination of optimum cell seeding density:
Before performing the formal clonogenic assay experiment, it is important to
determine the optimum seeding density for every individual cell line in order to yield
reasonable colonies, generally 100 to 150 colonies, which could help to avoid difficulty in
counting cell colonies.
Determination of optimum concentration of ITO NPs:
To be noted, in this thesis, the used concentration of all tested ITO NPs for all
clonogenic experiments was 50 µg/mL, because that concentration would give the best results
on the observation of cellular ROS generation and scavenging, and one of the object in this
thesis study is to link the ROS generation with higher cancerous cell cytotoxicity. Therefore,
the nanoparticle with a concentration of 50 µg/mL was set as an optimum concentration in
this thesis study.
In this thesis, clonogenic assays were performed to evaluate the long-term
cytotoxicity of the synthesized NPs. Cells were first seeded into T12.5 flasks (Falcon) and
incubation stopped at one-day before the cells reached 80% confluence, and then the
suspension of ITO NPs was added into the flasks for a total concentration of 50 µg/mL and
left for 24 hours. After 24 hours treatment, cells were trypsinised, plated at a cell density
range from 400 to 20000 (depending on the cell type) into 100 mm Petri dishes (BD Falcon)
with 10 mL complete cell culture medium, and incubated for 15 doubling times at 37 0 C and
5% (v/v) CO 2 . Colony formation of the cells was terminated by washing with 5 mL DPBS
(with Ca2+ and Mg2+), and the cell colonies were visualized by staining with a solution of
25% (v/v) crystal violet and 75% (v/v) ethanol. Cell colonies were counted using optical
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microscopy, with colonies defined by groups of at least fifty cells. The surviving fraction was
obtained by the comparison of the plating efficiency between the control and the treated
samples.
3.5.9.2 MTT Cell Viability Assay
The MTT cell viability assay is a colorimetric assay used to measure the activity of
mitochondrial enzymes, which reduce yellow MTT tetrazolium salt to water- insoluble
formazan, showing a purple color [44], as illustrated in Figure 3.27. This method is useful in
a variety of applications because it allows us to assess the cell viability, cell proliferation, and
cytotoxicity [45, 46].

Figure 3.27. Schematic illustration of the working principle of the MTT cell viability assay.
Theoretically, the use of the MTT cell viability assay to assess the cell proliferation is
assumed, as only viable cells with active metabolic activity are able to convert MTT into a
purple colored formazan product [44]. Therefore, an increase in cell proliferation is directly
proportional to an increased production of formazan, while a decrease in cell proliferation
(formazan) can indicate the toxic effects of potential drug agents and toxic materials, as those
agents would stimulate or inhibit cell viability and growth [46, 47]. The water- insoluble
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formazan crystals can be dissolved using various solvents, including typically DMSO,
acidified isopropanol, sodium dodecyl sulfate, and other combinations of detergents and
organic solvents [44]. The quantity of the formazan is examined using a plate reading
spectrophotometer to record changes in absorbance at 570 nm [44], as schematically
displayed in Figure 3.28.

Figure 3.28. Schematic illustration of the procedure for the MTT cell viability assay.
Determination of optimum cell seeding density:
Before performing the formal of MTT cell viability assay experiment, it is important
to determine the optimum seeding density for every individual cell line in order to yield an
absorbance of approximately 1.0, which could help one to avoid the creation of experimental
bias. The cell viability is determined using Equation (3.9), as described below:
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where

is the absorbance of the treatment and

is the absorbance of the control.

In this thesis work, MTT assay was used to evaluate the cell viability affacted by IZO
NPs in malignant PANC-1, MIA-PaCa-2, MDA-MB-231, and MCF-7 cells, and nonmalignant RWPE-1 and MCF-10A cells. Briefly, 1 × 104 cells/well were seeded in 96-well
plates and exposed to IZO NPs at the concentrations of 0 µg/mL, 50 µg/mL, 100 µg/mL, and
200 µg/mL for 24 hours. At the end of exposure, the culture medium was removed from each
well to avoid interference with the IZO NPs, replaced with 100 µL of medium containing 10
µL of MTT stock solution, and incubated for 4 hours at 37°C until a purple-colored formazan
product was formed. The resulting formazan product was dissolved in DMSO. Then, the 96well plate was centrifuged at 1500 rpm for 5 minutes to settle the remaining IZO NPs, and
100 μL of supernatant was transferred into a new well in a new 96-well plate. Finally, a
SpectraMax 384 Plaus (Molecular Devices) microplate reader was used to measure the
absorbance at 570 nm. The EC50 value, the concentration that gives a half- maximal response,
was calculated using Prism 7 for Mac (GraphPad Software, San Diego, CA).
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4.1 Preface
For decades, researchers have made a lot of efforts to combat cancer; however, one of
the major issues for current used anticancer drugs is their poor selectivity [1-4]. The use of
nanomaterials has become a new strategy to develop nanomedicines with multiple
functionalities, higher selectivity and improved therapeutic efficacy [5]. Many conventional
metal oxide materials with a size in nanoscale, have been recently reported to possess
superior anticancer ability with noticeable selectivity [6-9]. Tin doped indium oxide (ITO)
nanomaterial, a well-known material, has been extensively applied in a variety of fields [1014], however, only very limited studies have focused on the anticancer properties of ITO
nanoparticles (NPs). In fact, to the best of our knowledge, there has been almost no study
reported the possible selective cytotoxicity of ITO NPs between malignant and nonmalignant cells. Therefore, the potential anticancer properties and selective toxicity of ITO
NPs remain an undeveloped area that should be explored.
This study was designed to investigate the selective cytotoxic effect of ITO NPs
against cancerous 9L and MCF-7 cells, and non- malignant MDCK cells. The crystal structure
and morphology of the synthesized ITO NPs were characterized using a variety of tools,
including XRD, TEM, STEM, EDS, and XPS. Cellular internalization of ITO NPs was
demonstrated by flow cytometry. The clonogenic assay was used for further examination of
their cytotoxicity and the effects on cell proliferation.

4.2 Experimental Section
4.2.1 Materials
Indium metal (> 99.8%), anhydrous tin tetrachloride (> 99.9%), ammonium
hydroxide (28–30%), crystal violet solution (2.3% crystal violet, 0.1% ammonium oxalate,
20% ethyl alcohol), denatured ethanol, and reagent-grade ethanol were all purchased from
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Sigma-Aldrich (Australia). Hydrochloric acid (36%) was purchased from UNIVAR
(Australia). Dulbecco‟s Modified Eagle Medium (DMEM), fetal bovine serum (FBS),
penicillin, streptomycin, Dulbecco‟s phosphate-buffered saline (DPBS), phosphate-buffered
Saline (PBS), and trypsin ethylenediaminetetracacetic acid (trypsin-EDTA) were purchased
from Life Technologies (Australia).

4.2.2 Synthesis of Air-calcined ITO Nanoparticles via Coprecipitation
The ITO precursor were first synthesized through a classical coprecipitation method,
as described in Section 3.1.2. Briefly, 5 g of indium metal (0.044 mmol) was dissolved in 20
mL of 36% HCl with 0.514 mL (0.0045 mmol) of anhydrous tin tetrachloride. Then, 30%
ammonium hydroxide was added to the flask until a white precipitate precursor was obtained.
The precipitate precursor of ITO was then aged for 24 hours, filtered, and washed with
deionized water. The washed precursor, the so-called indium tin hydroxide (ITOH), was
dried for 12 hours at 353 K and was calcined in a horizontal LABEC tube furnace at 673 K
for 1.5 hours in air, yielding the air-calcined ITO NPs.

4.2.3 Characterizations of ITO Nanoparticles
A Mettler Toledo TGA/DSC 1 STARe system was used to determine the minimum
temperature for annealing the ITO precursor. The specific surface area of the ITO NPs was
determined by N 2 adsorption/desorption isotherms using BET equipment (Micromeritics
TriStar II 3020), before which, the powders were degassed at 150 °C for 10 h under vacuum.
An Enhanced Mini-Materials Analyzer (EMMA) X-ray diffractometer (XRD) from GBC
Scientific was used to identify the phases of the ITO nanostructure. The morphology and
crystal structure of the as-prepared products were observed through TEM (JEM-2011F, JEOL,
Tokyo, Japan) imaging. The crystal structure of the ITO NPs was confirmed by an HRTEM
image and the corresponding fast Fourier transform (FFT) pattern. The elemental
composition (purity) of the ITO NPs was determined by EDS, using a JSM7500FA cold field
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emission gun scanning electron microscope equipped with an X-Flash 4010 10 mm2 , 127 eV
silicon drift detector (SDD) energy dispersive X-ray detector (Bruker, USA). The elemental
mapping was carried out by EDS using the JEOL ARM200F. The chemical states of the
nanostructures were determined by XPS (PHOIBOS 100 Analyser from SPECS; Al K α Xrays, Berlin, Germany).

4.2.4 Cell Culture and Exposure to ITO Nanoparticles
Cell experiments were performed using GS-9L rat glioma cells, MCF-7 breast cancer
cells (mammary gland adenocarcinoma cell lines), and non- malignant epithelial Madin- Darby
Canine Kidney (MDCK) cells. All cells were purchased from the European Collection of Cell
Cultures (ECACC), and were cultured in DMEM medium supplemented with L-glutamine,
FBS (10% (v/v)), and penicillin/streptomycin (1% (v/v)) at 37°C with 5% (v/v) CO 2 . Cells
were maintained in T-75 cm2 tissue culture flasks (Falcon Franklin Lakes, New Jersey, USA),
and subcultured using 0.05% trypsin-EDTA. At 80% confluence, cells were transferred into
new flasks or into other sized flasks and plates for passaging or experiments as indicated
below. For cell passaging, cells were transferred into new T-75 flasks; for measurements of
cellular internalization, cells were transferred into T-25 flasks; for determination of cell
survival and proliferation, cells were first transferred into T-12.5 flasks, and after treatment
with ITO NPs, cells were then transferred into 100 mm Petri dishes (BD Falcon). All flasks
and plates with seeded cells were maintained in an incubator supplied with 5% (v/v) CO 2 at
37°C and. In all experiments, cells were grown until one day before 80% confluence, prior to
exposure to ITO NPs. Cells were exposed to ITO NPs with a total concentration of 50 µg/mL
for 24 hours, and then harvested to examine cellular internalization, and cytotoxicity. Cells
without ITO NP exposure served as control samples in each experiment.

4.2.5 Cellular Internalization of ITO Nanoparticles
Suspensions of ITO NPs were added to 9L, MCF-7, and MDCK cells, with a final
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concentration of 50 µg/mL. After treatment for 24 hours, the cells were harvested using
0.05% trypsin- EDTA, and then centrifuged and washed twice with PBS. The individual cell
pellets were resuspended in 500 µL of PBS, transferred into 5 mL polystyrene flow tubes,
and transferred to a BD-LSR-II flow cytometer for the measurements. The intensity of the
forward scattered (FSC) light is proportional to the size and surface area of the cell, while the
intensity of the side scattered (SSC) light is proportional to cell granularity and complexity,
so that this technique can be used to determine cellular internalization of NPs [15]. Data were
acquired using a LSR-II flow cytometer. FlowJo software (Tree Star, Ashland, OR) was used
to analyze the collected data and to determine the relative degree of cellular internalization of
the ITO NPs.

4.2.6 Clonogenic Cell Survival Assay
Clonogenic cell survival assays [16] were performed to evaluate the cytotoxicity of
ITO NPs. 9L, MCF-7, and MDCK cells were first seeded into T-12.5 flasks (Falcon), and
incubation was stopped at one-day before the cells reached 80% confluence. The suspension
of ITO NPs was then added into the flasks for a total concentration of 50 µg/mL and left for
24 hours. After 24 hours treatment, the cells were trypsinised, plated in triplicate at a cell
density range from 400 to 20000 cells (depending on the cell type) into 100 mm Petri dishes
(BD Falcon) with 10 mL complete cell culture medium, and incubated for 15 doubling times
at 37℃ with 5% (v/v) CO 2 . Colony formation of the cells was terminated by washing with 5
mL DPBS (with Ca2+ and Mg2+), and the cell colonies were visualized by staining with a
solution of 25% (v/v) crystal violet and 75% (v/v) ethanol. Cell colonies were counted using
optical microscopy, with colonies defined by groups of at least fifty cells. The surviving
fraction was obtained by comparing the plating efficiency of the control with those of the
treated samples.

4.3 Statistical Analysis
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Data were presented as the mean ± standard deviation (SD). All statistical differences
between the control and treatments were analyzed using the two-tailed t-test. Data analysis
was performed using Prism 7 for Mac (GraphPad Software, San Diego, CA). A value of p <
0.05 was considered statistically significant.

4.4 Results
4.4.1 TGA and BET Characterizations of ITO Nanoparticles
The TGA curve of the ITO precursor (indium tin hydroxide, ITOH) is displayed in
Figure 4.1, which demonstrates a total weight loss of about 20% when heating from room
temperature to over 1000℃, suggesting there may be around 20% H2 O 2 presented in the
synthesized ITO precursor. As can be seen in Figure 4.1, clearly, almost 18% weight loss
occured when the ITO precursor was heated until 289℃. After heating over 700℃, the mass
loss of the ITO precursor increased another 2%, reaching a total weight loss of 20%, and no
further weight chang was found beyond this termperature, indicating that the minimum
temperature for calcination of ITO NPs must be higher than 289 ℃ , and an expected
completely dried ITO NPs could be obtained when heated over 700℃. To evaluate the
specific surface area of the air-calcined ITO NPs, BET equipment was used, and the
measured BET specific surface area for the air-calcined ITO NP was 88.08 m2 g-1 .
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Figure 4.1. TGA curve demonstrating the weight loss of the ITO precursor during the heating
procedure.

4.4.2 XRD Characterization of ITO Nanoparticles
In order to determine the phase of the ITO crystal structure, X-ray diffraction was
used. First order diffraction peaks of the synthesized ITO NPs have been labelled (Figure 4.2)
after correlating the recorded data with the Joint Committee on Powder Diffraction Standards
file (JCPDS # 06-0416).
Using the obtained XRD data, the structure of the sample can be examined. The
recorded XRD pattern indicates that the air-calcined ITO nanomaterial is single phase In2 O3
powder with a body-centered cubic crystalline structure. Furthermore, no significant peaks
corresponding to tin oxide or other impurities were detected, and the ITO lattice parameter
showed no change, suggesting that the Sn atoms were well incorporated into the In2 O3 crystal
lattice, so that high quality ITO NPs were synthesized. The average crystallite size of the
prepared ITO NPs can be calculated by the Scherrer equation [17] based on the XRD pattern,
and it was 6.87 ± 1.55 nm.
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Figure 4.2. X-ray diffraction pattern of the synthesized ITO NPs.

4.4.3 TEM Characterization of ITO Nanoparticles
Figure 4.3 displays the TEM image (A), HRTEM image (B), and the fast Fourier
transform (FFT) pattern (C) of the ITO NPs. Figure 4.3(A) demonstrates the morphology and
the particle size of the air-calcined ITO NPs. The HRTEM image and the corresponding FFT
pattern displayed in Figure 4.3(B-C) present a well-defined crystalline structure with lattice
fringe spacings of 0.29, and 0.25 nm (B), corresponding to the (222) and (004) facets of cubic
spinel In2 O3 (C), respectively.

Figure 4.3. (A) TEM and (B) HRTEM images, and (C) FFT pattern of the synthesized ITO
NPs.
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4.4.4 EDS Characterization of ITO Nanoparticles
The elements of ITO NPs were confirmed by their EDS spectrum (Figure 4.4) and
high-resolution EDS mapping (Figure 4.5). It is clear from Figure 4.4 that In, Sn and O were
the main elemental species in the ITO sample, and Figure 4.5 displays a homogeneous
distribution of In, Sn, and O atoms. An expected weight ratio of approximately 9:1 of
In2 O 3 /SnO 2 for the ITO NPs was also confirmed by the EDS measurements.

Figure 4.4. EDS spectrum of the ITO NPs.

Figure 4.5. TEM images with high-resolution EDS mapping of ITO NPs.

4.4.5 XPS Characterization of ITO Nanoparticles
The chemical composition of the prepared ITO nanomaterials was examined using
XPS. Figure 4.6(A-B) shows the corresponding XPS spectra of the In 3d and Sn 3d core
levels of the synthesized ITO NPs. Figure 4.6(A) shows that two peaks located at 444 ± 0.4
eV and 452.0 ± 0.4 eV represented the binding energies of In 3d 3/2 , and In 3d5/2 , respectively,
and these peaks were associated with In ions present in the In-O bonds, whereas no peak
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corresponding to metallic In was found, suggesting that indium oxides were formed [18].
Figure 4.6(B) shows two symmetric peaks located at 486.6 ± 0.4 eV and 495.0 ± 0.4 eV
corresponding to the binding energies of Sn 3d 3/2 and Sn 3d5/2 , respectively, for the asprepared ITO NPs. The binding energy of the Sn 3d 3/2 peak for the as-prepared ITO NPs was
very close to that for SnO 2 (Snoxide 3d3/2 : 486.4 eV) [19], and far away from that for metallic
tin (Snmetal 3d3/2 : 484.9 eV) [22], suggesting that all the Sn ions were in the valence state of
Sn4+ and well incorporated into the crystalline structure of the as-prepared ITO NPs.

Figure 4.6. High-resolution XPS spectra of (A) In 3d and (B) Sn 3d of the ITO NPs.

4.4.6 Cellular Internalization of ITO Nanoparticles
Flow cytometry measurements of the mean side scattering (SSC) were used to
determine the relative cellular uptake of NPs into 9L, MCF-7, and MDCK cells. As can be
seen in Figure 4.7(A-C), the forward scattering (FSC) of all type of cells remained unchanged
after treatment with ITO NPs compared with their corresponding untreated control samples.
This suggested that, at least to a certain degree, the ITO NPs did not adhere to the surfaces of
the cells [15]. While the untreated cells exhibited the least SSC, after treatment with ITO NPs,
the cells exhibited a significant increase in SSC, indicating that an increase in the degree of
cell internal complexity had occurred, which thus confirmed the cellular uptake of ITO NPs
[15, 20]. The quantitative results in Figure 4.7(D) show that the ITO nanoparticles were
internalized by the 9L, MCF-7, and MDCK cells by factors of around 2.48, 1.89, and 1.53
fold over the corresponding untreated samples, respectively. The results also indicated a
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difference in cellular uptake of ITO NPs between malignant and non-malignant cells.
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Figure 4.7. Flow cytometry histograms (A), (B), and (C) show the cellular internalization of
ITO NPs through forward and side scattering, respectively, in 9L, MCF-7, and MDCK cells.
Comparisons of cellular internalization between different control and treated samples were
quantified and are presented in (D). In (A-C), the control and treated samples were the cells
without ITO NP exposure and the cells with treatment by ITO NPs at a concentration of 50
µg/mL for 24 hours, which are represented by the blue lines and the red lines, respectively. In
(D), the control and the treated samples in different cells are represented by blue bars, and red
bars, respectively. The *** indicates p < 0.001 for the comparison with the corresponding
control sample.

4.4.7 Selective Cytotoxicity of ITO Nanoparticles
The clonogenic assay was used to examine the cytotoxicity of the ITO NPs in
malignant 9L and MCF-7 cells, and in non- malignant MDCK cells. The surviving fractions
of 9L, MCF-7, and MDCK cells after 24 hours of treatment with ITO NPs at a concentration
of 50 µg/mL, as determined using the clonogenic assay, are presented in Figure 4.8. The
surviving fractions in both 9L and MCF-7 tumor cells were significantly decreased,
indicating very high mortality in malignant cells. In contrast, after treatment with ITO NPs,
the surviving fraction of MDCK cells presented no remarkable change compared with the
untreated control sample, which indicated the presence of selectivity and suggested that the
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prepared ITO NPs were biocompatible.

Figure 4.8. Quantitative clonogenic results for 9L (left), MCF-7 cells (middle), and MDCK
cells (right) treated with and without ITO NPs. The concentration of ITO NPs for the
treatment was 50 µg/mL, and “Control” represents the samples without treatment. ***
indicates p < 0.001, and **** indicates p < 0.0001 for the comparison with the untreated
control.

4.5 Discussion
For the past several decades, the application of metal oxide NPs for cancer treatment
has been the subject of a number of studies [21-23]. The development of a cytotoxic
nanomaterial with high selectivity that could only destroy tumor cells without posing much
risk to normal cells is highly desirable and will be beneficial to clinical application.
ITO NPs were first synthesized through a classic co-precipitation route and were
calcined in air. Through the co-precipitation method, NPs with higher homogeneity in their
component distribution and a more uniform particle size with weakly agglo merated particles
can be achieved [24]. Characterization of the air-calcined ITO NPs using XRD revealed
important properties that were essential for understanding the ir crystal structure. The results
show that the synthesized nanomaterial is a single phase of In2 O3 powder with a bodycentered cubic crystalline structure, existing as In2 O3 by comparison with the standard
diffraction pattern of indium oxide ((JCPDS # 06-0416) [25-27]. The broad diffraction peaks
confirm the nano-crystallinity of the ITO NPs, with the mean crystallite size measured to
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range from 6-8 nm. The TEM image shows that the air-calcined ITO NPs are highly
aggregated and seem to have some pores present in the particles. The HR-TEM image and the
corresponding FFT pattern of the air-calcined ITO NPs present the distinct lattice fringes and
support the presence of a body-centered cubic nanostructure with distances between
successive fringes of 0.29 and 0.25 nm, corresponding to the (222) and (004) facets of cubic
spinel In2 O3 , respectively. The results are in agreement with our XRD spectrum (Figure 4.2).
The EDS spectrum (Figure 4.4) shows that only the distinct peaks of In, Sn, and O are
obtained, and no other peak corresponding to any elemental impurity is present in the
prepared ITO crystal structure, while the high-resolution EDS mapping of ITO NPs (Figure
4.5) presents a homogeneous distribution of In, Sn, and O atoms. These results indicate that
the Sn atoms are well- incorporated into the In2 O3 nanostructure and that high quality ITO
NPs were fabricated. An expected weight ratio of approximately 9:1 of In2 O 3 /SnO 2 for the
ITO NPs is also confirmed from the EDS measurements. The chemical composition of the
prepared ITO nanomaterials was examined using XPS. The XPS spectrum of the In 3d core
level of the synthesized ITO NPs demonstrates that the chemical composition of In is only in
the form of oxides, with no metallic In detected. The XPS spectrum of the Sn 3d core level of
the synthesized ITO NPs indicates that the Sn ions are in the valence state of Sn4+ and are
well incorporated into the crystalline structure of the as-prepared ITO NPs. These XPS results
are also consistent with our results from XRD analysis. Flow cytometric analysis was used to
examine whether ITO NPs could be internalized into 9L, MCF-7, and MDCK cells. The
cellular internalization was confirmed as a result of increases in the measured cell side scatter,
while the forward scatter showed no change. The toxicity of air-calcined ITO NPs with
respect to 9L, MCF-7, and MDCK cells was tested to elucidate their clonogenic survival at a
concentration of 50 μg/ml. Following a 24 h incubation of 9L, MCF-7, and MDCK cells with
ITO NPs, significant toxic effects towards 9L and MCF-7 cells were observed with less than
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5% and around 35% surviving, respectively. In contrast, the surviving fraction of MDCK
cells showed almost no change compared with the untreated control sample, demonstrating
the biocompatibility and selectivity of the prepared ITO NPs. These clonogenic results
support the proposition that the synthesized ITO NPs are highly selective and extremely toxic
towards only the malignant cells. Although the mechanism of how the air-annealed ITO NPs
mediate the selectivity between malignant and non- malignant cells has not been clearly
explored in this chapter, the ITO NPs mediated ROS generation is hypothesized as the
possible mechanism to destroy cancer cells, based on some available research publications.
Several types of nanosized metal oxide materials have been reported to induce ROS, which
then activate apoptosis in cancer cells. Studies show that cuprous oxide NPs could selectively
activate the apoptosis of tumor cells through ROS generation [6, 7]. Zinc oxide NPs have also
been demonstrated a selective tumor-killing capability that acts through ROS induced
apoptosis of cancer cells [8, 9]. Similar to the above mentioned materials, the air-calcined
ITO NPs may possess the same property that can selectively generate sufficient ROS in
tumor 9L, and MCF-7 cells, and then trigger the ROS pathway to kill these malignant cells,
resulting in high cancer cell mortality.

4.6 Conclusion
In this study, air-calcined ITO NPs with high quality were synthesized, and the
cellular internalization of the ITO NPs in 9L, MCF-7, and MDCK cells was confirmed.
Furthermore, the as-prepared ITO NPs exhibited extremely high cytotoxicity towards
malignant 9L and MCF-7 cells, while they presented biocompatibility with non-malignant
MDCK cells. To the best of our knowledge, this is the first study to investigate the toxic
effects of ITO NPs in both malignant and non-malignant cells. Although the complete
mechanism of how the air-calcinaed ITO NPs to induce high selective cytotoxicity between
malignant and non-malignant cells requires more studies to be conducted, the cellular effects
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of air-calcined ITO NPs, evaluated by in vitro experiments on different cancer and normal
cell lines may provide some insights into their further application in cancer therapy.
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5.1 Preface
Oxidative stress, a globally damaging mechanism in all biological systems, is caused
by an imbalance between the production of ROS and the ability of biological systems to
readily detoxify the reactive intermediates or easily repair the resulting damage. ROS is a
term collectively describing reactive oxygen derived free radicals as well as non-radical
reactive oxygen derivatives [1]. Excessive ROS that cannot be eliminated by the human
biological antioxidant system will lead to oxidative stress damage to all cell components [24], and results in many diseases, the most importantly, cancer [5-8]. Nevertheless, ROS is a
double-edge sword; cellular production of ROS plays a very significant positive role in
physiological responses in a number of cases including cellular apoptosis (programmed cell
death), cell redox signaling, and cell homeostasis [2, 7, 9, 10], where induction of cellular
apoptosis in cancer cells has become a conventional strategy in nanomedicine for cancer
therapy. Recent nanomedicine including several types of nanosized metal oxide materials
have been reported to induce generation of intracellular ROS, which then activate apoptosis
in cancer cells and destroy the cells [11-15]. Although some authors of these studies have
pointed out that their materials possess “selectivity” between tumor and non-malignant cells,
they often refer to the “selectivity” as meaning no harm or only moderate toxicity to the
reference non- malignant cells rather than any claims for the ability of the studied materials to
protect the non- malignant cells from oxidative stress through ROS scavenging. On the other
hand, although some research results demonstrate that some nanosized metal oxide materials
can also act as ROS scavengers to prevent oxidative stress induced cell death [16-20], only
few studies, however, have explored the potential of metal oxide NPs to exhibit both useful
oxy/redox properties and an ability to act as ROS generators in tumor cells, but perform as
ROS scavengers in normal cells. In fact, to the best of our knowledge, only cerium oxide NPs
have been found to show ROS generation/scavenging behavio ur in cancer and normal cells,
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respectively, through their redox capability and oxygen defects [21-27]. The cerium oxide
NPs, however, do not exhibit high cytotoxicity when exposed to cancer cells alone, and they
may need to be combined with radiation or other anticancer drugs to maximize their
therapeutic efficacy [21, 24, 25, 27]. In addition, nanosized metal oxide NPs can be designed
as a perfect theranostic system where one material possesses all the required imaging,
therapeutic, and selective properties, rather than using a complex assembly of composite
theranostic particles containing different components, such as a drug carrier, drug age nt,
imaging agent, and target vector [28-30]. Although many metal oxide NPs demonstrate
multimodal imaging properties, which are highly beneficial and favourable for biomedical
applications, these theranostic systems often require complicated processes for synthesis [3133].
Therefore, the motivation behind this work is to investigate a novel, simple
synthesized nanotheranostic system which not only possesses distinguished selectivity given
by the mediation of controlled generation or prevention of oxidative stress, but also have
extremely efficient therapeutic efficacy on malignant cells in cancer treatment.
In the present work, we have studied a novel candidate for such a theranostic metal
oxide nanomaterial based on nano-engineered indium tin oxide (ITO). In particular, we
designed it to induce more oxygen defects on the surface and to induce changes to the
valence states of In in the synthesized ITO NPs. ITO NPs are well-known as an n-type
semiconductor and have been extensively applied in a variety of applications [34-38]. ITO
NPs have intrinsic fluorescence that could also be used for bioimaging due to the properties
of their band gap and the quantum size effect [39-41]. In addition, due to the high atomic
number of indium and tin elements, ITO could be used for anatomical contrast enhancement.
These features of ITO NPs can be useful for their novel application as a theranostic
therapeutic agent for anticancer therapy and other biomedical applications.
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In this study, the controlled oxidative stress, selective cytotoxic effect, and biomedical
potential of theranostic ITO NPs against MDA-MB-231 and MCF-7 human breast cancer
cells and non- malignant MCF-10A human breast cells are demonstrated. For the first time,
we reveal the dual functionality of this material, which can provide selective generation of
ROS in tumor cells, but ROS scavenging performance in normal cells, while also providing
multimodal imaging properties. The potential mechanism of the controlled oxidative stress
mediated by the synthesized ITO NPs is also discussed in this work. Cellular internalization
of ITO NPs was determined by flow cytometry and fluorescent microscope imaging.
Intracellular ROS generation was examined using a fluorescent dye, 2,7-dichlorofluorescein
diacetate (H2 DCF-DA), and cellular apoptosis was evaluated by an Annexin- V assay. A
clonogenic assay was used for further examination of the cytotoxicity and cell proliferation.

5.2 Experimental Section
5.2.1 Materials
Indium metal (> 99.8%), anhydrous Tin tetrachloride (> 99.9%), ammonium
hydroxide (28–30%), H2DCF-DA, N-acetyl- L-cysteine (NAC), hydrocortisone, cholera toxin,
crystal violet solution (2.3% crystal violet, 0.1% ammonium oxalate, 20% ethyl alcohol),
denatured ethanol, and reagent-grade ethanol were all purchased from Sigma-Aldrich
(Australia). Hydrochloric acid (36%) was purchased from UNIVAR (Australia). 7-Aminoactinomycin D (7-AAD) and Annexin- V, Alexa Fluor TM 488 conjugate were purchased
from Thermo Fisher Scientific (Australia). Dulbecco‟s Modified Eagle Medium (DMEM),
DMEM/F-12 medium, fetal bovine serum (FBS), horse serum, insulin, epidermal growth
factor (EGF), penicillin, streptomycin, Dulbecco‟s phosphate-buffered saline (DPBS),
phosphate-buffered Saline (PBS), and trypsin ethylenediaminetetracacetic acid (trypsinEDTA) were purchased from Life Technologies (Australia).
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5.2.2 Synthesis of ITO Nanoparticles
ITO NPs were synthesized as follows: First, in a three- neck flask, 5 g of metal Indium
(0.044 mmol) was dissolved in 20 mL of 36% hydrochloric acid with magnetic stirring at
70℃. When fully dissolved, 0.514 mL (0.0045 mmol) of anhydrous Tin tetrachloride was
added, and the solutions were allowed to mix by a controlled magnetic stirring and cool to
room temperature. Once room temperature was reached, 30% ammonium hydroxide was
added to the flask, and testing the pH value until it reached around 8, and a white precipitate
precursor was obtained. The precipitate precursor of ITO was then aged for 24 hours,
collected by filtration, and then washed with deionized water. After washing, the precursor of
ITO or so-called indium tin hydroxide (ITOH) was dried for 12 hours at 353 K. The dried
sample was annealed in a horizontal LABEC tube furnace at 673 K for 1.5 hours under a
reducing atmosphere (5% hydrogen mixed with argon gas).

5.2.3 Characterizations of ITO Nanoparticles
The optical absorption of the suspension of ITO NPs was measured using an UV3600 spectrophotometer from Shimadzu Corporation (Kyoto, Japan) over the range of
wavelength from 800 to 200 nm with quartz cuvettes. The crystalline structures of the
nanopowders were characterized using an Enhanced Mini- Materials Analyzer (EMMA) Xray diffractometer (XRD) from GBC Scientific. The XRD pattern of the ITO NPs was
acquired at room temperature with Cu Kα radiation (λ = 1.5418 Å ) at 40 kV and 25 mA in the
range of 20° to 65° at a scanning rate of 2° min -1 . A transmission electron microscope (TEM,
JEOL JEM 2010) operated at an accelerating voltage of 200 kV, was used to analyse the
particle morphology. High-resolution TEM images were captured using a JEM-ARM200F
atomic resolution microscope fitted with a Centrino SDD 100 mm 2 detector (JEOL,
Akishima). The fast Fourier transform (FFT) image was obtained using Gatan Digital
Micrograph software. The samples were prepared on carbon-coated copper grids, and the
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image processing was carried out using Gatan Digital Micrograph software. The elemental
composition (purity) of the ITO NPs was determined using a JSM7500FA cold field emission
gun scanning electron microscope equipped with an X-Flash 4010 10 mm2 , 127 eV SDD
energy dispersive X-ray detector (Bruker, USA) with an accelerating voltage of 20 kV.
Surface features, including the chemical composition and surface defects of the ITO
nanopowders, were evaluated using X-ray photoelectron spectroscopy (XPS), which was
conducted using a SPECS PHOIBOS 100 Analyzer installed in a high- vacuum chamber with
the base pressure below 10-8 mbar. The X-ray excitation source was provided by Al Kα
radiation with a photon energy of 1486.6 eV at the high voltage of 12 kV and power of 120
W. The binding energy scale of all measurements was calibrated using the C 1s peak at 284.8
eV. All XPS data was analysed using CasaXPS 2.3.15 software. The hydrodynamic diameter
of the ITO nanoparticles suspended in PBS was determined by dynamic light scattering (DLS)
using a Malvern-Zetasizer APS2000. The ITO NPs were first dispersed in PBS at the
concentration of 1 mg/mL and sonicated for 2 hours using a sonication bath (Branson 3800,
Ultrasonics Corp), and then a diluted final concentration of 50 µg/mL was used to perform
the DSL experiments in three independent measurements at room temperature.

5.2.4 Fluorescence Microscopy
Fluorescent microscopy was used to examine whether the intrinsic fluorescence of
ITO NPs could be detected in the cells. First, the cells were seeded on a µ-Slide 8 Well Glass
Bottom (ibidi, Germany) chamber slide, and were allowed to attach to the surface for 24
hours before the addition of ITO NPs at a concentration of 50 µg/mL. After 24 hours of
exposure to the ITO NPs, the cells were washed with PBS, and were then proceeded to
imaging. Briefly, slides of the live cells were imaged and the images captured using a Leica DMi8 Fluorescent Microscope and LAS X software (excitation at 400 nm, emissions
collected at 470-550 nm). Under a 63X oil immersion objective, the cells were imaged along
133

CHAPTER 5 – Implementation of Oxide Nano-particles in Medicine as Oxi-redox Theranostic Systems Based on Controlled
Generation or Prevention of Oxidative Stress: An Application of In-based Oxide Nanoparticles for Selective Breast Cancer
Treatment.

the z-axis from top to bottom with the same intervals, creating a number of z-sections with
different strengths of fluorescence emitted from the ITO NPs. Thereafter, the locations of the
ITO NPs could be navigated by analysing the z-sections of the cell images.

5.2.5 Computed Tomography (CT)
The capability for anatomical contrast enhancement of the ITO NPs alone was
demonstrated using computed tomography (CT). Suspensions of ITO NPs with a range of
concentrations from 0 to 20 mg/mL were placed in 1.5 mL vials and imaged together using a
Toshiba Asteion (model TSX-021A) whole body X-ray CT scanner with a 200 mA tube
current, 120 kV tube voltage, 1 mm slice thickness, and 93 mm field of view diameter. The
CT images were captured using the standard patient image reconstruction algorithms
integrated with the scanner.

5.2.6 Cell Culture and Exposure to ITO Nanoparticles
Human epithelial MDA-MB-231 and MCF-7 breast cancer cells (mammary gland
adenocarcinoma cell lines) and human epithelial MCF-10A normal breast cells (mammary
gland cell line) were all purchased from the European Collection of Cell Cultures (ECACC).
Both types of cancer cells were cultured in DMEM medium supplemented with L-glutamine,
FBS (10% (v/v)), and penicillin/streptomycin (1% (v/v)) at 37°C and 5% (v/v) CO 2 . MCF10A cells were cultured in DMEM/F-12 medium containing horse serum (5% (v/v)),
epidermal growth factor (EGF, 20 ng/mL), hydrocortisone (0.5 mg/mL), cholera toxin (100
ng/mL), insulin (10 μg/mL), and penicillin/streptomycin (1% (v/v)) at 37 0 C and 5% (v/v)
CO2 . Cells were maintained in T75 cm2 tissue culture flasks (Falcon Franklin Lakes, New
Jersey, USA), and subcultured using 0.05% trypsin- EDTA. At 80% confluence, cells were
transferred into new flasks or into other sized flasks and plates for passaging or experiments
as indicated below. For cell passaging, cells were transferred into T-75 flasks; for
measurements of cellular internalization and intracellular ROS, cells were transferred into T134
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25 flasks; for evaluation of apoptosis, cells were transferred into 6-well plates; for
determination of cell survival and proliferation, cells were first transferred into T-12.5 flasks,
after treatment of ITO NPs, cell were then transferred into 100 mm Petri dishes (BD Falcon).
All flasks and plates with seeded cells were maintained in an incubator supplied with 5% ( v/v)
CO2 at 37°C and. In all experiments, cells were grown until one day before 80% confluence,
prior to exposure to ITO NPs. Cells were exposed to ITO NPs with a total concentration of 50
µg/mL for 24 hours, and then harvested to examine apoptosis, ROS ge neration, and
cytotoxicity. Cells without ITO NP exposure served as control groups in each experiment.

5.2.7 Flow Cytometry for ITO Nanoparticles
Suspensions of ITO NPs were added to MDA-MB-231, MCF-7, and MCF-10A cells,
with a final concentration of 50 µg/mL. After treatment for 24 hours, the cells were harvested
using 0.05% trypsin- EDTA, and then centrifuged and washed twice with PBS. The individual
cell pellets were resuspended in 500 µL of PBS, transferred into 5 mL polystyrene flow tubes,
and transferred to a BD-LSR-II flow cytometer for the measurements. The intensity of the
forward scattered (FSC) light is proportional to the size and surface area of the cell, while the
intensity of the side scattered (SSC) light is proportional to cell granularity and complexity,
so that this technique can be used to determine cellular internalization of NPs [42]. Data were
acquired using a LSR-II flow cytometer. FlowJo software (Tree Star, Ashland, OR) was used
to analyse the collected data and to determine the relative degree of cellular internalization of
the ITO NPs.

5.2.8 Measurement of Intracellular Reactive Oxygen Species (ROS)
Generation of intracellular ROS was measured using 2,7-dichlorofluorescein diacetate
(H2 DCF-DA) [43]. In brief, cells were treated with ITO NPs at a concentration of 50 µg/mL
for 24 hours. At the end of treatment, cells were typsinized, followed by centrifugation and
washing three times with PBS. Afterwards, cells were incubated with 500 µL of 40 µM
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H2 DCFDA in the dark for 30 minutes, then washed three times with PBS. Cells were then
resuspended with 500 µL of PBS and transferred into 5 mL polystyrene tubes. Data was
acquired using a LSR-II flow cytometer (excitation at 488 nm, emissions collected with a
515/20 nm band-pass filter), and the relative fluorescent intensity of dichlorofluorescein
(DCF) was determined using FlowJo software.
In some MDA-MB-231 and MCF-7 experiments, ITO NP-induced ROS generation
was examined. MDA-MB-231, and MCF-7 cells were preincubated in the absence or
presence of 0.5 mM and 5 mM of the ROS scavenger, NAC, respectively for 1 hour prior to
ITO NPs addition. In the MCF-10A experiments, ITO NP-mediated ROS scavenging was
examined. Cells were incubated with ITO NPs for one hour, and then incubated in the
absence or presence of 0.5 mM H2 O2 , where H2 O2 served as an additional source of ROS. In
all experiments, cells incubated with NAC or H2 O2 alone served as negative or positive
control samples, respectively. Cells preincubated with NAC for 1 hour prior to addition of
H2 O 2 served as a quality control sample for testing the validation of the experiment.

5.2.9 Evaluation of Apoptosis Due to Intracellular ROS
ROS-induced apoptosis was measured using Annexin- V and 7-aminoactinomycin-D
(7-AAD) double staining [44-46]. In brief, cells were treated with ITO NPs at a concentration
of 50 µg/mL for 24 hours. At the end of treatment, cells were typsinized, centrifuged, and
washed once with Annexin-V binding medium (NaCl medium containing 5 mM CaCl2 ) [47].
Cells were then incubated with Annexin- V binding medium containing Annexin-V
conjugated Alexa-488 and 7-AAD at room temperature in the dark for 15 minutes. Data were
then acquired using a LSR-II flow cytometer (excitation at 488 nm, emissions collected with
515/20 nm and 695/40 nm band-pass filters for Annexin- V conjugated Alex 488 and 7-AAD,
respectively). The relative fluorescence intensities of Annexin- V conjugated Alex 488 and 7AAD were examined using FlowJo software.
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In some MDA-MB-231 and MCF-7 experiments, cells were preincubated in the
absence or presence of 0.5 mM and 5 mM of NAC, respectively, for 1 hour prior to addition
of ITO NPs, where NAC used as a ROS scavenger to assess whether the ITO NP-induced
ROS generation was associated with activation of cellular apoptosis. In some MCF-10A
experiments, cells were first incubated with ITO NPs for one hour and then incubated in the
absence or presence of 0.5 mM H2 O2 , where H2 O2 was used as an additional ROS source to
assess whether the ITO NP-mediated ROS scavenging behaviour was associated with
reduction of cellular apoptosis.

5.2.10 Cell Survival and Proliferation
Clonogenic assays [48] were performed to evaluate the cytotoxicity of ITO NPs.
MDA-MB-231, MCF-7, and MCF-10A cells were first seeded into T12.5 flasks (Falcon) and
incubation stopped at one-day before the cells reached 80% confluence, and then the
suspension of ITO NPs was added into the flasks for a total concentration of 50 µg/mL and
left for 24 hours. After 24 hours treatment, cells were trypsinised, plated at a cell density
range from 400 to 20000 (depending on the cell type) into 100 mm Petri dishes (BD Falcon)
with 10 mL complete cell culture medium, and incubated for 15 doubling times at 37 0 C and
5% (v/v) CO 2 . Colony formation of the cells was terminated by washing with 5 mL DPBS
(with Ca2+ and Mg2+), and the cell colonies were visualized by staining with a solution of
25% (v/v) crystal violet and 75% (v/v) ethanol. Cell colonies were counted using optical
microscopy, with colonies defined by groups of at least fifty cells. The s urviving fraction was
obtained by the comparison of the plating efficiency between the control and the treated
samples.

5.2.11 Statistical Analysis
Data were presented as the mean ± standard deviation (SD). Statistical differences
between the control and treatments for measurements of ROS generation, cell apoptosis, and
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the clonogenic results of MCF-10A cells, were evaluated by one-way analysis of variances
(ANOVA) paired with Tukey‟s HSD post-test. Statistical differences between the control and
treatments for clonogenic results of MDA-MB-231 and MCF-7 cells, as well as the results of
cellular internalization of ITO NPs in MDA-MB-231, MCF-7, and MCF-10A cells, were
analysed by the t-test. Data analysis was performed using Prism 7 for Mac (GraphPad
Software, San Diego, CA). A value of p < 0.05 was considered statistically significant.

5.3 Results and Discussion
5.3.1 Characterization of the Synthesized ITO Nanoparticles
The UV-Vis spectrum demonstrated in Appendix Figure A1 displays an absorption
band at around 330 nm, and also shows that the calculated bandgap energy of 3.43 eV
according to the Tauc's plot [49], and that is close to ZnO (3.37 eV) [50]. The X-ray powder
diffraction pattern of the obtained ITO NPs is shown in Figure 5.1. The corresponding peaks
in Fig. 5.1 demonstrate that the synthesized nanomaterials are a single phase of In2 O3
powders with body-centred cubic crystalline structure, in which no significant peaks
corresponding to Tin oxide or other impurities were detected, and the ITO lattice parameter
remained no change, according to the Joint Committee on Powder Diffraction Standards file
(JCPDS # 06-0416). The results suggest that the tin atoms were well incorporated into the
In2 O 3 crystal lattice. Figure 5.2 represents the results of the energy dispersive X-ray
spectroscopy (EDS) analysis, showing that no other elemental impurity was present in the
prepared ITO crystal structure. The characteristics of the final powders with an expected
weight ratio of approximately 9:1 of In2 O3 to SnO 2 are displayed in Table 5.1. The average
crystallite size of the prepared ITO NPs can be calculated by the Scherrer equation [51],
based on the XRD pattern. The calculated average crystallite size of the synthesized ITO NPs
was found to be 10.78 ± 1.42 nm. Figures 5.3(A-C) show transmission electron microscope
(TEM) image, high-resolution TEM (HRTEM) image and the corresponding fast Fourier
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transform (FFT) pattern of the ITO NPs. As can be seen from Figure 5.3(A), the synthesized
ITO NPs mainly formed aggregates greater than 50 nm in size. The HRTEM image displayed
in Figure 5.3(B) reveals the ITO nanostructure with lattice spacing of 0.29, 0.25, and 0.18 nm,
which are in accordance with the d-spacing of the (222), (004), and (440) planes, respectively.
The results are in agreement with our XRD spectrum (Figure 1). The FFT pattern in Figure
5.3(C) presents the major lattice planes, which also confirms the crystallinity of the ITO NPs.
Dynamic light scattering was performed to evaluate the hydrodynamic size of the
prepared ITO NPs dispersed in PBS, and the intensity-based size distributions of the particles
are presented in Table 5.2. The results show that the hydrodynamic diameters of the present
ITO NPs in PBS were less than 8% on the nanoscale, and the main hydrodynamic size o f the
ITO dispersion was 174.1 ± 14.02 nm. The larger size of the ITO NPs in aqueous suspension
differed from the size measured by XRD and TEM, which could be attributed to the high
tendency towards particle agglomeration in the aqueous state. This finding is supported by
others [15, 52, 53]. The original dynamic light scattering data are presented in Appendix
Figure A2.

Figure 5.1. X-ray diffraction pattern of the synthesized ITO NPs.
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Figure 5.2. EDS spectrum of the ITO NPs.
Table 5.1. EDS results for ITO precursors and ITO nanoparticles.
Sample

Indium : Tin (wt%)

ITOH (ITO Precursors)

90.01% In(OH)3 : 9.99% Sn(OH)2

ITO (400°C Annealed)

89.72% In2 O3 : 10.28% SnO 2

Abbreviations: ITO: Indium tin oxide; ITOH: Indium tin hydroxide

Figure 5.3. (A) TEM and (B) HRTEM images, and (C) FFT pattern of the synthesized ITO
NPs
Table 5.2. Hydrodynamic diameters and intensities (Int) of ITO NPs suspended in PBS after
2 hours of sonication and characterized via dynamic light scattering. The concentration of the
nanomaterials is 50 μg/mL.
Material

Peak 1 (nm)

Int 1 (%)

Peak 2 (nm)

Int 2 (%)

ITO

3.102 ± 0.1162

7.8

174.1 ± 14.02

92.2
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XPS was performed in order to examine the chemical compositio n and the surface
property of the present studied ITO NPs. Figures 5.4(A-C) display the corresponding XPS
spectra of the In 3d, Sn 3d, and O 1s core levels of the as-prepared ITO NPs. In Figure 5.4(A),
the peaks located at 444 ± 0.2 eV and 452.3 ± 0.2 eV were assigned to the binding energies of
In 3d3/2 , and In 3d5/2 , respectively, and these peaks were ascribed to In ions in the In-O bonds,
whereas no asymmetric peak corresponding to metallic In was found, suggesting that all In
ions were in the oxide forms [54]. Figure 5.4(B) shows two symmetric peaks located at 486 ±
0.2 eV and 494.6 ± 0.2 eV are corresponding to the binding energies of Sn 3d 3/2 and Sn 3d5/2 ,
respectively for the prepared ITO NPs. These binding energies of the Sn 3d peaks (Sn 3d 3/2 : >
486.2 eV) were very close to those of tin oxide (Snoxide 3d3/2 : 486.4 eV) [55], but far away
from that of metallic Sn (Snmetal 3d3/2 : 484.9 eV) [52], suggesting that all the Sn ions were in
the valence state of Sn4+ and well integrated into the crystalline structure of the prepared ITO
NPs. The results are consistent with our results from XRD analysis. In Figure 5.4(C), the O
1s peak was deconvoluted by a Gaussian function into three components with variable
intensities in approximately the same positions, namely, O I, O II, and O III, and all the
components could be assigned based on the literature on ITO materials [54-58]. Component
OI of O 1s at 529.6 eV ± 0.2 eV is due to bulk O 2- ions with neighbouring indium atoms that
possess a full complement of six nearest neighbour O 2- ions [54, 57], while O II at 531.5 ± 0.2
eV corresponds to O 2- ions in oxygen deficient sites, where the indium atoms are no longer
fully coordinated with oxygen atoms due to the generation of oxygen defects [54, 56, 57].
Peak O III at 533.1 ± 0.2 eV is associated with the oxygen of free hydroxyl groups, which is
possibly due to water molecules adsorbed onto the surface, a phenomenon that seems
inevitable and commonly exists in ITO materials [56, 58]. In addition, there are two oxygen
chemical states, O 2- and OH-, existing in both the O I and the O II areas of ITO materials, and
were very difficult to distinguish by fitting with binding energy. Therefore, the
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electroneutrality principle [56] was introduced to understand the possible oxygen chemical
states for our ITO NPs. In brief, when Sn exists solely as a substitutional dopant in the In2 O3
matrix, the theoretical ratio of (O I + O II) / (In + Sn) is 1.5 (1.55 for interstitial Sn) if all
oxygen exists in the form of O 2-; or 3.0 to 3.1 when all the oxygen is in the form of OH- [59].
Table 5.3 shows the experimental value of 1.80, which not only indicates a large prevalence
of O 2-, but also suggests the possible existence of OH- in the studied ITO NPs. Thus, by
integrating the deconvoluted O 1s, In 3d, and Sn 3d peak areas, it can be clearly identified
that oxygen deficiencies were introduced on the surfaces of our ITO NPs. Furthermore, the
binding energies of In 3d3/2 and Sn 3d3/2 for our ITO NPs were lower than 444.8 (In2 O 3 ) and
486.4 eV (SnO 2 ), respectively, which also confirm the existence of the oxygen deficiencies,
because the binding energies of In and Sn are also decreased by oxygen deficiency [60, 61].
Table 5.3. The atomic ratios of Sn, O I, and O II components normalised to In for the asprepared ITO NPs.
Sample
ITO-1 (In present study)

Sn

OI / O II

(OI / OII)/ (In + Sn)

0.22

0.83 / 1.37

1.80

ITO-2
0.21
0.69 / 1.09
Note: ITO-1 NPs are the material that we studied in this chapter.

1.50

ITO-2 NPs are the material synthesized under the same conditions as ITO but annealed
in air.
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Figure 5.4. High-resolution XPS spectra of (A) In 3d, (B) Sn 3d, and (C) O 1s of ITO NPs.
In order to further quantify the oxygen defects (vacancies) for the studied ITO NPs,
the relative ratio of the oxygen vacancy to total oxygen was calculated [58], and the results
are shown in Table 5.4. Clearly, the ITO NPs synthesized in a reducing environment created
more oxygen vacancies, and those oxygen defects may play a vital role in mediating the
reduction of reactive oxygen species.
Table 5.4. Quantitative results on ITO NPs obtained by XPS calculations.

O
(at %)

In
(at %)

Sn
(at %)

Sn / In

Vo / O total
(Oxygen deficiency %)

66.25%

27.58%

6.17%

22.37%

25.03%

ITO-2
65.60% 28.44% 5.96% 20.96%
Note: ITO-1 NPs are the material that we studied in this chapter.

20.36%

Sample

ITO-1 (Present studied)

ITO-2 NPs are the material synthesized under the same conditions as ITO-1 but
annealed in air.
ITO-2 NPs induced ROS generation in both types of cancer cells, but not in normal
cells, and they did not show any ROS-scavenging behaviour in normal cells. Data is
shown in Appendix Figure A3.
The high- resolution XPS spectrum of O 1s of ITO-2 NPs is shown in Appendix Figure
A4.

It is also worth understanding the chemical states of the synthesized indium oxide,
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although they are difficult to be observed directly from the XPS spectra, although the changes
in the chemical states of the synthesized ITO NPs could be examined though comparison of
the In 3d3/2 spectra of ITO-1 (present study) and ITO-2 (the ITO NPs synthesized under the
same condition with ITO-1, but annealed in air). Figures 5.5(A- B) display the high-resolution
XPS spectra of In 3d3/2 for ITO-1 and ITO-2 NPs, respectively. In both spectra, the In 3d3/2
peak was deconvoluted by a Gaussian function into two components of In 3d 3/2 (I), and In
3d3/2 (II) at the binding energies of approximately 444 and 445 eV, respectively. The In 3d 3/2
peak located at the lower binding energy of ~444 eV (In3d3/2 (I)) corresponds to the In2+
bonding state originating from a response associated with the loss of oxygen: the In2 O3− x
state, and the peak located at the higher binding energy of ~445 eV (In 3d 3/2 (II)) corresponds
to the In3+ bonding state from In2 O3 [62, 63]. The calculated ratios of the areas of the In 3d 3/2
peaks (In3d3/2 (I)/In3d3/2 (II)) in ITO-1 and ITO-2 were 0.95 and 0.72, respectively. The
increase for the In 3d3/2 (I) state in ITO-1 was due to an increase in In2+ [63], suggesting that
more In3+ was converted into In-O bonds in the ITO-1 NPs due to annealing in a reducing
atmosphere.

Figure 5.5. High-resolution XPS spectra of (A) In 3d 3/2 of ITO-1 NPs, (B) In 3d3/2 of ITO-2
NPs. Note: ITO-1 NPs are the material that we studied in this article. ITO-2 NPs are the
material that was synthesized under the same conditions as ITO-1 but annealed in air.
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5.3.2 Cellular Internalization and Fluorescence of ITO Nanoparticles
Flow cytometry measurements of the mean side scattering (SSC) were used to
determine the relative cellular uptake of NPs into MDA-MB-231, MCF-7, and MCF-10A
cells. As can be seen in Figure 5.6A, untreated cells exhibited the least SSC, but after
treatment with ITO NPs, the cells exhibited a significant increase in SSC, ind icating the
uptake of ITO NPs. While there was a change in the SSC, the forward scattering (FSC) of
cells remained unchanged by treatment with ITO NPs compared to the untreated cells (Figure.
5.6B). This suggested that the ITO NPs were internalized into the cells and did not adhere to
the surfaces of the cells [42]. The quantitative results in Figure 5.6C show that the ITO
nanoparticles were internalized by the MDA-MB-231, MCF-7, and MCF-10A cells by
factors of around 1.77, 1.93, and 1.35 fold over the corresponding untreated samples,
respectively. The results indicated a difference in cellular uptake of ITO NPs between
malignant and non- malignant human breast cells, and such different internalization rates may
be attributable to the different metabolic rates between tumor and normal cells.
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Figure 5.6. Flow cytometry histograms (A) and (B) show the cellular internalization of ITO
NPs through side and forward scattering, respectively, in MDA-MB-231, MCF-7, and MCF10A cells. Comparisons of cellular internalization between different control and treated
samples were quantified and are presented as (C). Note: In (A) and (B), the control and
treated samples were the cells without ITO NP exposure and the cells with treatment by ITO
NPs at a concentration of 50 µg/mL for 24 hours, respectively. The straight lines and dotted
lines represent the control samples and treated samples, respectively. The different colours,
green, red, and blue, represent the MDA-MB-231, MCF-7, and MCF-10A cell lines,
respectively. In (C), the control and the treated samples in different cells are represented by
blue bars, and red bars, respectively. The **** indicates p < 0.0001 for the comparison with
the corresponding control sample.
Cellular internalization can also be revealed through detection of the intrinsic
fluorescence emitted from ITO NPs. The fluorescence of ITO NPs was observed using
fluorescence microscopy. The images were representative of a large number of cells and have
been chosen to visually display the intrinsic fluorescence of the ITO NPs, which could be
further used to navigate the location of the ITO NPs, hence showing their cellular uptake. The
fluorescence (left), the bright field (middle), and the overlay of the fluorescence and bright
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field (right) images with the different top, middle, and bottom z-positions of the MDA-MB231, MCF-7, and MCF-10A cells treated with ITO for 24 h are shown in Figure 5.7(A),
5.7(B), and 5.7(C), respectively. In Figures 5.7(A-C), the top, middle, and bottom z-position
images correspond to the 1st , 21st , and 41 st (Figure 5.7 (A)), the 1st , 26th , and 51st (Figure
5.7(B)), and the 1st , 12th , and 23rd (Figure 5.7(C)) sections, respectively. A total of 41 slices
were imaged with 0.50 µm intervals, as shown in Figure 5.7(A), 51 slices were taken with
0.82 µm intervals, as shown in Figure 5.7(B), and 23 slices were captured with 1.96 µm
intervals, as shown in Figure 5.7(C). In Figures 5.7(A-C), the overlay of bright field and
fluorescence images of the middle slice of ITO NP-treated cells demonstrate the
internalization of the ITO particles, as marked by the red circle. In comparison to Appendix
Figure A5, clearly, the ITO NPs emitted a very strong fluorescence, even upon longer
exposure time, suggesting that the ITO NPs could be used for thera nostic purposes. The
fluorescent images of those cells without ITO NPs exposure are presented in Appendix
Figure A5, and the more detailed middle consecutive slices for MDA-MB-231, MCF-7, and
MCF-10A with ITO NPs are displayed in Appendix Figures. A6-A8, respectively.
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Figure 5.7. Fluorescent microscope images of (A) MDA-MB-231, (B) MCF-7, and (C)
MCF-10A cells treated with ITO NPs for 24 hours. Red circles highlight the presence of ITO
NPs in the cellular cytoplasm.

5.3.3 CT Imaging
X-ray CT is a very extensively used diagnostic imaging modality due to its high
resolution and deep tissue penetration. Therefore, a therapeutic agent with the capability for
CT imaging will be highly beneficial and in demand for advanced medical applications. We
have demonstrated the capability for anatomical contrast enhancement of ITO NPs using CT,
and the results are presented in Figure 5.8. As can be seen, the ITO NPs exhibited signal
enhancement as the CT values in Hounsfield units (HU) linearly increased with increasing
concentration of the ITO NPs with a slope of 25.5 HU L/g. Indeed, several studies have
shown CT values of commercial iobitridol with slopes in a range of 25 to 27 HU L/g [31, 64149
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66]. These results indicated that ITO NPs are comparable to iobitridol and could be
potentially applied as a contrast agent for application in CT imaging.

Figure 5.8. CT value as a function of ITO NP concentration in aqueous solution. Inset: CT
reconstruction images of the ITO NPs with concentrations from 0 to 20 mg/mL that were
imaged around 30 minutes after being placed on the patient couch.

5.3.4

ITO

Nanoparticles

Selectively

Promote

Intracellular

ROS

Generation in MDA-MB-231 and MCF-7 Cancer Cells, but
Scavenge the Intracellular ROS in MCF-10A Normal cells
To study the effects of the ITO NPs on intracellular ROS generation/scavenging in
cancer and normal cells, the MDA-MB-231 and MCF-7 breast cancer cells, and nonmalignant MCF-10A breast cells were exposed to ITO NPs with a concentration of 50 µg/mL
for 24 hours, whereas H2 O2 was used as an additional ROS source and NAC was used as a
ROS scavenger. ROS production/scavenging mediated by 50 µg/mL of ITO NPs was
assessed by H2 DCF-DA staining in MDA-MB-231, MCF-7, and MCF-10A cells, and they
were then measured by flow cytometry. The flow cytometric and quantitative results
displayed in Figures 5.9(A, a), and Figures 5.9(B, b) show that ITO NPs induced very
significant positive changes in ROS generation comparing to the untreated control samples in
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both MDA-MB-231 and MCF-7 cells, while the ITO NP induced ROS generation could be
scavenged by NAC in both types of cancer cells with concentrations of 0.5 mM and 5 mM,
respectively. In contrast, the results shown in Figures 5.9(C, c) demonstrate that ITO NPs
reduced the intracellular ROS levels in both the presence and the absence of H2 O2 (0.5 mM)
as well as NAC (5 mM) and presented the same characteristic in MCF-10A cells, suggesting
that our ITO NPs exhibited the same ROS scavenging property as NAC. These results
indicated that our ITO NPs were able to scavenge the hydrogen peroxide induced ROS.
It is meaningful to understand the possible mechanisms explaining how the ITO NPs
mediate the intracellular ROS generation or scavenging. Although the exact mechanisms of
the ITO NP-mediated ROS induction are still unknown, there are a number of studies that
have demonstrated that metal oxide NPs are able to induce ROS generation in cancer cells
[11-15, 25, 67-70]. In addition, ITO NPs have also been reported to be able to promote the
production of intracellular ROS in A549 human lung adenocarcinoma cells [71]. The studied
ITO NPs contain abundant oxygen defects and may have mixed In+2 /In+3 valence states was
postulated based on the obtained results. These characteristics were similar to the properties
of CeO 2 NPs [27, 71], and thus, the ITO NPs may possibly present the same oxidative
mechanism [72-75] that CeO 2 NPs present for promoting ROS generation in cancer cells was
assumed. Therefore the possible mechanism for the generation of ROS activated by the ITO
NPs were proposed as the following sequential chemical reactions (Equations (5.1-5.4)):

whereas, T−

red

In3+ + T− red → In2+ + Tox

(5.1)

In2+ + O2 → In3+ + O2 -

(5.2)

O2 - + O2 -+ 2H+ → O 2 + H2 O2

(5.3)

H2 O2 + In2+ → In3+ + OH− + OH·

(5.4)

refers to physiologically relevant reductants, such as thiol compounds and

ascorbate, and Tox refers to their oxidized states [75]. Although the possible mechanism was
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proposed, more parameters need to be further investigated in order to probe the actual
mechanism of the ITO NP induced ROS generation.
In regard to the mechanism for the ROS reduction mediated by the ITO NPs in
normal MCF-10A cells, based on the demonstrated results, it can be hypothesized that our
ITO NPs may possess catalase-like activity also in a similar way to cerium oxide NPs [72, 74,
76], so the assumed chemical reactions that represent the possible mechanism for the ROS
scavenging mediated by the synthesized ITO NPs are described as follows:
First, one molecule of H2 O2 is adsorbed onto the surface of In2 O 3 (Equation (5.5)),
and the adsorbed H2 O 2 subsequently reacts with In+3 , reducing it to In+2 and yielding protons,
molecular oxygen, and oxygen vacancy (V0 ) (Equation(5.6)). The In+2 could then react with
molecular oxygen or H2 O2 to form the initial In+3 state, and release H2 O (Equations (5.7) and
(5.8)).
H2 O 2(aq) + In2 O3(s) → H2 O 2(ads) + In2 O 3(s)

(5.5)

H2 O 2(ads) + 2In+3 (aq) → O 2(g) + 2H+(aq) + 2In+2 (aq) + V0

(5.6)

H2 O 2(ads) + 2H+(aq) + 2In+2 (aq) + V0 → 2H2 O(l) + 2In+3 (aq)

(5.7)

O2(g) + 4In+2 (aq) + 2V0 → 4In+3 (aq)

(5.8)

In the above assumed mechanism, the oxygen vacancy may play a role in oxygen storage,
and the imbalanced state of In+3 / In+2 may act as a two-way catalyst to perform the oxi-redox
reaction.
Although we have demonstrated that a reducing atmosphere for synthesis of ITO NPs
could produce ITO nanomaterial that exhibits a catalase- like property, there are still factors
such as pH conditions could possible affect the catalase-like property of ITO NPs. Therefore,
to explore the complete mechanism of the ROS reduction that activated by the ITO NPs,
further studies are needed.
In this study, the overall data demonstrated that the generation and prevention of
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oxidative stress in MDA-MB-231 and MCF-7 tumor cells and normal MCF-10A cells were
well controlled by the mediation of the synthesized ITO NPs through a possible two-way
catalytic approach.

Figure 5.9. ITO NPs mediated production or scavenging of the intracellular ROS in MDAMB-231, MCF-7, and MCF-10A cells. (A), and (B) Flow cytometric results of ITO NP
induced generation of intracellular ROS in breast cancer MDA-MB-231 and MCF-7 cells,
respectively. (C) Flow cytometric results of ITO mediated prevention of intracellular ROS in
normal MCF-10A breast cells. The flow cytometric results were further quantified and are
presented as (a), (b), and (c), respectively. The * indicates p < 0.05, ** indicates p < 0.01,
*** indicates p < 0.001, and **** indicates p < 0.0001 for the comparison with the untreated
control. ## indicates p < 0.01, ### indicates p < 0.001, and #### indicates p < 0.0001 for the
comparison between the corresponding treatments (N = not significant). Note: In (A), (B),
and (C), the different colours represent different treatments, and the change in the DCF153
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fluorescent intensity represents the change in the intracellular ROS level in MDA-MB-231,
MCF-7, and MCF-10A cells, respectively.

5.3.5

ITO Nanoparticle-mediated Intracellular ROS Levels Play a Vital
Role in Apoptosis in MDA-Mb-231 and MCF-7 Cells, but Offer
Cell Protection in MCF-10A Cells
It is well known that, when the ROS levels exceed the antioxidative capability of the

cell, the cell undertakes oxidative stress and could go through different cell death pathways,
leading to cell death [4], and one of the cell death pathways can be ROS-induced apoptosis
[1]. Therefore, to investigate the activation of apoptosis in MDA-MB-231 and MCF-7 cells
and the promotion of cell-protective effects in MCF-10A cells, which were associated with
the ITO NP-mediated ROS generation and scavenging, NAC was used as a ROS scavenger
for the negative control samples, while H2 O2 was used as an additional source of ROS for the
positive control samples. The fluorescent dyes, 7-AAD and Annexin-V conjugated Alexa-488
were used to stain the MDA-MB-231, MCF-7, and MCF-10A cells after 24 hours of exposure
to ITO NPs, and the data were measured by flow cytometry. Figure 5.10A shows the
quantitative results of cell death for the measured cells, where the live, apoptotic and dead
populations were defined on the basis of the measured 7-AAD fluorescence intensity using
the method developed by Philpott and Zembruski et al [77, 78], The analyzed forward scatter
versus 7-AAD dot plots for MDA-MB-231, MCF-7, and MCF-10A cells with and without
treatments are displayed in Appendix Figure A9. As can be seen in Figure 5.10A, ITO NPs
significantly increased cell death in MDA-MB-231 and MCF-7 cancer cells. When the cells
were exposed to both ITO NPs and the ROS scavenger NAC, the cell death was significantly
reduced to levels close to those of the untreated control samples. The results directly reflected
the results of ROS generation that we previously discussed, showing that death in cancer cells
increased with increasing intracellular ROS generation. This indicated that the death of
cancer cell induced by the ITO NPs was directly associated with the promotion of
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intracellular ROS induced by the ITO NPs. In additio n, death in normal MCF-10A cells that
were exposed to ITO NPs alone and NAC alone, were slightly lower than those in the
untreated control. Moreover, MCF-10A cells exposed to addition of both ITO NPs and the
ROS source H2 O2 even presented a significant decrease in cell death comparing with those
solely exposed to H2 O2 , while the cells exposed to the addition of both NAC and H2 O2
presented the same results. Taking the reduction of cell death and the ROS results into
account, the death in MCF-10A cells decreased with decreasing intracellular ROS levels in
both the absence and the presence of H2 O2 , indicating that the cell death could be reduced by
ITO NPs and NAC, and were directly associated with the reduction of the intracellular ROS
level by the ITO NPs and NAC. To be noted, in this experiment, phenomena were found
when the concentration of the added NAC exceeding 0.5 mM in MDA-MB-231 cells, a
majority of cell death would occur, and the expected scavenging effect from NAC would not
be clearly observed; moreover, in MCF-7 cells, when the concentration of the added NAC
lower than 5 mM, no significant scavenging effect could be observed (Data not shown).
Therefore, in this thesis study, 0.5 mM and 5 mM were used as the optimal concentrations of
NAC for MDA-MB-231 and MCF-7, respectively.
Annexin-V binding is wildly used for detection of apoptosis [44], where a positive
change in Annexin-V binding intensity indicates an increase in cell apoptosis. Figure 5.10B
displays the flow cytometric results of the relative Annexin-V fluorescein binding intensity
for various treatments. Significantly, apoptosis was induced by exposure to ITO NPs, but was
reduced by the addition of NAC in both MDA-MB-231 and MCF-7 cancer cells, while, a
decreased rate of apoptosis was mediated by the exposure of ITO NP and by the addition of
NAC in both the absence and the presence of H2 O2 in normal MCF-10A cells. Consequently,
the results of Annexin- V binding present the same trend as the results of 7-AAD staining,
confirming that ITO NP-induced production of intracellular ROS can promote apoptosis in
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both MDA-MB-231 and MCF-7 breast cancer cells. The Annexin- V results also clearly
demonstrate that the ITO NP-mediated prevention of intracellular ROS can reduce the
apoptosis occurring in MCF-10A normal breast cells.

Figure 5.10 ITO NPs mediated cell death in MDA-MB-231, MCF-7, and cell protection in
MCF-10A cells. (A), Analysed quantitative results based on the 7-AAD binding intensity as
detected by flow cytometry for the cell deaths induced by the treatments consisting of ITO
NPs alone and ITO NPs with NAC in MDA-MB-231 (left) and in MCF-7 (middle), and those
induced by the treatments with ITO NPs, NAC, H2O2 , ITO NPs with H2 O 2 , and NAC with
H2 O 2 in MCF-10A (right) cell lines. Data was shown in combination of early and late
apoptotic/dead cells. The * indicates p < 0.05, and **** indicates p < 0.0001 for the
comparison with the untreated control. The #### indicates p < 0.0001 for the comparison
between the corresponding treatments; (B), Flow cytometric results on Annexin-V
fluorescein binding intensity to indicate the apoptosis induced by the treatments with ITO
NPs alone and ITO NPs with NAC in MDA-MB-231 (left) and in MCF-7 (middle), and that
induced by the treatments with ITO NPs, NAC, H2O2 , ITO NPs with H2 O 2 , and NAC with
H2 O 2 in MCF-10A (right) cell lines. Note: In Figure 5B, the different colours represent
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different treatments (with “Basal” representing the untreated control without any staining),
and the change in the Annexin-V binding intensity represents the change in the rate of cell
apoptosis.

5.3.6

ITO Nanoparticles Selectively Kill MDA-MB-231 and MCF-7 Cells
While Protecting MCF-10A cells
The clonogenic assay was used to further investigate the cytotoxicity of the ITO NPs

towards MDA-MB-231, MCF-7, and MCF-10A cells. The surviving fractions of MDA-MB231, MCF-7, and MCF-10A cells after 24 hours of treatment with ITO NPs at a concentration
of 50 µg/mL, as determined using clonogenic assay, are illustrated in Figures 5.12 - 5.13. For
both MDA-MB-231 and MCF-7 malignant cells, the surviving fractions were significantly
decreased, with less than 10% and around 30%, respectively, showing very high mortality in
malignant cells. In contrast, the surviving fraction of MCF-10A cells was remarkably
increased after treatment with ITO NPs compared with the untreated control sample,
indicating that ITO NPs supported the cell proliferation. In addition, the surviving fraction of
MCF-10A cells treated with both ITO NPs and H2 O2 was even significantly higher than for
the cells treated with H2 O2 alone, suggesting that ITO NPs protected the cells from an
increased external oxidative stress. These results further supported the proposition that ITO
NPs could selectively mediate the production or prevention of intrace llular ROS, and
promote or suppress cellular apoptosis, finally resulting in cell death or in cell protection for
malignant and non-malignant cells, respectively.
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Figure 5.12. Quantitative clonogenic results for MDA-MB-231 (left) and MCF-7 cells
(middle) treated with and without ITO NPs, and for MCF-10A cells (right) without treatment
and treated with ITO NPs, H2 O2 , and ITO NPs with H2 O2 . The concentration of ITO NPs for
the treatment was 50 µg/mL, and “Control” represents the samples without treatment. *
indicates p < 0.05, ** indicates p < 0.01, *** indicates p < 0.001, and **** indicates p <
0.0001 for the comparison with the untreated control. # indicates P < 0.05, and #### indicates
p < 0.0001 for the comparison between the corresponding treatments.

Figure 5.13. Photographs of colony formation with and without treatment by ITO NPs in
MDA-MB-231 (upper- left) and in MCF-7 cells (upper-right). MCF-10A (bottom) without
treatment and treated with ITO NPs alone, H2 O2 alone, and H2 O2 with ITO NPs. The
concentration for the ITO NP treatment was 50 µg/mL.
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As previously mentioned, CeO 2 NPs have been extensively reported to possess ROS
generation and scavenging behaviours in cancer and normal cells, respectively [21-27],
however, CeO 2 NPs seem not to have distinguished cytotoxicity towards cancer cells, and
often require combination of anticancer drugs or radiation therapy to enhance their
therapeutic efficacy [21, 24, 25, 27]. Moreover, experimental results from other researcher
group [79] shows that no significant ROS generation and anticancer ability are found in both
human breast cancer MCF-7 cells and fibrosarcoma HT-1080 cells, even tested with a
relative higher concentration of 200 µg/mL of CeO 2 suspension (Figure 5.14). Although
different cell types may have different sensitivity to therapeutic NPs, in this case, at least to
human breast cancer MCF-7 cells, the engineered ITO NPs show more promising therapeutic
effect compared with the CeO 2 NPs, in which a used concentration of 50 µg/mL ITO NPs can
lead very high mortality in human breast cancer MCF-7 cells. Aside from the outstanding
therapeutic efficacy, the designed ITO NPs also demonstrate their multimodality which
makes this material a more attractive nano-theranostic system in anticancer therapy.

Figure 5.14. Potential effects of CeO 2 NPs on ROS generation in human breast cancer MCF7 cells and fibrosarcoma HT-1080 cells compared with ZnO NPs taken as positive control
(left panel). Viability of human breast cancer MCF-7 cells and fibrosarcoma HT-1080 cells
after 24 hours treatment with CeO 2 NPs determined by MTT assay at indicated
concentrations (right panel). Values are mean ± standard deviation (SD) from three
independent experiments. Triplicates of each treatment group were used in each independent
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experiment. * Denotes a signification difference from the control (p < 0.05). Adapted from
[79].
To be noted, basically, the author synthesized two different kinds of ITO NP by using
the same batch of ITO precursors (ITOH). The only difference in s ynthesis of these two
different types of ITO NPs is using two different atmospheres (air, and 5% hydrogen-argon
mixed gas) for calcination. During the calcination process, the settings of temperature and
annealing time are kept the same to ensure a good co mparison can be investigated. Notably,
based on the experimental results presented in chapter 4 and 5, the change of the annealed
atmosphere from air to 5% hydrogen-argon mixed gas seems not influence much on the
anticancer ability in all tested malignant cells, however, such a change does greatly influence
on the anti-oxidative ability in non- malignant cells. As presented in chapter 5, the aircalcined ITO NPs do not exhibit any ROS scavenging ability in breast normal MCF-10A
cells, but the ITO NPs annealed through 5% hydrogen-argon mixed gas present a
distinguished ROS scavenging ability in both with or without presence of additional ROS
inducer, H2 O 2 . These results make the ITO NPs (calcination in 5% hydrogen-argon mixed
gas) more attractive due to the realization of solid selectivity between malignant and nonmalignant cells, where the ITO NPs can generate ROS to kill malignant cells but protect nonmalignant cell from ROS damage.

5.4 Conclusions
In this study, we provided the first evidence that nano-engineered ITO NPs can
selectively mediate the generation and reduction of intracellular ROS in malignant MDAMB-231and MCF-7, and non-malignant MCF-10A breast cells. The generated oxidative
stress could further promote cancer cell apoptosis and resulted in a high cell mortality in both
MDA-MB-231 and MCF-7 cells. In contrast, for MCF-10A cells, ITO NPs can promote
scavenging of intracellular ROS, which suppresses the cell apoptosis and further supports cell
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proliferation in both the absence and the presence of H2 O 2 . In addition, the ITO NPs feature
attractive multimodal imaging properties such as strong fluorescence and comparable
anatomical contrast enhancement capability for CT imaging, which makes this nanomaterial a
promising theranostic agent for cancer treatment and also gives it potential for treatment of
other oxidative stress related conditions.
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6.1 Preface
Nanotechnology is a unique platform that allows well established products to be
advanced with totally new features and functions, which have enormous potential in a wide
range of applications [1]. By using this new technology, advanced materials can be fabricated
and controlled on the nanoscale (100 nm) [2]. Materials with reduced size down to nanoscale
have unique and versatile physicochemical properties, which are attributable to their size,
shape, surface characteristics, mechanical properties, element composition, and crystal
structure, that enable them to interact with biological systems in a unique way [3-6]. With the
fast growth of nanotechnology, the research on undoped nanostructures no longer satisfies the
demands of general scientific interest and specific applications. Deliberately designed
element doping in ceramic semiconductors is critical, because the dopant can greatly alter
their basic physical and chemical properties, such as the ir electrical, optical, and magnetic
properties, as well as their anticancer properties, and it is now emerging as a significant new
field [7].
Zinc oxide (ZnO) nanoparticles (NPs) have been extensively studied for their
potential application in cancer therapy. Many studies have demonstrated that zinc oxide NPs
exhibit strong killing ability towards a variety of cancerous cells, while posing no harm to
normal cells. Ostrovsky et al. [8] reported that ZnO nanoparticles exhibited cytotoxic effect
towards several types of human glioma cells but posed no cytotoxic risk to normal human
astrocytes. Premanathan et al. [9] demonstrated that ZnO NPs were able to selectively kill
human myeloblastic leukemia cells (HL60), and Akhtar et al. [10] also observed that ZnO
NPs exerted preferential cytotoxicity towards human lung and liver cancer cells. These
studies provide the insight that Zn element could be a good dopant, as that could possibly
endow a nanomaterial with potential selective cytotoxic effects between malignant and nonmalignant cells. Therefore, on the basis of the aforementioned outstanding selectivity and
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anticancer property of ZnO nanomaterials, it would be significant and of our interest to
investigate whether a substitution of tin by zinc in the synthesis of indium-based
nanoparticles will still exhibit remarkable selectivity and cytotoxicity as well as ITO NPs
present or even show an enhanced anticancer property. Moreover, as discussed in chapter 5,
although the synthesized tin doped indium oxide (ITO) NPs exhibited significant selective
cytotoxic effects between human breast tumor and normal cells, it would be important to
evaluate the selectivity and cytotoxicity of the prepared indium-based nanomaterials by the
test of more cell types.
Herein, this study is designed to evaluate the c ytotoxicity and selectivity of zinc
doped indium oxide (IZO) nanomaterials between malignant and non-malignant cells on a
broader scale of cell types. Malignant cells, including human pancreatic cancer PANC-1 and
MIA-PaCa-2 cells, and human breast cancer MDA-MB-231, and MCF-7 cells were selected
for examination of cell viability; non-malignant cells, including human prostate normal
RWPE-1 cells and human breast normal MCF-10A cells were chosen for investigation of
cytotoxicity. The crystal structure and morphology of the synthesized IZO NPs were
characterized through a variety of experimental tools, including XRD, TEM, S TEM, and
EDS. The MTT assay was used to evaluate the cell viability for all the cells, and the
clonogenic assay was used for further examination of the cytotoxicity and cell proliferation
for MDA-MB-231, MCF-7, and MCF-10A cells.

6.2 Experimental Section
6.2.1 Materials
Indium metal (> 99.8%), zinc metal (> 99.9%), ammonium hydroxide (28–30%),
crystal violet solution (2.3% crystal violet, 0.1% ammonium oxalate, 20% ethyl alcohol),
denatured ethanol, and reagent-grade ethanol were all purchased from Sigma-Aldrich
(Australia). Hydrochloric acid (36%) was purchased from UNIVAR (Australia). Dulbecco‟s
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Modified Eagle Medium (DMEM), DMEM/F-12 medium, Roswell Park Memorial Institute
(RPMI) 1640 Medium, horse serum, insulin, epidermal growth factor (EGF), fetal bovine
serum (FBS), penicillin, streptomycin, Dulbecco‟s phosphate-buffered saline (DPBS),
phosphate-buffered Saline (PBS), trypsin ethylenediaminetetracacetic acid (trypsin- EDTA),
3-(4,5- dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT, 98%), and dimethyl
sulfoxide (DMSO, ≥99.9%) were purchased from Life Technologies (Australia).

6.2.2 Synthesis of IZO Nanoparticles
IZO NPs were also synthesized using the standard coprecipitation route [11]. First, 4
g of indium metal (0.035 mmol) and 0.204 g of zinc metal (0.003 mmol) were dissolved in 40
mL of 36% HCl. Then, 30% NH4 OH was added dropwise until a white precipitate was
formed. The precipitate was filtered via centrifugation (Eppendorf), and washed seven times
with deionized (DI) water. After washing, the precursor of IZO or so-called indium zinc
hydroxide (IZOH) was dried for 12 hours at 353 K. The dried sample was annealed in a
horizontal LABEC tube furnace at 673 K for 1.5 hours under argon atmosphere.

6.2.3 Characterizations of IZO Nanoparticles
The crystalline structures of the nanopowders were characterized using an Enhanced
Mini-Materials Analyzer (EMMA) X-ray diffractometer (XRD) from GBC Scientific. The
XRD pattern of the ITO NPs was acquired at room temperature with Cu Kα radiation (λ =
1.5418 Å ) at 40 kV and 25 mA in the range of 20° to 65° at a scanning rate of 2° min -1 . A
transmission electron microscope (TEM, JEOL JEM 2010), operated at an accelerating
voltage of 200 kV, was used to analyze the particle morphology. High-resolution TEM
(HRTEM) images were captured using a JEM-ARM200F atomic resolution microscope fitted
with a Centrino SDD 100 mm2 detector (JEOL, Akishima). The corresponding fast Fourier
transform (FFT) image was obtained using Gatan Digital Micrograph software. The samples
were prepared on carbon-coated copper grids, and the image processing was carried out using
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Gatan Digital Micrograph software. The elemental composition (purity) of the IZO NPs was
determined using a JSM7500FA cold field emission gun scanning electron microscope
equipped with an X-Flash 4010 10 mm2 , 127 eV SDD energy dispersive X-ray detector
(Bruker, USA) with an accelerating voltage of 20 kV. The hydrodynamic diameter of the ITO
nanoparticles suspended in PBS was determined by dynamic light scattering (DLS) using a
Malvern-Zetasizer APS2000. The IZO NPs were first dispersed in PBS at the concentration
of 1 mg/mL and sonicated for 2 hours using a sonication bath (Branson 3800, Ultrasonics
Corp), and then a diluted final concentration of 50 µg/mL was used to perform the DLS
experiments in three independent measurements at room temperature.

6.2.4 Cell Culture and Treatment of IZO Nanoparticles
Cells were purchased from the European Collection of Cell Cultures (ECACC) and
the American Type Culture Collection (ATCC). Human breast cancer MCF-7, and MDAMB-231 cells were cultured with DMEM culture medium. Human pancreatic cancer PANC-1
and MIA-PaCa-2 cells, and human breast non- malignant MCF-10A cells were cultured with
DMEM/F-12 medium. Human prostate non- malignant RWPE-1 cells were cultured with
RPMI 1640 Medium. All media contained phenol red, L- glutamine, and glucose, and were
supplemented with FBS (10% (v/v)) and penicillin/streptomycin (1% (v/v)). In addition, the
medium for culturing MCF-10A cells was additionally supplemented with horse serum,
insulin, epidermal growth factor (EGF, 20 ng/mL), hydrocortisone (0.5 mg/mL), and cholera
toxin. All cell cultures were maintained at 37℃ with 5% (v/v) CO 2 in a cell culture incubator
(Heracell 150i). Cells were maintained in T75 cm2 tissue culture flasks (Falcon Franklin
Lakes, New Jersey, USA), and subcultured using 0.05% trypsin- EDTA. At 80% confluence,
cells were transferred into new flasks or into other sized flasks and plates for passaging or
experiments as indicated below: for cell passaging, cells were transferred into T-75 flasks; for
MTT measurements, cells were transferred into 96-well plates; for determination of cell
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survival and proliferation using the clonogenic assay, cells were first transferred into T-12.5
flasks, and after treatment with IZO NPs, cells were then transferred into 100 mm Petri dishes
(BD Falcon). All flasks and plates with seeded cells were maintained in an incubator supplied
with 5% (v/v) CO 2 at 37°C. In MTT experiments, cells were first allowed to attach for 24
hours and then were exposed to IZO NPs with total concentrations of 0, 50, 100, and 200
µg/mL. After 24 hours of incubation, cells were harvested to examine the viability. In
clonogenic experiments, cells were grown until one day before 80% confluence, prior to
exposure to IZO NPs. Cells were exposed to IZO NPs with a total concentration of 50 µg/mL
for 24 hours, and then harvested to examine the cytotoxicity. Cells without IZO NP exposure
served as control samples in each experiment.

6.2.5 MTT Cell Viability Assay
Cell viability of malignant PANC-1, MIA-PaCa-2, MDA-MB-231, and MCF-7 cells,
and non- malignant RWPE-1 and MCF-10A cells was assessed by the MTT assay, as
proposed by Mossman [12] with some modification [13, 14]. Briefly, 1 × 104 cells/well were
seeded in 96-well plates and exposed to IZO NPs at the concentrations of 0 µg/mL, 50 µg/mL,
100 µg/mL, and 200 µg/mL for 24 hours. At the end of exposure, the culture medium was
removed from each well to avoid interference with the IZO NPs, replaced with 100 µL of
medium containing 10 µL of MTT stock solution, and incubated for 4 hours at 37°C until a
purple-colored formazan product was formed. The resulting formazan product was dissolved
in DMSO. Then, the 96-well plate was centrifuged at 1500 rpm for 5 minutes to settle the
remaining IZO NPs, and 100 μL of supernatant was transferred into a new well in a new 96well plate. Finally, a SpectraMax 384 Plaus (Molecular Devices) microplate reader was used
to measure the absorbance at 570 nm. The EC50 value, the concentration that gives a halfmaximal response, was calculated using Prism 7 for Mac (GraphPad Software, San Diego,
CA).
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6.2.6 Clonogenic Cell Survival Assay
Clonogenic cell survival assays [15] were performed to evaluate the cytotoxicity of
IZO NPs towards MDA-MB-231, MCF-7, and MCF-7 cells. Cells were first seeded into T12.5 flasks (Falcon) and incubation stopped at one-day before the cells reached 80%
confluence. Then, the suspension of ITO NPs was added into the flasks for a total
concentration of 50 µg/mL and left for 24 hours. After 24 hours treatment, the cells were
trypsinised, plated in triplicate in a cell density range from 400 to 20000 cells (depending on
the cell type) into 100 mm Petri dishes (BD Falcon) with 10 mL of complete cell culture
medium, and incubated for 15 doubling times at 37℃ with 5% (v/v) CO 2 . Colony formation
of the cells was terminated by washing with 5 mL DPBS (with Ca2+ and Mg2+), and the cell
colonies were visualized by staining with a solution of 25% (v/v) crystal violet and 75% (v/v)
ethanol. Cell colonies were counted using optical microscopy, with colonies defined by
groups of at least fifty cells. The surviving fraction was obtained by comparison of the plating
efficiency between the control and the treated samples.

6.3 Statistical Analysis
Data were presented as the mean ± standard deviation (SD). For the MTT results in all
cells, statistical differences between the control and treatments were determined by one-way
analysis of variance (ANOVA) followed by Dunnett‟s multiple comparison test. For the
clonogenic results in MDA-MB-231, MCF-7, and MCF-10A cells, statistical differences
between the control and treatments were analyzed using the two-tailed t-test. Data analysis
was performed using Prism 7 for Mac (GraphPad Software, San Diego, CA). A value of p <
0.05 was considered statistically significant.

6.4 Results and Discussion
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6.4.1 Characterizations of IZO Nanoparticles
X-ray diffraction was used to investigate the phase purity and crystal structure of the
synthesized IZO NPs, and the obtained X-ray powder diffraction pattern is displayed in
Figure 6.1. The diffraction pattern demonstrates that the IZO NPs are crystalline, and the
diffraction peaks of the synthesized IZO NPs are in good agreement with those in the
standard diffraction pattern of In2 O3 , according to the Joint Committee on Powder Diffraction
Standards file (JCPDS # 06-0416). The results that indicate the synthesized nanomaterials are
a single phase of In2 O3 powders with body-centered cubic crystalline structure. Furthermore,
no significant peaks corresponding to crystalline Zn, ZnO, or other impurities were obtained,
and the ITO lattice parameter showed no remarkable change, suggesting that the zinc atoms
were well incorporated into the In2 O 3 crystal lattice, so that high quality of IZO NPs were
fabricated.

Figure 6.1. X-ray diffraction pattern of the synthesized IZO NPs.
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The morphology of the IZO NPs was investigated by TEM. The TEM image
presented in Figure 6.2(A) shows that the as-obtained IZO NPs are almost spherical shaped
and mainly form aggregates with a size bigger than 100 nm. The HRTEM image (Figure
6.2(A)) and the corresponding FFT (Figure 6.2 (B)) pattern demonstrate that they have a
well-defined crystalline structure with lattice spacings of 0.15 nm and 0.18 nm (B),
corresponding to the (226) and (440) planes of the cubic In2 O3 structure (C), respectively,
with an angle of 65 degree. The results further support our XRD data (Figure 6.1).

Figure 6.2. (A) TEM and (B) HRTEM images, and (C) FFT pattern of the synthesized IZO
NPs
The elemental purity and composition were confirmed by EDS analysis. The EDS
spectrum (Figure 6.3) shows that only the distinct peaks of In, Zn, and O were obtained, and
no other peak corresponding to any elemental impurity was present in the as-prepared IZO
crystal structure. The high-resolution EDS map of ITO NPs displayed in Figure 6.4 presents a
homogeneous distribution of In, Zn, and O atoms. These results indicate that the Zn atoms
were well- incorporated into the In2 O 3 nanostructure, suggesting that high quality IZO NPs
were fabricated. The expected weight ratio of approximately 95:5 of In2 O 3 /ZnO for the asprepared IZO NPs was also confirmed by EDS analysis. The EDS results are also in good
agreement with the XRD data (Figure 6.1).
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Figure 6.3. EDS spectrum of the IZO NPs.

Figure 6.4. TEM images with high-resolution EDS mapping of IZO NPs.
A dynamic light scattering experiment was performed to evaluate the hydrodynamic
size of the as-prepared ITO NPs dispersed in PBS, and the intensity-based size distributions
of the particles are presented in Table 6.1. The results show that the as-prepared IZO NPs
were present mainly in form of aggregates, some of them were still on the nanoscale, but
most of them were bigger than 100 nm in size. The size of the ITO NPs in aqueous
suspension observed from DLS was much bigger than that observed from XRD and TEM,
which could be attributed to the high tendency towards particle agglomeration in the aqueous
state. This finding is supported by other reports [10, 16-18].
Table 6.1. Hydrodynamic diameters and intensities (Int) of IZO NPs suspended in PBS after
2 hours of sonication and characterized via dynamic light scattering. The concentration of the
nanomaterials is 50 μg/mL.
Material

Peak 1 (nm)

Int 1 (%)

Peak 2 (nm)

Int 2 (%)

Peak 3 (nm)

Int 3 (%)

ITO

12.84 ± 1.078

7.4

149.1 ± 23.96

9.9

945.1 ± 255.5

82.4
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6.4.2 IZO Nanoparticles Selectively Kill Malignant Cells
The MTT assay was used to determine the cytotoxicity of the IZO NPs towards
normal RWPE-1 and MCF-10A cells, and towards cancerous MDA-MB-231, MCF-7,
PANC-1, and MIA PaCa-2 cells. The cell viability of normal and tumor cells after 24 hours
of treatment with IZO NPs at concentrations of 0, 50, 100, 200 µg/mL, as determined using
the MTT assay, is illustrated in Figures 6.5. Clearly, the MTT cell viabilities of all malignant
cells show that there is a significant cytotoxic response to IZO NPs in a dose-dependent
manner. In contrast, the cell viabilities of RWPE-1 and MCF-10A cells remained at more
than 80% after treatment with a range of concentrations of IZO NPs from 0 to 200 µg/mL
compared with the untreated control sample, suggesting that IZO NPs are biocompatible.
Cytotoxicity studies through MTT assays represent the damage to mitochondrial [1921], where the MTT assay serves as a sensitive index to investigate the growth inhibitory
effect of the IZO NPs on cell proliferation. Through our results, it was found that pancreatic
cancer MIA-PaCa-2 and PANC-1 cells seem more sensitive to IZO NPs than breast cancer
MCF-7 and MDA-MB-231 cells. The EC50 values [22] for MDA-MB-231, MCF-7, PANC-1,
and MIA PaCa-2 cells estimated by MTT assays were 144.1, 82.58, 61.57, and 19.08 µg/ml,
respectively, for the as-prepared IZO NPs.
Our MTT results suggest that IZO NPs have selectively killing capability towards
malignant MDA-MB-231, MCF-7, PANC-1, and MIA PaCa-2 cells without posing much
risk to normal RWPE-1 and MCF-10A cells.
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Figure 6.5. IZO NP-induced selective cytotoxicity in RWPE-1, MCF-10A, MDA-MB-231,
MCF-7, PANC-1, and MIA PaCa-2 cells, measured by using the MTT assay. The colours
represent different treatments with different concentrations of IZO NPs. The data represented
are the mean ± SD of three identical experiments conducted in three replications.
*Statistically significant difference as compared to the controls (p < 0.05 for each). ****
indicates p < 0.0001 for the comparison with the untreated control (0 µg/mL).

6.4.3 IZO Nanoparticles Exhibit No Remarkable Cytotoxic Effect on Nonmalignant Cells even after a prolonged period
The clonogenic assay was used to further investigate the long-term cytotoxic response
of the IZO NPs towards MDA-MB-231, MCF-7, and MCF-10A cells. To perform this assay,
cell were first treated with or without IZO NPs at a concentration of 50 µg/mL for 24 hours,
and were incubated for 15 doubling times prior to determination of the cytotoxicity.
Figure 6.6 displays the surviving fractions of MDA-MB-231, MCF-7, and MCF-10A
cells, as determined by clonogenic assay. As can be seen, for both the breast cancer MDAMB-231 and MCF-7 cells, the surviving fractions were significantly decreased, with less than
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20% and around 30% surviving, respectively, indicating remarkable mortality in breast
malignant cells. In contrast, the surviving fraction of MCF-10A cells presented no significant
change, with survival still above 80%, after treatment with IZO NPs compared with the
untreated control sample, indicating that IZO NPs are harmless to breast non- malignant cells.
Although it is not difficult to understand that cancer cells do not easily survive after being
exposed to a toxic agent for a longer period, the long-term clonogenic results still
significantly demonstrate that the IZO NPs possess outstanding anticancer ability. More
importantly, even after a prolonged period of exposure to IZO NPs, the cell proliferation of
the breast non-malignant MCF-10A cells was not significantly affected, indicating that IZO
NPs feature selectivity between malignant and non-malignant cells.
Although only MCF-10A cells have been used for performing the clonogenic assay to
observe the selectivity of IZO NPs in this study, through the data obtained from MTT and
clonogenic experiments performed in breast malignant and non- malignant cells, a correlation
has been revealed. In fact, a study of drug-screening tests has revealed the good correlation
coefficients between MTT and clonogenic assays, depending on the type of the cytotoxic
compounds that were used [23]. In this study, as the cells were exposed to the same
concentration of IZO NPs at 50 µg/mL, the MTT measured cytotoxicity is much lower than
that obtained from the clonogenic assay in breast malignant MDA-MB-231 and MCF-7 cells.
In non- malignant MCF-10A cells, however, the results obtained from both assays are very
close with a very slight decrease in the clonogenic assay. Therefore, it could be highly
predicable that other cell lines used in this study will exhibit the same correlation once
clonogenic assays are undertaken.
The demonstrated MTT and clonogenic results support the proposition that t he
synthesized IZO NPs have selectivity between malignant and non- malignant cells, and are
highly toxic towards the malignant cells. Although the synthesized IZO NPs do not present
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any expected enhanced properties on their selectivity and cytotoxicity comparing with those
of the previously reported ITO NPs, they still exhibit notable selectivity and excellent
anticancer ability.

Figure 6.6. Quantitative clonogenic results for MDA-MB-231 (left) and MCF-7 cells (middle)
treated with and without IZO NPs, and for MCF-10A cells (right) without treatment and
treated with IZO NPs. The concentration of IZO NPs for the treatment was 50 µg/mL, and
“Control” represents the samples without treatment. ** indicates p < 0.01, *** indicates p <
0.001 for the comparison with the untreated control (ns = not significant).
Although the exact mechanisms of the IZO NP-mediated selectivity are still unknown,
many studies have reported that zinc oxide NPs are able to selectively kill cancer cells
through two possible mechanisms [8-10, 24, 25]. One is the ROS pathway [8-10], and the
other is through the dissolution of Zn2+ ions [24, 25]. Based on the experimental results
demonstrated, the possible mechanism of IZO NPs can be hypothesized as attributions of IZO
mediated ROS generation and the dissolution of Zn2+ ions. Although zinc oxide NPs
mediated ROS pathway have been wildly reported as one of the major mechanism to destroy
cancer cells [8-10], the release of the Zn2+ ions would be more specific in an acidic condition,
particular in the acidic micro-environment of a cell. Generally, malignant cells present lower
pH comparing with non- malignant cells, thus, a zinc-contained nanomaterial would be much
easier dissolved in malignant cells than in non- malignant cells, and the released Zn2+ ions
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will further damage the cancer cells [24, 25]. In this chapter, the MTT results demonstrate
that a dose-response manner is clearly presence in all types of cancer cells, and the
clonogenic results show very high cell mortality in only malignant cells after a pro longed
time with a fixed concentration of IZO NP. These results imply that, at least, the release of
Zn2+ ions should be consider as one of the mechanism to contribute the selectivity.

6.5 Conclusions
In this study, IZO NPs with high quality were synthesized and well characterized.
Furthermore, the MTT data revealed that the synthesized IZO NPs exhibited cytotoxicity
towards malignant MDA-MB-231, MCF-7, PANC-1, and MIA PaCa-2 cells in a dosedependent manner, while they presented biocompatibility with non- malignant RWPE-1 and
MCF-10A cells. Clonogenic data demonstrated that IZO NPs were highly cytotoxic towards
malignant MDA-MB-231 and MCF7 cells without posing much risk to non- malignant MCF10A cells. Future research to explore the underlying selective cytotoxic mechanism of IZO
NPs between malignant and non-malignant cells is warranted.
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7.1 Thesis Conclusions
In this doctoral work, various aspects related to the synthesis and characterization of
Indium-based nanomaterials were investigated, and the selectivity and cytotoxicity of those
nanomaterials in a variety of non- malignant and malignant cells were also explored.
Furthermore, an Indium-based theranostic system with highly selective cytotoxicity towards
breast malignant cells has been developed. Considering the lack of selectivity in conventiona l
cancer therapy, two types of indium-based nanomaterials including tin doped indium oxide
nanoparticles (ITO NPs) and zinc doped indium oxide nanoparticles (IZO NPs), have been
fabricated and successfully demonstrated their selectivity and cytotoxicity.
In this doctoral thesis, for the first time, air-annealed ITO NPs were proposed to
examine the use of ITO NPs as an anticancer agent. The air-annealed ITO NPs exhibited high
in vitro toxicity towards malignant 9L and MCF-7 cells, making this nanomaterial a potential
theranostic agent in cancer therapy. More significantly, ITO NPs exhibited negligible toxicity
in normal, non- malignant, MDCK cells, suggesting that there was a high selectivity.
Moreover, another type of ITO NPs was further designed and fabricated by calcination in
hydrogen-argon mixed gas (5% H2 ), with the aim of altering their physicochemical properties
by creating more oxygen defects compared with those synthesized in air. The novelty of this
work is that the designed ITO NPs exhibited cytotoxic and protective effects between breast
malignant MDA-MB-231 and MCF-7, and non- malignant MCF-10A cells in terms of ROS
generation and scavenging. It was demonstrated that the ITO NPs were able to increase the
intracellular ROS level in both MDA-MB-231 and MCF-7 breast cancer cells, and the
increased ROS would further trigger the activation of apoptosis, resulting in cell death. In
contrast, the ITO NPs exhibited the ability to scavenge an increased intracellular ROS level
induced by the addition of H2 O 2 to breast non- malignant MCF-10A cells, and such ROS
scavenging was then proven, as it was in association with decreased apoptosis in MCF-10A
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cells, suggesting that the designed ITO NPs are toxic to malignant cells but are protective
towards non- malignant cells. Moreover, results from clonogenic assays demonstrated that
both MAD-MB-231 and MCF-7 breast cancer cells presented very low surviving fractions
after treatment with ITO NPs. In contrast, the surviving fraction of MCF-10A cells was
remarkably increased after treatment with ITO NPs compared with the untreated control
sample, indicating that ITO NPs supported the cell proliferation. In addition, the surviving
fraction of MCF-10A cells treated with both ITO NPs and H2 O 2 was even significantly higher
than for the cells treated with H2 O2 alone, suggesting that ITO NPs protected the cells from
increased external oxidative stress. These results further support the proposition that the asprepared ITO NPs are able to block the proliferation of cancer cells, but support it in normal
cells. In addition, the ITO NPs are fluorescent and exhibit anatomical contrast enhancement,
which makes them a promising theranostic nanomaterial for cancer therapy. This theranostic
nanomaterial can realize the combination of four different functions, including therapy,
selectivity, imaging, and protection, in a single platform, which makes it highly desirable and
demonstrates that a ceramic metal oxide nanomaterial is most attractive for applications in
cancer therapy.
In this doctoral thesis work, IZO NPs were successfully fabricated through a
coprecipitation route and were well characterized. As many studies have reported that ZnO
NPs have an inherent preferential cytotoxicity towards cancer cells, the cellular interactions
of Zn doped In2 O3 nanostructures attracted our interest, particularly from the aspects of
cytotoxicity and selectivity. Through MTT assay, it was demonstrated that IZO NPs feature
high cytotoxicity towards malignant MDA-MB-231, MCF-7, PANC-1, and MIA PaCa-2
cells in a dose-dependent manner, while presenting biocompatibility in non-malignant
RWPE-1 and MCF-10A cells. Clonogenic data demonstrated that IZO NPs were also highly
cytotoxic towards malignant MDA-MB-231 and MCF7 cells without posing much risk to
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non- malignant MCF-10A cells. These results all suggest that IZO NPs are highly selective
between non- malignant and malignant cells, even at a higher dose, and also imply that the
doped ZnO still keeps its inherent preferential cytotoxicity towards cancer cells.

7.2 Future Prospects
Although therapeutic NPs have been studied and developed for many decades, how
their physiochemical properties affect cellular interactions and the underlying toxic/selective
mechanisms are still matters of great uncertainty. The physiochemical properties of NPs can
be changed by a number of factors, such as the ratio of dopants, the synthesis environment,
the synthesis temperature, etc. As a consequence, the cellular interactions and the
mechanisms of toxicity/selectivity of NPs are largely unknown, although this doctoral work
has provided some insights into the physiochemical properties of indium-based nanomaterials
and their toxic/selective mechanisms in a number of malignant and non-malignant cells based
on the promising obtained results. Further studies to deeply and completely investigate the
actual mechanisms of the indium-based NPs would be beneficial and warranted. Besides,
how the aggregate states of the used indium-based NPs modify their selectivity and
cytotoxicity between malignant and non- malignant cells should also be studied in further
works.
For the study of air-annealed ITO NPs, although the selectivity and cytotoxicity of
this nanomaterial have been demonstrated, the mechanism of action remains unknown and
needs to be further investigated, including by ROS measurements, apoptosis measurements,
and gene expression.
For the study of 5% H2 -Ar annealed ITO NPs, although the toxicity of the NPs has
been revealed as due to increased ROS levels in cancer cells, the initial experimental
evidence provided in this work has only demonstrated how the physiochemical change s in
ITO NPs would make them protective, but the mechanism of the protection in non-malignant
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cells is still not fully understood. More importantly, more human non-malignant cells need to
be tested to verify the early claims made in this work regarding the protection provided by the
as-prepared ITO NPs. Moreover, in future work, other factors should be taken into account,
such as sensitivity responses to stimuli, differential gene expression, and different pH
environments. Furthermore, in vivo tests should be conducted on the nanomaterial in order to
understand the real cytotoxic response and to evaluate the theranostic efficacy of the ITO NPs
in the human body.
For study of IZO NPs, although selective cytotoxicity has been demonstrated in a
number of malignant and non- malignant cells, future work should be conducted on
investigating the underlying toxic mechanism, such as by cellular internalization and ROS
measurements, apoptosis measurements, gene expression, and examination of different pH
environments with respect to toxicity. Moreover, in vivo tests should be conducted to reveal
the real cytotoxic response of IZO NPs, which will give important insights into the ir real
application in the field of future cancer therapy.
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Figure A1. UV-Visible spectrum and the calculated band gap (inset) of ITO NPs.
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Figure A2. Hydrodynamic diameter of ITO NPs suspended in PBS, determined via dynamic
light scattering. The concentration of the suspension of ITO NPs was 50 μg/mL.
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Figure A3. ITO-2 NP induced generation of intracellular ROS in MDA-MB-231 (left), MCF7 (middle), and MCF-10A cells (right). The different colours represent different treatments,
and the change in the dichlorofluorescein (DCF)- fluorescent intensity represents the change
in the intracellular ROS level in MDA-MB-231, MCF-7, and MCF-10A cells, respectively.
The control curves represent the cells without any treatment. Cells treated with ITO-2 NPs in
a concentration of 50 µg/mL induced significant production of ROS in cancerous MDA-MB231(left panel) and MCF-7 (middle panel) cells. No noticeable ROS change was detected in
the non- malignant MCF-10A cells after treatment with ITO-2 NPs (50 µg/mL), and no ROS
suppression was observed after MCF-10A cells were treated with ITO-2 NPs (50 µg/mL) and
H2 O 2 (0.5 mM) (right panel).
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Figure A4. High-resolution XPS O 1s spectrum for ITO-2 NPs. ITO-2 NPs are the material
synthesized under the same conditions as ITO-1 but annealed in air.
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Figure A5. Fluorescent (left), bright field (middle), and overlay of fluorescence and bright
field images (right) of MDA-MB-231, MCF-7, and MCF-10A cells without treatment by ITO
NPs.
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Figure A6. Fluorescence images (left), bright field images (middle), and overlays of the
fluorescence and bright field images (right), with the z-positions analysed through the 17 th ,
19th , 23rd, and 25th sections of the MDA-MB-231 cells treated with ITO for 24 h. Red circles
highlight the presence of ITO NPs in the cellular cytoplasm.
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Figure A7. Fluorescence images (left), bright field images (middle), and overlays of the
fluorescence and bright field images (right), with the z-positions analysed through the 23 rd,
25th , 28th , and 30th sections of MCF-7 cells treated with ITO for 24 h. Red circles highlight
the presence of ITO NPs in the cellular cytoplasm.
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Figure A8. Fluorescence images (left), bright field images (middle), and overlays of the
fluorescence and bright field images (right), with the z-positions analysed through the 9 th ,
10th , 11th , and 13th sections of MCF-10A cells treated with ITO for 24 h. Red circles highlight
the presence of ITO NPs in the cellular cytoplasm.
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Figure A9. Scattergrams of 7-AAD stained cells with gating are shown. (A), Untreated
MDA-MB-231 cells (left), MDA-MB-231 cells treated with ITO NPs (middle), MDA-MB202
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231 cells treated with ITO NPs and 0.5 mM of NAC (right); (B), Untreated MCF-7 cells (left),
MCF-7 cells treated with ITO NPs (middle), MCF-7 cells treated with ITO NPs and 5 mM of
NAC (right); (C), Untreated MCF-10A cells (upper- left), MCF-10A cells treated with ITO
NPs (upper- middle), MCF-10A cells treated with 5 mM of NAC (upper-right), MCF-10A
cells treated with 5 mM of NAC and 1 mM of H2 O2 (bottom- left), MCF-10A cells treated
with ITO NPs and 1mM of H2 O2 (bottom- middle), and MCF-10A cells treated with 1 mM of
H2 O 2 (bottom-right). Note: The concentration of the ITO NPs used for treatments was 50
µg/mL. The legend “Late apoptosis” in all panels represents both late apoptotic and dead cell
populations.
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Scholarships


Faculty Scholarship, Institute for Superconducting and Electronic Materials, University
of Wollongong, Australia, 2017



International Postgraduate Tuition Award, University of Wollongong, Australia, 2016.

Publication


Nai-Sheng HSU, Moeava Tehei, Md Shahriar Hossain, Anatoly Rosenfeld, Muhhamad
Shiddiky, Ronald Slyuter, Shi Xue Dou, Yusuke Yamauchi and Konstantin
Konstantinov, Implementation of Oxide Nano-particles in Medicine as Universal Oxiredox Theranostic Systems Based on Controlled Generation or Prevention of Oxidative
Stress: An Application of In-based Oxide Nanoparticles for Selective Breast Cancer
Treatment. Submitted to Nature Communications, 2019.
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